Pyrrolidine compounds
Through pyrrolidine compounds and pharmaceutically acceptable salts, the problem of difficulty in reducing plasma Lp(a) levels in the prior art is solved, providing effective treatment options, and improving cardiovascular health.
Patent Information
- Application Number
- CN202380030099.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-05
- Filing Date
- 2023-01-19
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively reduce Lp(a) levels in plasma. Elevated Lp(a) is closely related to cardiovascular disease and there are limited existing treatment options, especially drug therapy is not approved.
A pyrrolidine compound and its pharmaceutically acceptable salt are provided, which are used to reduce plasma Lp(a) levels by a specific structural connection and functional group combination, as a new therapeutic option.
This compound can effectively reduce plasma Lp(a) levels, provide additional treatment options for patients with cardiovascular disease, especially patients with dyslipidemia, and improve cardiovascular health.
Smart Images

Figure CN118974013A_ABST
Abstract
Description
[0001] The present invention relates to pyrrolidine compounds, their pharmaceutically acceptable salts, pharmaceutical compositions and therapeutic uses of said compounds, in particular their use in lowering lipoprotein (a) (Lp (a)) plasma levels. The present invention also relates to intermediates for preparing therapeutic pyrrolidine compounds.
[0002] Significant progress has been made in the treatment of cardiovascular disease (CVD). Despite advances in treatment, patients continue to experience CVD events such as angina, myocardial infarction, and stroke, which, if untreated, can lead to death. Dyslipidemia, or abnormal blood lipids, remains a major risk factor for CVD. Dyslipidemia can be divided into four general risk factors: elevated low-density lipoprotein cholesterol (LDL-c), low high-density lipoprotein cholesterol (HDL-c), elevated triglycerides (TG), and elevated Lp(a). Various treatment options are available for elevated LDL-c, low HDL-c, and elevated triglycerides. For patients with elevated Lp(a) concentrations, there are few approved treatment options. In some cases, apheresis can be used to filter the blood to remove LDL and Lp(a); however, the effect is temporary and usually needs to be repeated every two weeks. There are no approved pharmacological therapies for lowering Lp(a) levels. The physiological functions of Lp(a) are complex; however, elevated plasma levels of Lp(a) have been reported to be an independent risk factor for CVD.
[0003] Lp(a) may exhibit prothrombotic and antithrombotic properties, as well as atherogenic and atherothrombotic properties. Lp(a) may inhibit fibrinolysis and accumulate in the vessel wall to induce thrombosis and atherosclerotic lesions. Plasma levels of Lp(a) vary widely between individuals. Unlike other risk factors, Lp(a) plasma levels do not change significantly with diet and exercise. Lp(a) plasma levels may be related to genetic predisposition.
[0004] Lp(a) is similar to LDL-c in that it includes an LDL lipid core and an attached apolipoprotein B (apoB), but unlike LDL-c, Lp(a) also contains a unique apolipoprotein (a) (apo(a)) bound to apoB via a disulfide bond. Apo(a) is synthesized in the liver. Assembly of Lp(a) from apo(a) and LDL particles can occur in hepatocytes, on cell walls, or in plasma. Inhibition of the assembly of LDL particles with apo(a) can reduce Lp(a) levels. Patients with cardiovascular disease, particularly those with dyslipidemia or abnormal lipid profiles, need additional treatment options. Patients whose cardiovascular risk cannot be adequately managed using current standard of care therapies (such as diet, exercise, and / or use of one or more drugs, such as statins, fibrates, and niacin) need additional treatment options. The present invention provides another treatment option for patients with CVD. Pharmaceutically acceptable compounds and treatment options are needed to reduce plasma Lp(a) levels.
[0005] In a first aspect, there is provided a compound of formula III:
[0006]
[0007] in
[0008] L 1 Connect in A 1 , A 2 or A 3 and selected from a bond, -(CH2) p NHC(O)NH(CH2) p -、-(CH2) p C(O)NH(CH2) p -、-(CH2) p S(O)2NH(CH2) p -、-(CH2) q -、-(CH2) p NH(CH2) p -、
[0009]
[0010]
[0011] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0012]
[0013] R 1 , R 1’ , R 2 and R2’ independently selected at each occurrence from H, C 1-4 Alkyl and F;
[0014] R 3 , R 3’ , R 4 and R 4’ is H or F independently at each occurrence;
[0015] R 5 and R 5’ H, C independently at each occurrence 1-4 Alkyl or cyclopropyl;
[0016] Z and Z' are independently H, C 1-4 Alkyl, OH, cyclopropyl, CH2OH, CH2NH2 or CH2OCH2phenyl;
[0017] Y and Y' are independently CH2, CH(CH3), O or S at each occurrence;
[0018] A 1 , A 1’ , A 2 , A 2’ , A 3 , A 3’ , A 4 , A 4’ , A 5 , A 5’ and A 6 is independently C or N at each occurrence, wherein each ring A 1 , A 2 , A 3 , A 4 and A 5 No more than two of them are N, or A on each ring 1’ , A 2’ , A 3’ , A 4’ , A 5’ and A 6 No more than two of them are N;
[0019] Q 3 and Q 3’ is independently H at each occurrence; -(CH2) n O(CH2) n R 10 ; -(CH2) n NR 15 (CH2) n R 10 ;-CN;-(CH2) n CO2R 10; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH2) n R 10 ; -(CH2) n NR 15 S(O) m (CH2) n R 10 ; -(CH2) n S(O) m NR 15 (CH2) n R 10 ; -(CH2) n NHCONR 15 R 10 ; -NHCO(CH2) n R 10 ;-NHCOOR 10 ; NO2; CF3; C 3-6 Cycloalkyl; -NH(C=NH)CH2CN; 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; indoline optionally substituted by one or two CH3 groups; indoline optionally substituted by (CH2)CF3, CH3 or (CH2) n Phenyl substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally substituted by OH or OCH3; indolin-2-one, isoindolin-1-one or benzimidazol-2-one optionally substituted by one or two substituents independently selected from OCH3, CH3 and halogen; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH2, C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted with 1 to 3 substituents independently selected from -OCH3, CF3, CH3, CN and halogen, or pyridine optionally substituted with CH2OH; or
[0020]
[0021] Q 4 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0022] m is independently 0, 1, or 2 at each occurrence;
[0023] n is independently 0, 1, 2, or 3 at each occurrence;
[0024] R 10 is independently H at each occurrence; halogen; OH; carboxyl; -S(O)2OH; C optionally substituted with 1 to 4 OH or with OCH3 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH3; NH2; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted with one or two halogens; indoline optionally substituted with C(O)CH3; 1-4 Alkyl, C 1-4 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, -(CH2)2C(O)OH, -C(O)NHNH2, -OCF3, -N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OCH2C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH2) n (5- or 6-membered heterocyclic group) or -(CH2) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens;
[0025] R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0026] L 2 Connect in A 1’ , A 2’ or A 3’ and is C 1-3an alkylene group or a bond; and
[0027] p ranges from 0 to 3 independently at each occurrence;
[0028] q is 1 to 5;
[0029] r is 1, 2, or 3;
[0030] R 15 Is H or C 1-3 alkyl;
[0031] or a pharmaceutically acceptable salt thereof,
[0032] Wherein the compound is not of the formula:
[0033]
[0034] in
[0035] L 1 Selected from -CH2NHCH2-, -CH2NH-, -NH-,
[0036] The group composed of;
[0037] R 5 is H or CH3; and
[0038] Z is H or CH3.
[0039] In a second aspect, there is provided a compound of formula IV:
[0040]
[0041] in
[0042] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0043] R 3 and R 4 are independently H or F;
[0044] R 5 It is H, C 1-4 Alkyl or cyclopropyl;
[0045] Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH2OH, CH2NH2 or CH2OCH2phenyl;
[0046] Y is CH2, CH(CH3), O or S;
[0047] A 1 , A 2 , A3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N;
[0048] Q 1 Yes - (CH2) n O(CH2) n R 10 ; -(CH2) n NR 15 (CH2) n R 10 ;-CN;-(CH2) n CO2R 10 ;-B(OR 10 )2; ethylene glycol borate; pinacol borate; propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N3; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH2) n R 10 ; -(CH2) n NR 15 S(O) m (CH2) n R 10 ; -(CH2) n S(O) m NR 15 (CH2) n R 10 ; -(CH2) n NHCONR 15 R 10 ; -NHCO(CH2) n R 10 ;-NHCOOR 10 ; NO2; CF3; C 3-6 Cycloalkyl; -NH(C=NH)CH2CN; 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; indoline optionally substituted by one or two CH3 groups; indoline optionally substituted by (CH2)CF3, CH3 or (CH2) nPhenyl substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally substituted by OH or OCH3; indolin-2-one, isoindolin-1-one or benzimidazol-2-one optionally substituted by one or two substituents independently selected from OCH3, CH3 and halogen; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH2, C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted with 1 to 3 substituents independently selected from -OCH3, CF3, CH3, CN and halogen, or pyridine optionally substituted with CH2OH; or
[0049]
[0050] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0051] m is 0, 1, or 2;
[0052] n is 0, 1, 2, or 3;
[0053] R 10 is H; halogen; OH; carboxyl; -S(O)2OH; C optionally substituted by 1 to 4 OH or by OCH3 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH3; NH2; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted with one or two halogens; indoline optionally substituted with C(O)CH3; 1-4 Alkyl, C 1-45- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, -(CH2)2C(O)OH, -C(O)NHNH2, -OCF3, -N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OCH2C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH2) n (5- or 6-membered heterocyclic group) or -(CH2) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens;
[0054] R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0055] r is 1, 2, or 3; and
[0056] R 15 Is H or C 1-3 alkyl;
[0057] or a pharmaceutically acceptable salt thereof.
[0058] In an alternative embodiment, a compound of Formula I is provided:
[0059]
[0060] in
[0061] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0062] R 3 and R 4 are independently H or F;
[0063] R 5 It is H, C 1-4 Alkyl or cyclopropyl;
[0064] Z is H, C 1-4 Alkyl or cyclopropyl;
[0065] A 1 , A 2 , A 3 , A 4 and A 5 can be independently C or N, wherein A 1 , A 2 , A3 , A 4 or A 5 No more than two of them are N;
[0066] Q 1 Yes - (CH2) n O(CH2) n R 10 、-(CH2) n NH(CH2) n R 10 、-CN、-(CH2) n CO2R 10 、-B(OR 10 )2, ethylene glycol borate, pinacol borate, propane-1,3-diol borate, 2,2-dimethyl-propane-1,3-diol borate, -N3, C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, halogen, -C(O)-R 10 、-C(O)NHR 10 、-NH-NH2、-S(O) m (CH2) n R 10 、-(CH2) n NHS(O) m (CH2) n R 10 、-(CH2) n S(O) m NH(CH2) n R 10 、-(CH2) n NHCONHR 10 、-NHCO(CH2) n R 10 、-NHCOOR 10 or aryl or heteroaryl selected from the group consisting of phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine and pyrazine, wherein the aryl and heteroaryl groups are optionally substituted with halogen or OCF3 substituents;
[0067] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0068] m is 0, 1, or 2;
[0069] n is 0, 1, or 2;
[0070] R 10is H; hydroxyl; carboxyl; C optionally substituted by OH 1-4 Alkyl; C 3-6 Cycloalkyl; 4,4-difluorocyclohexyl; C 1-4 haloalkyl; 3-(1H)-benzimidazol-2-yl; thiazole optionally substituted with methyl; methyl(phenyl)carbamoyl; 1-benzyl-4-piperidinyl; 8-quinolyl; 2-methoxyethyl; 3-methoxypropyl; 3-phenyl-1,2,4-oxadiazol-5-yl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, (CH2)2C(O)OH, C(O)NHNH2, OCF3, N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl and OCH2C 3-6 Cycloalkyl;
[0071] and R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0072] or a pharmaceutically acceptable salt thereof.
[0073] In a third aspect, there is provided a compound of Formula V:
[0074]
[0075] in
[0076] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0077] R 3 and R 4 are independently H or F;
[0078] R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group;
[0079] X is OH, -OR 6 or
[0080] R 6 It is C 1-4 alkyl;
[0081] D and E are each independently O or S;
[0082] R 7 It is H, C 1-4alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0083] R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0084] Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH2OH, CH2NH2 or CH2OCH2phenyl;
[0085] Y is CH2, CH(CH3), O or S;
[0086] A 1 , A 2 , A 3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N;
[0087] Q 1 Yes - (CH2) n O(CH2) n R 10 ; -(CH2) n NR 15 (CH2) n R 10 ;-CN;-(CH2) n CO2R 10 ;-B(OR 10 )2; ethylene glycol borate; pinacol borate; propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N3; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m(CH2) n R 10 ; -(CH2) n NR 15 S(O) m (CH2) n R 10 ; -(CH2) n S(O) m NR 15 (CH2) n R 10 ; -(CH2) n NHCONR 15 R 10 ; -NHCO(CH2) n R 10 ;-NHCOOR 10 ; NO2; CF3; C 3-6 Cycloalkyl; -NH(C=NH)CH2CN; 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; indoline optionally substituted by one or two CH3 groups; indoline optionally substituted by (CH2)CF3, CH3 or (CH2) n Phenyl substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally substituted by OH or OCH3; indolin-2-one, isoindolin-1-one or benzimidazol-2-one optionally substituted by one or two substituents independently selected from OCH3, CH3 and halogen; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH2, C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted with 1 to 3 substituents independently selected from -OCH3, CF3, CH3, CN and halogen, or pyridine optionally substituted with CH2OH; or
[0088]
[0089] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0090] m is 0, 1, or 2;
[0091] n is 0, 1, 2, or 3;
[0092] R 10 is H; halogen; OH; carboxyl; -S(O)2OH; C optionally substituted by 1 to 4 OH or by OCH3 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH3; NH2; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted with one or two halogens; indoline optionally substituted with C(O)CH3; 1-4 Alkyl, C 1-4 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, -(CH2)2C(O)OH, -C(O)NHNH2, -OCF3, -N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OCH2C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH2) n (5- or 6-membered heterocyclic group) or -(CH2) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens; R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0093] r is 1, 2, or 3; and
[0094] R 15 Is H or C 1-3 alkyl;
[0095] or a salt thereof,
[0096] If X is OH, then R 5a must be a protecting group; and
[0097] Wherein the compound is not:
[0098] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0099] 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-2-methyl-propionic acid;
[0100] 3-[2-[4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester;
[0101] tert-Butyl 3-[(2-[4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0102] 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid;
[0103] 2-[(1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-(3-nitrophenyl)propanoic acid;
[0104] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0105] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate;
[0106] tert-Butyl 3-[(2-tert-butoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0107] tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0108] tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate;
[0109] tert-Butyl 3-[1-[[3-(Aminomethyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0110] tert-Butyl 3-[1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0111] tert-Butyl 3-[2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0112] [3-[3-tert-Butoxy-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]boronic acid;
[0113] Tert-butyl 3-[2-tert-butoxy-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate.
[0114] In an alternative embodiment, a compound of Formula II is provided:
[0115]
[0116] in
[0117] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0118] R 3 and R 4 are independently H or F;
[0119] R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group;
[0120] X is OH, -OR 6 or
[0121] R 6 It is C 1-4 alkyl;
[0122] D and E are each independently O or S;
[0123] R 7 It is H, C 1-4 alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0124] R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0125] Z is H, C 1-4 Alkyl or cyclopropyl;
[0126] A 1 , A 2 , A3 , A 4 and A 5 can be independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N;
[0127] Q 1 Yes - (CH2) n O(CH2) n R 10 、-(CH2) n NH(CH2) n R 10 、-CN、-(CH2) n CO2R 10 、-B(OR 10 )2, ethylene glycol borate, pinacol borate, propane-1,3-diol borate, 2,2-dimethyl-propane-1,3-diol borate, -N3, C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, halogen, -C(O)-R 10 、-C(O)NHR 10 、-NH-NH2、-S(O) m (CH2) n R 10 、-(CH2) n NHS(O) m (CH2) n R 10 、-(CH2) n S(O) m NH(CH2) n R 10 、-(CH2) n NHCONHR 10 、-NHCO(CH2) n R 10 、-NHCOOR 10 or aryl or heteroaryl selected from the group consisting of phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine and pyrazine, wherein the aryl and heteroaryl groups are optionally substituted with halogen or OCF3 substituents;
[0128] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0129] m is 0, 1, or 2;
[0130] n is 0, 1, or 2;
[0131] R 10 is H; hydroxyl; carboxyl; C optionally substituted by OH 1-4 Alkyl; C 3-6 Cycloalkyl; 4,4-difluorocyclohexyl; C 1-4 haloalkyl; 3-(1H)-benzimidazol-2-yl; thiazole optionally substituted with methyl; methyl(phenyl)carbamoyl; 1-benzyl-4-piperidinyl; 8-quinolyl; 2-methoxyethyl; 3-methoxypropyl; 3-phenyl-1,2,4-oxadiazol-5-yl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, (CH2)2C(O)OH, C(O)NHNH2, OCF3, N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl and -OCH2C 3-6 Cycloalkyl;
[0132] and R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0133] If X is OH, then R 5a Must be a protecting group;
[0134] or a salt thereof.
[0135] In a fourth aspect, there is provided a compound of the formula:
[0136]
[0137] in
[0138] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0139] R 3 and R 4 are independently H or F;
[0140] R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group;
[0141] D and E are each independently O or S;
[0142] R 7 It is H, C 1-4alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0143] R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0144] Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH2OH, CH2NH2 or CH2OCH2phenyl;
[0145] or a salt thereof,
[0146] Wherein the compound is not:
[0147]
[0148] In a fifth aspect, there is provided the use of a compound of formula I, II, IV, V or VI in the preparation of an oligomer.
[0149] In a sixth aspect, an oligomer prepared from a compound of Formula I, II, IV, V or VI is provided.
[0150] In a seventh aspect, a pharmaceutical composition comprising the above oligomer is provided.
[0151] In one embodiment of the compound of Formula III, L 1 Connect in A 1 , A 2 or A 3 and selected from a bond, -(CH2) p NHC(O)NH(CH2) p -、-(CH2) p C(O)NH(CH2) p -、-(CH2) p S(O)2NH(CH2) p -、-(CH2) q -、-(CH2) p NH(CH2) p -、
[0152]
[0153] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0154]
[0155] R 1 , R 1’ , R 2 and R 2’ independently selected at each occurrence from H, C 1-4 Alkyl and F;
[0156] R 3 , R 3’ , R 4 and R 4’ is H or F independently at each occurrence;
[0157] R 5 and R 5’ H, C independently at each occurrence 1-4 Alkyl or cyclopropyl;
[0158] Z and Z' are independently H, C 1-4 Alkyl, OH or cyclopropyl;
[0159] Y and Y' are independently CH2, O or S at each occurrence;
[0160] A 1 , A 1’ , A 2 , A 2’ , A 3 , A 3’ , A 4 , A 4’ , A 5 , A 5’ and A 6 is independently C or N at each occurrence, wherein each ring A 1 , A 2 , A 3 , A 4 and A 5 No more than two of them are N, or A on each ring 1’ , A 2’ , A 3’ , A 4’ , A 5’ and A 6 No more than two of them are N;
[0161] Q 3 and Q 3’is independently H, -(CH2) n O(CH2) n R 10 、-(CH2) n NH(CH2) n R 10 、-CN、-(CH2) n CO2R 10 , C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, halogen, -C(O)-R 10 、-C(O)NHR 10 、-S(O) m (CH2) n R 10 、-(CH2) n NHS(O) m (CH2) n R 10 、-(CH2) n S(O) m NH(CH2) n R 10 、-(CH2) n NHCONHR 10 、-NHCO(CH2) n R 10 、-NHCOOR 10 , NO2, cyclopropyl, -O-cyclopropyl, CF3, OCF3, OH or an aryl or heteroaryl group selected from the group consisting of phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine and pyrazine, wherein the aryl and heteroaryl groups are optionally substituted with halogen or OCF3 substituents;
[0162] Q 4 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0163] m is independently 0, 1, or 2 at each occurrence;
[0164] n is independently 0, 1, or 2 at each occurrence;
[0165] R 10 is independently H at each occurrence; halogen; hydroxy; carboxyl; C optionally substituted with OH 1-4 Alkyl; C 3-6 Cycloalkyl; 4,4-difluorocyclohexyl; C 1-4haloalkyl; 3-(1H)-benzimidazol-2-yl; thiazole optionally substituted with methyl; methyl(phenyl)carbamoyl; 1-benzyl-4-piperidinyl; 8-quinolyl; 2-methoxyethyl; 3-methoxypropyl; 3-phenyl-1,2,4-oxadiazol-5-yl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, (CH2)2C(O)OH, C(O)NHNH2, OCF3, N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl and -OCH2C 3-6 Cycloalkyl;
[0166] R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0167] L 2 Connect in A 1’ , A 2’ or A 3’ and is C 1-3 an alkylene group or a bond; and
[0168] p ranges from 0 to 3 independently at each occurrence;
[0169] q is 1 to 5;
[0170] or a pharmaceutically acceptable salt thereof,
[0171] Wherein the compound is not of the formula:
[0172]
[0173] in
[0174] L 1 Selected from -CH2NHCH2-, -CH2NH-, -NH-,
[0175] The group composed of;
[0176] R 5 is H or CH3; and
[0177] Z is H or CH3.
[0178] In the compound of formula III, L 1 Can be attached at different points on each ring. In one embodiment of the compound of formula III, L 1 A connected to each ring 2 A on a ring2 A on another ring 3 A on each ring 3 A in a ring 1 A on another ring 2 In a further embodiment, L 1 A connected to each ring 2 A on a ring 2 A on another ring 3 or A on each ring 3 In a preferred embodiment, L 1 A connected to each ring 2 Place.
[0179] In one embodiment of the compound of Formula III, L 1 Selected from:
[0180] bond, -(CH2) p NHC(O)NH(CH2) p -、
[0181] -(CH2) p C(O)NH(CH2) p -、-(CH2) p S(O)2NH(CH2) p -、-(CH2) q -、
[0182]
[0183]
[0184] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0185]
[0186] In one embodiment of the compound of Formula III, L 1 Yes - (CH2) p NH(CH2) p -、
[0187] And at least one Q 3 Not H.
[0188] In one embodiment of the compound of Formula III, L 1 Selected from: bond, -(CH2) pNHC(O)NH(CH2) p -、-(CH2) p C(O)NH(CH2) p -、-(CH2) p S(O)2NH(CH2) p -、-(CH2) q -、-(CH2) p NH(CH2) p -、
[0189]
[0190] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0191] In a further embodiment, L 1 Selected from: bond, -NHC(O)NH-, -NHC(O)NHCH2-, -C(O)NH-, -S(O)2NH-, -CH2CH2CH2-, -NH-,
[0192]
[0193] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0194] In a preferred embodiment, L 1 Selected from: key,
[0195] -NHC(O)NH-, -NHC(O)NHCH2-, -NH-,
[0196]
[0197] or L 1 With a position A on the ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
[0198]
[0199] In one embodiment of the compound of Formula III, L 1 Selected from:
[0200]
[0201] In a further embodiment, L 1 Selected from:
[0202]
[0203] In a further embodiment, L 1 Selected from:
[0204]
[0205]
[0206] In a preferred embodiment, L 1 Selected from:
[0207]
[0208] In one embodiment of the compound of formula III, on each ring R 1 and R 2 All H or R 1 and R 2 One is H and the other is CH3.
[0209] In one embodiment of the compound of formula III, on each ring R 3 and R 4 All H or R 3 and R 4 All F.
[0210] In one embodiment of the compound of formula III, at each occurrence of R 5 It's H.
[0211] In one embodiment of the compound of formula III, Z at each occurrence is H, CH3 or OH.
[0212] In one embodiment of the compound of formula III, on each ring A 1 , A 2 , A 3 , A 4 and A 5 All C; or A in a ring 1 , A 2 , A 3 , A 4 and A 5 The two are N and A on the other ring 1 , A 2 , A 3 , A 4 and A 5 All C; or A on each ring 3is N and the others are C. In a preferred embodiment, A 1 , A 2 , A 3 , A 4 and A 5 All are C.
[0213] In one embodiment of the compounds of Formula III, at each occurrence of Q 3 is H, F, CF3 or CN. In a preferred embodiment, at each occurrence of Q 3 It is H, F or CF3.
[0214] In one embodiment, the compound of formula III is selected from:
[0215]
[0216] or a pharmaceutically acceptable salt thereof.
[0217] In one embodiment of the compound of formula IV:
[0218] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0219] R 3 and R 4 are independently H or F;
[0220] R 5 It is H, C 1-4 Alkyl or cyclopropyl;
[0221] Z is H, C 1-4 Alkyl, OH or cyclopropyl;
[0222] Y is CH2, O or S;
[0223] A 1 , A 2 , A 3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N;
[0224] Q 1 Yes - (CH2) n O(CH2) n R 10 、-(CH2) n NH(CH2)n R 10 、-CN、-(CH2) n CO2R 10 、-B(OR 10 )2, ethylene glycol borate, pinacol borate, propane-1,3-diol borate, 2,2-dimethyl-propane-1,3-diol borate, -N3, C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, halogen, -C(O)-R 10 、-C(O)NHR 10 、-NH-NH2、-S(O) m (CH2) n R 10 、-(CH2) n NHS(O) m (CH2) n R 10 、-(CH2) n S(O) m NH(CH2) n R 10 、-(CH2) n NHCONHR 10 、-NHCO(CH2) n R 10 、-NHCOOR 10 , NO2 or aryl or heteroaryl selected from: phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine and pyrazine, wherein the aryl and heteroaryl groups are optionally substituted with halogen or OCF3 substituents;
[0225] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0226] m is 0, 1, or 2;
[0227] n is 0, 1, or 2;
[0228] R 10 is H; halogen; hydroxyl; carboxyl; C optionally substituted by OH 1-4 Alkyl; C 3-6 Cycloalkyl; 4,4-difluorocyclohexyl; C 1-4haloalkyl; 3-(1H)-benzimidazol-2-yl; thiazole optionally substituted with methyl; methyl(phenyl)carbamoyl; 1-benzyl-4-piperidinyl; 8-quinolyl; 2-methoxyethyl; 3-methoxypropyl; 3-phenyl-1,2,4-oxadiazol-5-yl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, - (CH2)2C(O)OH, C(O)NHNH2, OCF3, N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl and -OCH2C 3-6 Cycloalkyl;
[0229] and R 11 It is H, C 1-4 Alkyl or cyclopropyl.
[0230] In a further embodiment, the compound according to formula IV is a compound of formula IV':
[0231]
[0232] or a pharmaceutically acceptable salt thereof.
[0233] In one embodiment, the compound according to formula I is a compound of formula I':
[0234]
[0235] or a pharmaceutically acceptable salt thereof.
[0236] In another embodiment, the compound according to formula I or IV is selected from:
[0237]
[0238] or a pharmaceutically acceptable salt thereof.
[0239] In another further embodiment, the compound of Formula I or IV is selected from:
[0240]
[0241] or a pharmaceutically acceptable salt thereof.
[0242] In one embodiment, the compound of formula I or IV is selected from:
[0243]
[0244]
[0245]
[0246]
[0247]
[0248] or a pharmaceutically acceptable salt thereof.
[0249] In yet another embodiment, the compound of Formula I or IV is selected from:
[0250]
[0251]
[0252] or a pharmaceutically acceptable salt thereof.
[0253] In a further embodiment, the compound of Formula I or IV is selected from:
[0254]
[0255] or a pharmaceutically acceptable salt thereof.
[0256] In one embodiment of the compound of Formula I, I', IV or IV', Q 1 Selected from: -(CH2) n O(CH2) n R 10 ; -(CH2) n NR 15 (CH2) n R 10 ;-CN;-(CH2) n CO2R 10 ;-N3;C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH2) n R 10 ; -(CH2) n NR 15 S(O) m (CH2) n R 10 ; -(CH2) n S(O) m NR 15(CH2) n R 10 ; -(CH2) n NHCONR 15 R 10 ; -NHCO(CH2) n R 10 CF3;C 3-6 Cycloalkyl; -NH(C=NH)CH2CN; 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; indoline optionally substituted by one or two CH3 groups; indoline optionally substituted by (CH2)CF3 or (CH2) n Phenyl substituted imidazolidinone or imidazolidin-2,5-dione, wherein the phenyl group is optionally substituted by OH; indolin-2-one or benzimidazol-2-one optionally substituted by CH3; phenyl, 5- or 6-membered heteroaryl or 9-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the following: halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, C 1-4 Alkoxy, optionally substituted by OH or halogen 1-6 Alkyl, phenyl or benzyl, said phenyl or benzyl being optionally substituted with 1 to 3 substituents independently selected from -OCH3 and halogen; or
[0257]
[0258] In one embodiment of the compound of Formula I, I', IV or IV', Q 2 is H, CH3, F or Br.
[0259] In one embodiment of the compound of Formula I, I', IV or IV', R 5 is H. In another embodiment of the compound of Formula I, I', IV or IV', R 1 , R 2 , R 3 and R 4 At least one of is F. In yet another embodiment of the compound of Formula I, I', IV or IV', R 1 , R 2 , R 3 and R 4 At least two of are F. In a further embodiment of the compound of Formula I, I', IV or IV', R 1 , R 2 , R 3 and R 4 In a further embodiment of the compound of Formula I, I', IV or IV', R 1 and R2 is H, and R 3 and R 4 It's F.
[0260] In one embodiment of the compound of formula I, I', IV or IV', Z is selected from H, methyl, CH2OH, CH2NH2 and CH2OCH2phenyl. In another embodiment of the compound of formula I, I', IV or IV', Z is selected from H, methyl, ethyl, n-propyl and isopropyl.
[0261] In one embodiment, the compound according to formula I or IV is selected from:
[0262]
[0263] or a pharmaceutically acceptable salt thereof,
[0264] Where R 13 is selected from OH, OCH3, CH3 and NH2;
[0265] Where R 14 Selected from Br, OH, C(O)H, CH2OH, CH2NH2 and B(OH)2.
[0266] In one embodiment of the compound of Formula V:
[0267] R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F;
[0268] R 3 and R 4 are independently H or F;
[0269] R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group;
[0270] X is OH, -OR 6 or
[0271] R 6 It is C 1-4 alkyl;
[0272] D and E are each independently O or S;
[0273] R 7 It is H, C 1-4 alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4Alkylamino and di-C 1-4 Alkylamino;
[0274] R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino;
[0275] Z is H, C 1-4 Alkyl, OH or cyclopropyl;
[0276] Y is CH2, O or S;
[0277] A 1 , A 2 , A 3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N;
[0278] Q 1 Yes - (CH2) n O(CH2) n R 10 、-(CH2) n NH(CH2) n R 10 、-CN、-(CH2) n CO2R 10 、-B(OR 10 )2, ethylene glycol borate, pinacol borate, propane-1,3-diol borate, 2,2-dimethyl-propane-1,3-diol borate, -N3, C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, halogen, -C(O)-R 10 、-C(O)NHR 10 、-NH-NH2、-S(O) m (CH2) n R 10 、-(CH2) n NHS(O) m (CH2) n R 10 、-(CH2) n S(O)m NH(CH2) n R 10 、-(CH2) n NHCONHR 10 、-NHCO(CH2) n R 10 、-NHCOOR 10 , NO2 or aryl or heteroaryl selected from: phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine and pyrazine, wherein the aryl and heteroaryl groups are optionally substituted with halogen or OCF3 substituents;
[0279] Q 2 YesR 11 , CF3, OR 11 , OCF3, halogen or CN;
[0280] m is 0, 1, or 2;
[0281] n is 0, 1, or 2;
[0282] R 10 is H; halogen; hydroxyl; carboxyl; C optionally substituted by OH 1-4 Alkyl; C 3-6 Cycloalkyl; 4,4-difluorocyclohexyl; C 1-4 haloalkyl; 3-(1H)-benzimidazol-2-yl; thiazole optionally substituted with methyl; methyl(phenyl)carbamoyl; 1-benzyl-4-piperidinyl; 8-quinolyl; 2-methoxyethyl; 3-methoxypropyl; 3-phenyl-1,2,4-oxadiazol-5-yl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF3, CN, (CH2)2C(O)OH, C(O)NHNH2, OCF3, N(CH3)2, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl and -OCH2C 3-6 Cycloalkyl;
[0283] and R 11 It is H, C 1-4 Alkyl or cyclopropyl;
[0284] If X is OH, then R 5a must be a protecting group; and
[0285] Wherein the compound is not:
[0286] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0287] 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-2-methyl-propionic acid;
[0288] 3-[2-[4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester;
[0289] tert-Butyl 3-[(2-[4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0290] 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid;
[0291] 2-[(1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-(3-nitrophenyl)propanoic acid;
[0292] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0293] tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate;
[0294] tert-Butyl 3-[(2-tert-butoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0295] tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0296] tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate;
[0297] tert-Butyl 3-[1-[[3-(Aminomethyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0298] tert-Butyl 3-[1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate;
[0299] tert-Butyl 3-[2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate;
[0300] [3-[3-tert-Butoxy-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]boronic acid;
[0301] Tert-butyl 3-[2-tert-butoxy-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate.
[0302] In one embodiment of the compound of Formula V: Q 1 is -CN; -(CH2) n CO2R 10 ; Ethylene glycol borate; Pinacol borate; Propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N3; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; -C(O)NR 15 R 10 ; -S(O) m (CH2) n R 10 ; -(CH2) n NR 15 S(O) m (CH2) n R 10 ; -(CH2) n S(O) m NR 15 (CH2) n R 10 ; -(CH2) n NHCONR 15 R 10 ; -NHCO(CH2) n R 10 ;-NHCOOR 10 CF3;C 3-6 Cycloalkyl; -NH(C=NH)CH2CN; 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; indoline optionally substituted by one or two CH3 groups; indoline optionally substituted by (CH2)CF3, CH3 or (CH2) n Phenyl substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally substituted by OH or OCH3; indolin-2-one, isoindolin-1-one or benzimidazol-2-one optionally substituted by one or two substituents independently selected from OCH3, CH3 and halogen; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH2, C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted with 1 to 3 substituents independently selected from -OCH3, CF3, CH3, CN and halogen, or pyridine optionally substituted with CH2OH; or
[0303]
[0304] In one embodiment of the compounds of Formula II, V or VI, R 5a R may represent a protecting group ("PG") for the pyrrolidine nitrogen. The following protecting groups may be considered (the abbreviation of PG is indicated in parentheses): carbamates such as tert-butyloxycarbonyl (Boc), carboxybenzyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), trichloroethoxycarbonyl (Troc); amides such as trifluoroacetamide (Tfa), benzamide (Bz); amines such as benzylamine (Bn), triphenylmethylamine (Tphm), sulfonamides such as p-toluenesulfonamide. In particular, PG may be selected from the group consisting of: Boc, Cbz, Fmoc, Alloc, Teoc, Troc, Tfa, Bz, Bn, Tphm and p-toluenesulfonamide. In a specific embodiment, R 5a It's Boc.
[0305] In another embodiment of the compound of Formula II or V, X is selected from:
[0306]
[0307] Where R 12 H or C independently at each occurrence 1-4 alkyl.
[0308] The compound of formula VI is an alternative intermediate useful in the preparation of compounds of formula I, I', III, IV or IV' and other oligomeric compounds. The chirality of the compound of formula VI can be selected to direct the stereoselectivity of the alkylation step (Scheme 2). In one embodiment of the compound of formula VI, when R 7 When it is benzyl, R 1 , R 2 , R 3 , R 4 , R 5 , R 8 and R 9At least one of is not H. In an alternative embodiment, D or E is not O.
[0309] Preferred aryl and heteroaryl groups: phenyl, pyrrole, imidazole, pyrazole, triazole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, benzothiophene, indazole, indole, imidazopyridine, benzothiazole and benzimidazole.
[0310] As mentioned above, one aspect of the present disclosure includes the use of compounds according to formula I, I', II, IV, IV', V or VI in the preparation of oligomers. In another aspect, the present disclosure includes oligomers made from compounds according to formula I, I', II, IV, IV', V or VI. In one embodiment, the oligomer comprises two pyrrolidine moieties. In another embodiment, the oligomer comprises three pyrrolidine moieties. Therefore, another aspect of the present disclosure includes pharmaceutical compositions comprising such oligomers.
[0311] In another embodiment, a pharmaceutically acceptable composition is provided, comprising a compound of Formula I, I', III, IV or IV', or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient.
[0312] In one embodiment, a method of treating a patient in need of treatment for cardiovascular disease is provided, comprising administering an effective amount of a compound of Formula I, I', III, IV or IV', or a pharmaceutically acceptable salt thereof. In one embodiment, a method of treating a patient in need of treatment for elevated plasma levels of Lp(a) is provided, comprising administering an effective amount of a compound of Formula I, I', III, IV or IV', or a pharmaceutically acceptable salt thereof.
[0313] In one embodiment, a compound of Formula I, I', III, IV or IV', or a pharmaceutically acceptable salt thereof, is provided for use in therapy.
[0314] In one embodiment, a compound of Formula I, I', III, IV or IV' or a pharmaceutically acceptable salt thereof is provided for use in treating cardiovascular disease. In one embodiment, a compound of Formula I, I', III, IV or IV' or a pharmaceutically acceptable salt thereof is provided for use in treating elevated plasma levels of Lp(a).
[0315] In one embodiment, the use of a compound of Formula I, I', III, IV or IV' or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cardiovascular disease is provided. In one embodiment, the use of a compound of Formula I, I', III, IV or IV' or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating elevated plasma levels of Lp(a) is provided.
[0316] The term "halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.
[0317] The term "C 1-n "Alkyl" refers to a straight or branched chain saturated hydrocarbon containing 1 to n carbon atoms. 1-4 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, and tert-butyl. 1-3 Examples of alkyl groups include, but are not limited to, methyl, ethyl, and propyl. 1-2 The alkyl group is methyl or ethyl.
[0318] The term "C 1-3 "Alkylene" refers to a divalent C 1-3 alkyl.
[0319] The term "C 1-4 "Haloalkyl" refers to a C 1-4 Alkyl. C 1-4 Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, and pentafluoroethyl.
[0320] The term "C 1-4 "Alkoxy" refers to a straight or branched saturated hydrocarbon containing 1 to 4 carbon atoms with a terminal "O" in the chain, i.e. -O(alkyl). 1-4 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and butoxy.
[0321] The term "C 2-6 "Alkenyl" refers to a straight or branched chain hydrocarbon containing 2 to 6 carbon atoms and at least one double bond.
[0322] The term "C 2-6 "Alkynyl" refers to a straight or branched chain hydrocarbon containing 2 to 6 carbon atoms and at least one triple bond.
[0323] The term "C 3-6 "Cycloalkyl" refers to a monocyclic saturated carbocyclic ring containing 3 to 6 carbon atoms. Specifically, it refers to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0324] The term "heteroaryl" refers to a monocyclic aromatic ring containing one or more heteroatoms, preferably selected from: N, S and O. Examples of 5-membered heteroaryls include, but are not limited to, pyrazole, triazole and thiazole. Examples of 6-membered heteroaryls include, but are not limited to, pyridine and pyridazine.
[0325] The term "bicyclic heteroaryl" refers to a bicyclic aromatic ring containing one or more heteroatoms, preferably selected from: N, S and O. Examples of 9-membered bicyclic heteroaryls include, but are not limited to, indole, isoindole, indazole and pyrazolopyridine. Examples of 10-membered bicyclic heteroaryls include, but are not limited to, quinoline and benzopyran.
[0326] The term "5- or 6-heterocyclyl" refers to a 5- or 6-membered monocyclic saturated ring containing one or more heteroatoms, for example pyrrolidine and piperidine.
[0327] As used herein, the term "oligomer" refers to a compound having at least two pyrrolidine moieties given in Formula I, I', II, IV, IV' or V. As used herein, "pyrrolidine moiety" refers to an optionally substituted pyrrolidine. The pyrrolidine moieties in the oligomer may be the same or different.
[0328] As used herein, the term "elevated Lp(a) plasma levels" refers to Lp(a) plasma levels equal to or greater than about 50 mg / dL. The compounds or oligomers provided herein can be used in treatments that reduce Lp(a) plasma levels.
[0329] The term "pharmaceutically acceptable salt" as used herein refers to a salt of a compound that is clinically and / or veterinarily acceptable. Examples of pharmaceutically acceptable salts and common methods for preparing them can be found in "Handbook of Pharmaceutical Salts: Properties, Selection and Use" P. Stahl et al., Second Revised Edition, Wiley-VCH, 2011 and SM Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 1977, 66 (1), 1-19. The compounds of formula I, I', IV and IV' can be zwitterions, monoacids, diacids or triacid addition salts.
[0330] The pharmaceutical composition of the present invention can be prepared using pharmaceutically acceptable additives. The term "pharmaceutically acceptable" refers to one or more carriers, diluents and / or excipients that are compatible with the other components of the composition and are pharmaceutically harmless to the patient. Examples of pharmaceutical compositions and methods for preparing them are well known to the skilled person and can be found in, for example, "Remington: The Science and Practice of Pharmacy", Loyd, V. et al., ed., 22nd edition, Mack Publishing Co., 2012.
[0331] As used herein, the term "effective amount" refers to a dosage effective for treating a disorder. The effective amount for a particular patient can be determined by an experienced health care professional.
[0332] As used herein, the term "treating / to treat / treatment" includes slowing, alleviating, preventing or reversing the progression or severity of an existing symptom, disorder, condition or disease. As used herein, "treating cardiovascular disease" refers to slowing, alleviating, preventing or reversing the progression of heart or vascular disease.
[0333] As used herein, the term "patient" refers to a mammal. The patient is preferably a human.
[0334] The pharmaceutical composition can be formulated as a tablet or capsule for oral administration, a solution for oral administration, or an injectable solution. In one embodiment, the composition is suitable for oral administration.
[0335] Certain abbreviations are defined as follows: "ACN" means acetonitrile; "Apo" means apolipoprotein; "BOC" means tert-butyloxycarbonyl; "Bn" means benzyl; "BSA" means bovine serum albumin; "CDI" means carbonyldiimidazole; "DAD" means diode array detector; "DCM" means dichloromethane or methylene chloride; "de" means diastereomeric excess; "DMA" means N,N-dimethylacetamide; "DMAP" means 4-dimethylaminopyridine; "DMEA" means dimethylethylamine; "DMEM" means Dulbecco's modified Eagle's medium; "DMF" means N,N-dimethylformamide; "DMSO" means dimethyl sulfoxide; "ee" means enantiomeric excess; "EACA" means ε-aminocaproic acid or 6-aminocaproic acid; “ELISA” means enzyme-linked immunosorbent assay; “equiv” means equivalent; “Et2O” means diethyl ether; “EtOAc” means ethyl acetate; “EtOH” means ethanol or ethyl alcohol; “Ex” means example; “FBS” means fetal bovine serum; “h” means hour; “HATU” means 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; “HEC” means hydroxyethyl cellulose; “HEK” means human embryonic kidney; “HepG2” means human hepatoma cell line; “HEPES” means 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; “HLB” means hydrophile-lipophile balance; “HPLC” means high performance liquid chromatography; “HRP” means horseradish peroxidase; “IC 50 ” refers to the concentration of the reagent that produces 50% of the maximum inhibitory response possible for that reagent; “IPA” refers to isopropanol; “min” refers to minutes; “MeOH” refers to methanol or methyl alcohol; “MTBE” refers to methyl tert-butyl ether; “RP-HPLC / MS” refers to reversed-phase high performance liquid chromatography-mass spectrometry; “RT” refers to room temperature; “SFC” refers to supercritical fluid chromatography; “SPA” refers to scintillation proximity analysis; “t (R) ” refers to retention time; “TEA” refers to triethylamine; “THF” refers to tetrahydrofuran; “TMB” refers to 3,3′,5,5′-tetramethylbenzidine and “Tris” refers to tris(hydroxymethyl)aminomethane.
[0336] Those of ordinary skill in the art may separate or resolve the individual isomers, enantiomers and diastereomers at any convenient point in the synthesis of the following compounds by methods known to the skilled artisan, such as selective crystallization techniques or chiral chromatography.
[0337] The compounds of formula I, I', II, III, IV, IV' or V or any depicted formula are readily converted to and can be isolated as pharmaceutically acceptable salts. Salt formation can occur upon addition of a pharmaceutically acceptable acid to form an acid addition salt or upon addition of a pharmaceutically acceptable base to form a base addition salt. Salts can also be formed upon deprotection of nitrogen or oxygen, i.e., removal of protecting groups. Examples, reactions and conditions for forming salts are known to those of skill.
[0338] Compounds of formula I, I', II, III, IV, IV' or V or any depicted formula or salts thereof can be prepared by a variety of procedures, some of which are described in the following preparations and examples. The specific synthetic steps of each of the routes described can be combined in different ways, or with steps from different routes, to prepare the compounds or salts of the present invention. The products of each step in the following preparations can be recovered by conventional methods, including extraction, evaporation, precipitation, chromatography, filtration, trituration and crystallization.
[0339] In the following schemes, unless otherwise indicated, all substituents are as defined above. Reagents and raw materials are readily available to those of ordinary skill in the art. The following schemes, preparations and examples are provided to further illustrate the present invention without limiting the scope of the invention. The compounds of the above formulas or their salts can be prepared using starting materials or intermediates having the corresponding desired stereochemical configuration.
[0340] Schema 1
[0341]
[0342] Scheme 1 depicts the preparation of compounds of the invention starting from ester intermediate 1, which is treated with a strong organic base such as lithium diisopropylamide or potassium bis(trimethylsilyl)amide at -78°C, followed by addition of halide 18 in step 1 to give 2. The ester can be hydrolyzed in step 2 using a strong inorganic base such as lithium hydroxide or sodium hydroxide to give 3, and if R 5a is a protecting group which can be removed in step 3 to give the acid 4 (e.g. if R 5a =Boc, which can be removed under acidic conditions).
[0343] Schema 2
[0344]
[0345] Scheme 2 depicts the use of a chiral auxiliary to direct the stereoselectivity of the alkylation of intermediate 5 to prepare compounds of the invention, which is prepared in step 1 from acid 24 with the aid of an acid chloride and heterocycle 25 at 0°C. In step 2, intermediate 5 is treated with a strong organic base such as lithium bis(trimethylsilyl)amide at low temperature (-78-0°C), followed by the addition of halide 18 to give 6. In step 3, the chiral auxiliary is hydrolyzed using H2O2 and aqueous LiOH at 0°C, followed by quenching the reaction with NaHSO3 to give acid 3. Optionally, 3 is esterified in step 4a to give 2, or if R 5a is a protecting group which can be removed to give 4 (step 4b).
[0346] Diagram 3
[0347]
[0348] Scheme 3 shows functional groups that can be prepared from amino compounds 8, which can be prepared by reducing nitro compounds 7 with hydrogen using palladium on carbon, or by coupling 13 with ammonium hydroxide at elevated temperatures using a copper catalyst such as copper (II) acetylacetonate, 2,2,6,6-tetramethyl-3,5-heptanedione, and a carbonate base. Amino compounds 8 can then be reacted with an alkyl halide and a carbonate base to give 9. Alternatively, 9 can be obtained by reductive amination of compound 8 (e.g., using an aldehyde and a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride). Urea compounds 10 can be prepared by treating 8 with potassium cyanate (to give 13 wherein R 10 =H 10), or 1,1'-carbonyldiimidazole can be used, followed by amine H2NR 10 Treatment of 8. Amide compound 11 can be prepared by reacting 8 with an acid chloride (R 10 C(O)Cl) and an organic base such as triethylamine, or by reacting 8 with a carboxylic acid (R 10 CO2H) under amide coupling conditions (e.g., using HATU and an organic base). Compound 8 is reacted with sulfonyl chloride (R 10 SO2Cl) and an organic base to give the sulfonamide 12. Aniline 8 is oxidized with sodium nitrite and HCl, and then reduced with stannous chloride to give the hydrazine compound 54. 8 is reacted with tert-butyl nitrite and trimethylsilyl azido to give the azide 55.
[0349] Schema 4
[0350]
[0351] When Q 1When Q of 13 is a group that can undergo metal-halogen exchange (e.g., Cl, Br, I, or -OSO2CF3- compound 13), many derivatives can be obtained through various functional group transformations. Sonogashira coupling with alkynes, palladium catalysts, and organic bases at elevated temperatures gives aryl alkynes, such as 14 (the product of coupling with ethynyl(trimethyl)silane followed by removal of the trimethylsilyl group under alkaline conditions). 1 When bromine, ureas and amino heterocycles can be coupled to aryl rings using palladium catalysts and sodium tert-butoxide to give 15 and 16, respectively. Negishi coupling on 13 is achieved using organozinc compounds and palladium catalysts at elevated temperatures, such as (2-tert-butoxy-2-oxoethyl)(chloro)zinc, to give 17. Aldehydes 22 can be prepared from 13 via catalytic carbonylation, and boronates 27 can be prepared by coupling 13 with, for example, bis(pinacolato)diboron, potassium acetate, and a palladium catalyst at elevated temperatures.
[0352] Diagram 5
[0353]
[0354] Compound 13 can also be used to prepare sulfonamide 21 as shown in Scheme 5. In step 1, compound 13 is coupled with benzyl mercaptan using a palladium catalyst and an organic base at elevated temperature to give thioether 19, which is converted to sulfonyl chloride 20 in step 2 using 1,3-dichloro-5,5-dimethylhydantoin in a mixture of ACN, water and acetic acid at 0°C. Then, amine (H2NR 10 ) and an organic base to prepare sulfonamide 21.
[0355] Diagram 6
[0356]
[0357] Scheme 6 shows the preparation of amine 23 from aldehyde 22 by reacting amine (H2NR 10 ) and a reducing agent such as sodium triacetoxyborohydride. Amine 29 can be prepared from 28 by hydrogenation in the presence of a palladium-on-carbon catalyst.
[0358] Diagram 7
[0359]
[0360] Scheme 7 shows the preparation of compound 32, which can be an ether or a thioether. In step 1, intermediate 30 is brominated with the aid of a silyl enol ether (prepared by treating intermediate 30 with lithium diisopropylamide at -78°C and adding chlorotrimethylsilane) and N-bromosuccinimide to give bromide 31. In step 2, bromide 31 is reacted with 33 and a base (a carbonate base if 33 is a phenol, or sodium methoxide if 33 is a thiophenol).
[0361] Diagram 8
[0362]
[0363] Scheme 8 shows the hydroxylation of intermediate 34. Intermediate 34 was first treated with lithium diisopropylamide at -78 °C and then with 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine to give hydroxy compound 35.
[0364] Diagram 9
[0365]
[0366] Scheme 9 shows the preparation of polyurea compounds 37, 39 and 40. Compound 37 can be prepared by reacting amino compound 36 with CDI. Disubstituted amino compound 38 [prepared by reductive amination of 36 with aldehyde 22 (Scheme 4) or if p=0, Buchwald coupling of aniline intermediate 8 (Scheme 3) with intermediate 13 (Scheme 4)] is reacted with amino compound 36 and CDI to give trisubstituted urea 39. Amine 38 can also be reacted with sodium cyanate followed by 1-2 equivalents of TFA to give urea 40.
[0367] Figure 10
[0368]
[0369] Scheme 10 shows the preparation of tetrameric compound 41, wherein amine 38 undergoes reductive amination with glyoxal and a reducing agent such as sodium triacetoxyborohydride.
[0370] Schema 11
[0371]
[0372] Scheme 11 shows the preparation of dimeric compound 42, wherein intermediate 13 is coupled with boronate ester 27 using a palladium catalyst and a carbonate base at elevated temperature. Intermediate 13 can also be coupled with protected pyrazole boronic acid (56) using a palladium catalyst and a carbonate base at elevated temperature to give intermediate 57, which can be deprotected and coupled with another equivalent of intermediate 13 using copper (II) acetate and pyridine as solvent at elevated temperature to give 58.
[0373] Diagram 12
[0374]
[0375] Scheme 12 shows the preparation of cyclic urea compounds 43, 44 and 45. Intermediate 13 was coupled with tetrahydro-2(1H)-pyrimidinone using a palladium catalyst and sodium tert-butoxide at elevated temperature to give 43, or with imidazolidin-2-one to give 44. Intermediate 13 was also coupled with 1,3-dihydrobenzimidazol-2-one using cuprous iodide, N,N'-dimethylethylenediamine and a carbonate base at elevated temperature to give 45.
[0376] Diagram 13
[0377]
[0378] Scheme 13 shows the preparation of compound 47. Intermediate 36 is reacted with chloroacetyl chloride and an organic base to give the chloroacetyl intermediate 46, which is then dimerized using a carbonate base at elevated temperature to give the dioxopiperazine compound 47.
[0379] Diagram 14
[0380]
[0381] Scheme 14 shows the preparation of compound 50. Alcohol compound 48 was first subjected to Mitsunobu reaction with (3-hydroxyphenyl)acetate, diethyl azodicarboxylate and triphenylphosphine, and the acetyl group was removed using carbonate base / MeOH to give intermediate 49. Intermediate 48 and phenol 49 were further subjected to Mitsunobu reaction to give intermediate 50.
[0382] Figure 15
[0383]
[0384] Scheme 15 shows the one-pot preparation of compound 53 from intermediates 51 and 22. In step 1, fluoro-nitro compound 51 reacts with 2-phenylethylamine at elevated temperature. NAr reacts to give intermediate 52. Na2S2O4 is then added to the reaction followed by the aldehyde intermediate 22 (see Scheme 4) and heating is continued to give the cyclic compound 53.
[0385] Diagram 16
[0386]
[0387] Scheme 16 shows the preparation of compound 59 (prepared by click chemistry, where alkyne 14 and azide 55 were cyclized to 1,2,3-triazole using copper sulfate, sodium ascorbate and benzoic acid in a mixture of tert-butanol and water), compound 61 (prepared by coupling aniline 8 with acid 60 under amide coupling conditions, such as using HATU in the presence of an organic base), and compound 63 (prepared by reacting aniline 8 with sulfonyl chloride 62 in the presence of an organic base).
[0388] Diagram 17
[0389]
[0390] Scheme 17 shows the preparation of the propyl-linked dimeric compound 66. Aryl halide 13 is first coupled with boronate ester 67 using a palladium catalyst and a carbonate base at elevated temperature to give compound 64, which then undergoes Heck coupling with another equivalent of halide 13 using a palladium catalyst and an organic base at elevated temperature to give olefin 65. Reduction of the olefin using a palladium-on-carbon catalyst under hydrogen subsequently gives 66.
[0391] Preparation 1
[0392] (3R)-3-[2-methoxy-2-oxo-1-[[3-(2-trimethylsilylethynyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyrate
[0393]
[0394] To a mixture of (3R)-tert-butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429, 1.95 g, 4.73 mmol), cuprous iodide (0.90 g, 0.47 mmol), 1,3-bis(diphenylphosphino)propane (390 mg, 0.94 mmol) and tris(dibenzylideneacetone)dipalladium(0) (433 mg, 0.47 mmol) in TEA (39 mL) was added ethynyl(trimethyl)silane (2.67 mL, 1.86 g, 18.9 mmol). The resulting mixture was stirred at 120 °C overnight. The mixture was cooled to room temperature and heated to room temperature. Filter and wash with EtOAc. The solvent was removed in vacuo to give 4.2 g of a brown oil, which was then purified by silica gel chromatography using a gradient of 10 to 40% MTBE in hexanes to give the title compound as a brown oil (1.80 g, 84%). ES-MS m / z 374 (M-tBu+H)
[0395] Preparation 2
[0396] 2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-(3-ethynylphenyl)propanoic acid - Isomer 1 and Isomer 2
[0397]
[0398] Aqueous NaOH (2M, 21 mL, 42 mmol) was added to a solution of (3R)-tert-butyl 3-[2-methoxy-2-oxo-1-[[3-(2-trimethylsilylethynyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylate (1.8 g, 4.2 mmol) in THF (21 mL) and MeOH (10 mL). The mixture was stirred at room temperature for 3 days, then EtOAc was added, followed by aqueous HCl (1 M) until pH = 3. The aqueous phase was extracted with EtOAc and the organic layer was dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was then loaded onto an HLB column. The column was eluted with water, then ACN, and the ACN fraction was concentrated to give a brown oil containing the title compound as a mixture of diastereomers.
[0399] The diastereomers were separated by SFC [column: 20×250 mm, SFC 2-ethylpyridine stationary phase, 5 μm; mobile phase: 10% (10 mM NH 4 HCO 3 / MeOH, pH 8) in CO 2] to give isomer 1 (610 mg, 42%, first eluting isomer) as a yellow solid and isomer 2 (454 mg, 27%, second eluting isomer) as a light brown solid. Isomer 1 and Isomer 2: ES-MS m / z 288 (M-tBu+H).
[0400] Preparation 3
[0401] (3R)-tert-Butyl 3-[1-[(6-chloro-3-pyridinyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[0402]
[0403] Lithium diisopropylamide (2.0M in THF / heptane / ethylbenzene, 0.49mL, 0.99mmol) was added dropwise under N2 to a -78°C solution of (3R)-3-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 200mg, 0.82mmol) in THF (4mL) and the reaction was stirred at -78°C for 1 hour. A solution of 5-(bromomethyl)-2-chloropyridine (357mg, 1.64mmol) in THF (2mL) was then added and the reaction was stirred at -78°C for 30 minutes. The reaction was quenched with saturated NH4Cl aqueous solution and extracted with EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. The residue was purified by silica gel chromatography using a gradient of 25 to 100% EtOAc in hexanes to give the title compound as a colorless oil (mixture of diastereomers, 256 mg, 84%). ES-MS m / z 313 (M-tBu+H).
[0404] Preparation 4
[0405] 2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-(6-chloro-3-pyridinyl)propanoic acid - Isomer 1 and Isomer 2
[0406]
[0407] To a solution of (3R)-3-[1-[(6-chloro-3-pyridinyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (256 mg, 0.69 mmol) in THF (4 mL) was added LiOH (1 M in water, 4 mL, 4 mmol). The reaction was stirred at room temperature overnight and then at 50 °C for 1 hour. The reaction was quenched with 1N HCl and extracted with EtOAc. The organic layer was separated, dried over MgSO4 and concentrated in vacuo. The residue was purified by silica gel chromatography using 10% MeOH / DCM, and then the diastereomers were separated by chiral SFC [column: Chiralpak AD 20×250 mm, 5 μm; mobile phase: 25% (MeOH+0.2% DMEA) in CO2, 65 mL / min] to give Isomer 1 (107 mg, 43%, first eluting isomer) and Isomer 2 (70 mg, 28%, second eluting isomer) of the title compound. Isomer 1 and Isomer 2: ES-MS m / z 299 (M-tBu+H).
[0408] Preparation 5
[0409] (2S)-3-(3-Bromo-5-methyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0410]
[0411] Lithium bis(trimethylsilyl)amide (1.0M in THF, 6.8mL, 6.8mmol) was added to a solution of (3R)-3-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 2.2g, 5.7mmol) in THF (40mL) at 0°C. The mixture was stirred for 30 minutes, and then a solution of 1-bromo-3-(bromomethyl)-5-methyl-benzene (1.6g, 6.2mmol) in THF (6.6mL) was added dropwise. The resulting mixture was allowed to reach room temperature and stirred overnight. The reaction was quenched with saturated NH4Cl aqueous solution and extracted with EtOAc. The organic phases were combined and washed with saturated NaCl aqueous solution, dried over Na2SO4, filtered and concentrated to dryness. THF (39 mL) and water (7.4 mL) were added to the residue, and the mixture was cooled to 0 ° C. Aqueous hydrogen peroxide solution (3.1 M, 4.8 mL, 57 mmol) was added, followed by a solution of LiOH (0.24 g, 10 mmol) in water (11 mL). The reaction was stirred at 0 ° C for 50 minutes, then the reaction was quenched by the addition of NaHSO3 and the mixture was warmed to room temperature. The mixture was extracted with EtOAc, and the organic matter was then washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 10 to 40% EtOAc / hexane + 1% acetic acid to obtain the title compound (1.4 g, 45%) as a white solid. ES-MSm / z 355,357 (M-tBu+H).
[0412] Preparation 6
[0413] (2S)-3-(3-Amino-5-methyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0414]
[0415] To a mixture of (2S)-3-(3-bromo-5-methyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.37 g, 0.68 mmol), sodium azide (0.088 g, 1.4 mmol) and L-proline (0.10 g, 0.88 mmol) in DMSO (3.4 mL) was added Cu2O (97 mg, 0.68 mmol). The mixture was purged with nitrogen and heated at 100°C overnight. The mixture was cooled to room temperature, saturated aqueous NH4Cl solution was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography using a gradient of 20 to 50% ACN in water to give the title compound (0.11 g, 46%) as a light yellow solid. ES-MS m / z 249 (M-Boc+H)
[0416] Preparation 7
[0417] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-(3-methyl-5-ureido-phenyl)propanoic acid
[0418]
[0419] To a solution of (2S)-3-(3-amino-5-methyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propionic acid (90 mg, 0.26 mmol) in acetic acid (2.1 mL) was added potassium cyanate (0.105 g, 1.29 mmol) in water (1.7 mL). The mixture was stirred at room temperature for 30 minutes and then concentrated. The reaction was acidified with HCl (1N aqueous solution) and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was passed through a silica gel pad, eluted with EtOH, and then purified by reverse phase HPLC (column: C18, 19×100 mm, 5 μm; mobile phase gradient: 20 to 40% ACN in 20 mM NH 4 HCO 3 aqueous solution, pH 9) to give the title compound as a white solid (62 mg, 59%). ES-MS m / z 392 (M+H).
[0420] Preparation 8
[0421] tert-Butyl (4-(cyanomethyl)-3,3-difluoro-pyrrolidine-1-carboxylate
[0422]
[0423] Methanesulfonyl chloride (8.7 mL, 110 mmol) was slowly added to a solution of tert-butyl 3,3-difluoro-4-(hydroxymethyl)pyrrolidine-1-carboxylate (prepared essentially as described in McAlpine, I. et al., J. Org. Chem. 2015, 80, 7266-7274; 13.6 g, 57.3 mmol) in TEA (16 mL, 115 mmol) at 0°C under a nitrogen atmosphere, and the mixture was stirred at 0°C for 1.5 hours. Water was added at 0°C, and the mixture was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was dissolved in DMF (260 mL) and potassium cyanide (14.5 g, 218 mmol) was added. The mixture was heated at 75°C under nitrogen for 3 days and then allowed to cool to room temperature. The mixture was then quenched with water and extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 10 to 40% acetone in hexanes to give the title compound (10.2 g, 54%). ES-MS (m / z): 191 (M+H-tert-butyl).
[0424] Preparation 9
[0425] 2-[1-tert-Butoxycarbonyl-4,4-difluoro-pyrrolidin-3-yl]acetic acid
[0426]
[0427] Potassium hydroxide (40% mass in water, 63.5 mL, 628 mmol) was added to a solution of tert-butyl (4-(cyanomethyl)-3,3-difluoro-pyrrolidine-1-carboxylate (10.3 g, 31.4 mmol) in MeOH (125 mL) and the resulting mixture was heated at reflux for 17 h. The reaction was cooled to room temperature, HCl (1 M in water) was added to bring the pH to 7, and then citric acid (5% in water) was added to bring the pH to 3. The mixture was extracted with DCM, washed with saturated aqueous NaCl solution, and the organic layer was passed through a phase separator cartridge. The eluate was concentrated to obtain the title compound (8.32 g, 90%). ES-MS (m / z): 264 (MH).
[0428] Preparation 10
[0429] 4-[2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester
[0430]
[0431] To a solution of 2-[1-tert-butoxycarbonyl-4,4-difluoro-pyrrolidin-3-yl]acetic acid (7.51 g, 28.3 mmol) in anhydrous THF (75 mL) at 0°C was added TEA (9.9 mL) followed by dropwise addition of pivaloyl chloride (4.58 mL, 36.8 mmol). The reaction was stirred at 0°C for 1 hour, a solution of lithium chloride (1.52 g, 35.5 mmol) in anhydrous THF (82.6 mL) was added dropwise, followed by a solution of (S)-4-benzyl-2-oxazolidinone (5.07 g, 28.3 mmol) in anhydrous THF (82.6 mL). The mixture was stirred at 0°C for 1.5 hours and then at room temperature for 20 hours. HCl (1 M, 70 mL) was added and the aqueous layer was extracted with EtOAc. The organic layer was separated and dried over anhydrous Na2SO4, then filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / hexanes to give the title compound (7.27 g, 61%). ES-MS m / z 369 (M+H-tert-butyl).
[0432] Preparation 11
[0433] 4-[(1S)-2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester
[0434]
[0435] To a solution of 4-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (7.44 g, 17.5 mmol) in anhydrous THF (37 mL) was added dropwise bis(trimethylsilyl)amide lithium (1 M) in toluene (21 mL) at -78 °C. The reaction was stirred at -78 °C for 2 hours, and a solution of 3-bromobenzyl bromide (4.92 g, 19.3 mmol) in anhydrous THF (14.9 mL) was added dropwise. The reaction was stirred at room temperature overnight, then saturated NH4Cl aqueous solution was added, and the aqueous layer was extracted with EtOAc. The organic layer was washed with saturated NaCl aqueous solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 10 to 40% EtOAc / hexanes to give the title compound (7.32 g, 70%). ES-MS m / z 537 / 539 (M+H-tert-butyl).
[0436] Preparation 12
[0437] (2S)-3-(3-bromophenyl)-2-(1-tert-butoxycarbonyl-4,4-difluoro-pyrrolidin-3-yl)propanoic acid - Isomer 1 and Isomer 2
[0438]
[0439] To a stirred solution of 4-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (7.32 g, 12.3 mmol) in THF (123 mL) was added hydrogen peroxide (35.5 mass % in water, 22.5 mL, 263 mmol) at 0°C, followed by lithium hydroxide solution (1 M in water, 18.5 mL, 18.5 mmol). The mixture was stirred at 0°C for 6.5 hours, then sodium bisulfite solution (15% in water) was added and the reaction was warmed to room temperature. The pH was adjusted to 12 by the addition of NaOH (5N aqueous solution), and the aqueous mixture was extracted with EtOAc. The organic layer was washed with saturated NaCl aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / hexanes + 1% acetic acid to give the title compound (3.58 g, 65.5%). ES-MS m / z 378 / 380 (M+H-tert-butyl) as a mixture of diastereomers.
[0440] A portion (3.44 g) of the diastereomeric mixture was separated using chiral SFC chromatography (column: Chiralcel OJ (25×2 cm, 5 μm) at 40° C.; flow rate: 80 mL / min; mobile phase: isocratic 7% (IPA+0.2% DMEA) in CO 2 ) to give Isomer 1 (first eluting isomer, 1.58 g, 46%,>98% de) and Isomer 2 (second eluting isomer, 1.93 g, 56%,>95% de). These two isomers—ES-MS m / z 378 / 380 (M+H-tert-butyl).
[0441] Preparation 13
[0442] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-[(3-fluoro-5-methoxy-phenyl)methylamino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0443]
[0444] To a solution of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 153 mg, 0.39 mmol) in DCM (4 mL) was added 3-fluoro-5-methoxy-benzaldehyde (0.091 g, 0.59 mmol) and sodium triacetoxyborohydride (0.17 g, 0.78 mmol). The reaction was stirred at room temperature for 1 hour, then saturated NaHCO3 aqueous solution was added, and the aqueous layer was extracted with DCM. The organic layer was washed with water, then with saturated NaCl aqueous solution, dried over MgSO4, filtered, and then evaporated under reduced pressure. The residue was purified by reverse phase HPLC [column: XBridge TM C18 (19×100 mm, 5 μm); mobile phase: solvent A=20 mM ammonium bicarbonate / water (pH 9), solvent B=ACN; flow rate: 25 mL / min] to obtain the title compound (155 mg, 75%). ES-MS m / z 529 (M+H).
[0445] These were prepared substantially as described in Preparation 13 using the appropriate aldehyde:
[0446]
[0447]
[0448] A. Use sodium cyanoborohydride as reducing agent and MeOH or MeOH / THF as solvent. Temperature is RT or 60-65°C
[0449] B. Silica gel chromatography using a gradient of EtOAc / hexanes
[0450] C. Gradient reverse phase chromatography using ACN / NH4CO3 aqueous solution (ACN in aqueous NH4CO3) (pH 9) (column: Claricep C-series)
[0451] Preparation 20
[0452] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-[(3-fluoro-5-methoxy-anilino)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0453]
[0454] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[(3-formylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 425mg, 1.05mmol) in DCM (10mL) was added 3-fluoro-5-methoxy-aniline (0.223g, 1.58mmol) and a drop of acetic acid. The reaction was stirred at room temperature for 1 hour, then sodium triacetoxyborohydride (0.456g, 2.11mmol) was added and stirring was continued for 1 hour. Saturated NaHCO3 aqueous solution was added, and the water layer was extracted with DCM. The organic layer was washed with water, then with saturated NaCl aqueous solution, then dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by reverse phase chromatography [column: Claricep C-series; mobile phase: gradient from 70 to 100% ACN / NH4CO3 aqueous solution (pH 9)] to give the title compound (433 mg, 78%). ES-MS m / z 417 [M+H-(2×tert-butyl)]
[0455] Prepare the following essentially as described in Preparation 20 using the appropriate amine:
[0456]
[0457]
[0458] A. Aldehyde + amine + catalytic toluenesulfonic acid were heated at reflux in toluene using a Dean Stark trap for 4 hours. The solvent was removed, the residue was redissolved in MeOH and sodium borohydride was added.
[0459] B.RP-HPLC / MS; Column XBridge TM C18 (10×100 mm, 5 μm); mobile phase: solvent A = 20 mM ammonium bicarbonate / water (pH 9); solvent B = ACN; flow rate: 25 mL / min
[0460] Preparation 23
[0461] (2S)-2-[(3R)-1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-[3-[(2-fluoro-3-methoxy-phenyl)carbamoylamino]phenyl]propanoic acid
[0462]
[0463] To a solution of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429, 200 mg, 0.50 mmol) in 1,4-dioxane (0.1 M, 5.021 mL) was added (2-fluoro-3-methoxy-phenyl)urea (0.277 g, 1.51 mmol), tBuXPhos-Pd-G3 (0.040 g, 0.050 mmol) and sodium tert-butoxide (0.149 g, 1.51 mmol). The mixture was heated at 100 °C under a nitrogen atmosphere for 4 hours, then diluted with NaOH (1N aqueous solution) and extracted with EtOAc. The organic layer was discarded and the aqueous layer was then acidified with HCl (1N aqueous solution) and extracted with EtOAc. The organic layer was dried over Na2SO4, then filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 50 to 100% EtOAc / hexanes to give the title compound (88 mg, 32%). ES-MS m / z 502 (M+H).
[0464] These are prepared substantially as described in Preparation 23 using the appropriate amine or urea:
[0465]
[0466]
[0467]
[0468] A. Using alternative reagents: tris(dibenzylideneacetone)dipalladium(0) (0.1 equiv), 2-(di-tert-butylphosphino)-2',4',6'-triisopropyl-3,6-dimethoxy-1,1'-biphenyl (0.15 equiv), tripotassium phosphate (1.5 equiv), and tert-butanol (0.1 M); heating the reaction to 120°C; starting with the ammonium salt of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid, which was prepared as follows: (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid in MTBE was treated with 2 equiv of ammonia (7 M in MeOH), stirred for 1 hour, filtered, washed with MTBE, and then dried in vacuo
[0469] B. Silica gel chromatography using a gradient of 5 to 20% acetone / hexanes + 1% acetic acid
[0470] C.RP-HPLC / MS[Column:XBridge TMC18 (10×100 mm, 5 μm); mobile phase: solvent A = 20 mM NH4HCO3 aqueous solution (pH 9); solvent B = ACN; flow rate: 25 mL / min]
[0471] Preparation 34
[0472] (3R)-3-[(1S)-1-[[3-[[2-(2-bromophenyl)acetyl]amino]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0473]
[0474] To a solution of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 1 g, 2.56 mmol) and TEA (1.04 g, 1.43 mL, 10.2 mmol) in DCM (12.8 mL) was slowly added 2-bromophenylacetyl chloride (0.671 g, 0.427 mL, 2.82 mmol). The mixture was stirred at room temperature for 3.5 hours, then more 2-bromophenylacetyl chloride (0.305 g, 0.194 mL, 1.28 mmol) was added and the mixture was stirred at room temperature for 2.5 hours. Saturated NaHCO3 aqueous solution was added, and the water layer was extracted with DCM. The organic layer was washed with saturated NaCl aqueous solution, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / hexanes to give the title compound (860 mg, 57%). ES-MS m / z 587 / 589 (M+H).
[0475] Preparation 35
[0476] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[[3-(3-hydroxypropionylamino)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0477]
[0478] HATU (0.298 g, 0.77 mmol) and 2,4,6-trimethylpyridine (0.047 g, 0.051 mL, 0.38 mmol) were added to a solution of 3-hydroxypropionic acid (0.127 g, 0.42 mmol) in DMF (4.3 mL). The mixture was stirred for 30 minutes and (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 150 mg, 0.38 mmol) was added. The reaction was stirred at room temperature for 18 hours, then the reaction was concentrated and the residue was purified by reverse phase chromatography using a gradient of 20 to 70% ACN / NH4CO3 aqueous solution (pH 9) (column: Claricep C-series). Secondary purification was performed by RP-HPLC / MS [column: XBridge TM C18 (19×100 mm, 5 μm); mobile phase: solvent A = 20 mM NH4HCO3 aqueous solution (pH 9); solvent B = ACN; flow rate: 25 mL / min] to obtain the title compound (33.6 mg, 19%). ES-MS m / z 463 (M+H).
[0479] Preparation 35 Prepare the following essentially as described in Preparation 35 using the appropriate carboxylic acid:
[0480]
[0481] A. Reverse phase flash chromatography with a gradient of 20 to 70% ACN / NH4CO3 aqueous solution (pH 9). Secondary purification by basic SFC [stationary phase: ethylpyridine; column size: 30×150 mm, 5 μm; mobile phase: 10 mM NH4CO3 / MeOH (NH4CO3 in MeOH) / CO2 (pH 8)]; flow rate: 100 mL / min]
[0482] Preparation 37
[0483] (3R)-tert-Butyl 3-[(1S)-2-tert-Butoxy-1-[[3-(3-hydroxypropylcarbamoylamino)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0484]
[0485] To a solution of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 200 mg, 0.49 mmol) in THF (5 mL) was added 1,1'-carbonyldiimidazole (0.164 g, 0.98 mmol). The mixture was stirred at room temperature for 18 hours, and then 3-amino-1-propanol (0.0569 mL, 0.0556 g, 0.74 mmol) was added. The mixture was stirred at 110 ° C for 1 hour, then diluted with DCM and concentrated to dryness. The residue was purified by silica gel chromatography using a gradient of 10 to 40% acetone / DCM (acetone in DCM) to give the title compound (176 mg, 73%). ES-MS m / z 492 (M+H).
[0486] Preparation 38
[0487] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(2,2,2-trifluoroethylsulfonylamino)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0488]
[0489] To a solution of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 130 mg, 0.33 mmol) in anhydrous DCM (3 mL) under a nitrogen atmosphere was added TEA (0.101 g, 0.139 mL, 1.00 mmol). The mixture was cooled to -78 ° C and 2,2,2-trifluoroethanesulfonyl chloride (0.0608 g, 0.33 mmol) was added. The mixture was warmed to room temperature and stirred for 18 hours. Saturated NaHCO3 aqueous solution was added, and the aqueous layer was extracted with DCM. The layers were separated and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 15 to 60% acetone / hexane to give the title compound (123 mg, 66%). ES-MS m / z 425 (M+H-(2×tert-butyl)).
[0490] Prepare the following essentially as described in Preparation 38 using the appropriate sulfonyl chloride:
[0491]
[0492]
[0493] A. Add 4-dimethylaminopyridine (0.1 equivalent)
[0494] B. Reverse phase chromatography using a gradient of ACN / NH4CO3 aqueous solution (pH 9) (column: Claricep C-series)
[0495] Preparation 41
[0496] (3R)-3-[(1S)-1-[(3-Benzylsulfanylphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0497]
[0498] Nitrogen was bubbled through a suspension of tert-butyl (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429, 7.8 g, 17.2 mmol) in toluene (10 mL). Tris(dibenzylideneacetone)dipalladium(0) (1.59 g, 1.72 mmol), 1,1'-bis(diphenylphosphino)ferrocene (1.99 g, 3.45 mmol), N,N-diisopropylethylamine (3.31 mL, 2.45 g, 19.0 mmol) and benzyl mercaptan (2.06 mL, 2.18 mL, 17.4 mmol) were added to the suspension and the mixture was stirred at 100 °C for 16 hours. EtOAc was added and the mixture was filtered. Water was added to the filtrate, and the aqueous layer was extracted with EtOAc. The organic layer was separated, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography using a gradient of 5 to 20% EtOAc / hexane to give the title compound (6.89 g, 80%). ES-MS m / z 398 (M+H-Boc).
[0499] Preparation 42
[0500] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0501]
[0502] To a 0°C solution of (3R)-3-[(1S)-1-[(3-benzylsulfanylphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (1500 mg, 3.01 mmol) in ACN:acetic acid:water 40:1.5:1 (30 mL) was slowly added 1,3-dichloro-5,5-dimethylhydantoin (1.76 g, 6.03 mmol) in portions. The mixture was stirred at 0°C for 20 minutes and then concentrated in vacuo. The residue was dissolved in DCM, cooled to 0°C and NaHCO3 (5% aqueous solution) was added. The mixture was stirred for 5 minutes and the organic layer was separated. The organics were dried over MgSO4 and concentrated in vacuo to give the title compound which was used immediately in the next step without purification. ES-MS m / z 364 (M+H-Boc).
[0503] Preparation 43
[0504] (3R)-3-[(1S)-2-tert-Butyl-1-[[3-[[(3-chlorophenyl)methyl]sulfamoyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0505]
[0506] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.446 g, 0.60 mmol, 64 mass %) in DCM (3 mL) was added TEA (0.122 g, 0.168 mL, 1.21 mmol) and 3-chlorobenzylamine (0.102 g, 0.0888 mL, 0.72 mmol). The reaction was stirred at room temperature for 16 hours, then HCl (1N aqueous solution) was added and the aqueous layer was extracted with DCM. The organic layer was separated and dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by RP-HPLC / MS [column: XBridge TM C18 (10×100 mm, 5 μm); mobile phase: solvent A = 20 mM NH4HCO3 aqueous solution (pH 9); solvent B = ACN; flow rate: 25 mL / min] to obtain the title compound (156 mg, 45%). ES-MS m / z 479 (M+H-Boc).
[0507] Prepare the following essentially as described in Preparation 43 using the appropriate amine:
[0508]
[0509] Preparation 47
[0510] (3R)-tert-Butyl 3-[2-methoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0511]
[0512] To a solution of (3R)-3-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 6 g, 24.7 mmol) in THF (170 mL) was added potassium bis(trimethylsilyl)amide (0.5 M in toluene, 60 mL, 30 mmol) at -78 ° C under nitrogen. The mixture was stirred at -78 ° C for 45 minutes, and then a solution of 1-(bromomethyl)-3-nitrobenzene (5.9 g, 27 mmol) in THF (25 mL) was added. The mixture was warmed to room temperature and stirred for 1.75 hours, then quenched with saturated NH4Cl and extracted with MTBE. The combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 7 to 30% acetone / hexane to give the title compound (3.4 g, 36%) as a yellow oil. ES-MS m / z 279 (M-Boc+H).
[0513] Preparation 48
[0514] (3R)-tert-Butyl 3-[1-[(3-aminophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[0515]
[0516] A mixture of (3R)-tert-butyl 3-[2-methoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (3.4 g, 9.0 mmol) and palladium (10% on activated carbon, 340 mg, 0.32 mmol) in MeOH (45 mL) was stirred at room temperature under a hydrogen balloon for 4 hours. The reaction mixture was washed with water and then quenched with water. The mixture was filtered through a pad of Celite®, and the filtrate was concentrated to dryness to give the title compound as a colorless oil (2.9 g, 93%). ES-MS m / z 249 (M-Boc+H).
[0517] Preparation 49
[0518] (3R)-tert-butyl 3-[2-methoxy-2-oxo-1-[[3-(prop-2-ynylamino)phenyl]methyl]ethyl]pyrrolidine-1-carboxylate
[0519]
[0520] (3R)-3-[1-[(3-aminophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (710mg, 2.04mmol) was dissolved in DMF (7mL), and K2CO3 (0.285g, 2.04mmol) and 3-bromoprop-1-yne (80% by mass in toluene, 0.242mL, 0.333g, 2.24mmol) were added. The mixture was stirred at room temperature overnight. Water was added and the aqueous layer was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 10 to 40% EtOAc / hexane to give the title compound (0.252g, 31%) as a colorless oil. ES-MS m / z 287 (M-Boc+H).
[0521] Preparation 50
[0522] 2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(prop-2-ynylamino)phenyl]propanoic acid
[0523]
[0524] To a solution of (3R)-tert-butyl 3-[2-methoxy-2-oxo-1-[[3-(prop-2-ynylamino)phenyl]methyl]ethyl]pyrrolidine-1-carboxylate (252 mg, 0.65 mmol) in MeOH (4 mL) and THF (8 mL) was added NaOH (2M in water, 2 mL, 4 mmol). The mixture was stirred at room temperature overnight, then HCl (1N in water) was added until the solution pH = 4. The aqueous layer was extracted three times with EtOAc, and the combined organics were dried over Na2SO4, filtered and concentrated. The residue was loaded onto an HLB column and eluted first with water, then with 1:1 water:ACN, then with ACN. The appropriate fractions were concentrated and the resulting solid was dried in vacuo at 40°C to give the title compound (237 mg, 98%) as a brown solid, which was a mixture of diastereomers. ES-MS m / z 273 (M-Boc+H).
[0525] Preparation 51
[0526] Tert-butyl (3R)-3-[(1S)-2-tert-butoxy-1-[[3-(2-tert-butoxy-2-oxoethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0527]
[0528] To a 2-necked round-bottom flask with a reflux condenser was added: bis(dibenzylideneacetone)palladium (15.8 mg, 0.028 mmol) and 1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphino)ferrocene (39.5 mg, 0.055 mmol) and the flask was purged with nitrogen. Then a solution of (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 250 mg, 0.55 mmol) in THF (3 mL) was added, followed by (2-tert-butoxy-2-oxoethyl)(chloro)zinc (0.5 M in Et2O, 3 mL, 1.38 mmol). The reaction was heated under gentle reflux for 1.5 hours and once cooled, saturated aqueous NH4Cl solution was added and the mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 5 to 20% EtOAc / hexanes to give the title compound (212 mg, 79%) as a colorless oil. ES-MS m / z 390 (M-Boc+H).
[0529] Preparation 52
[0530] (3S)-3-[2-[(4R)-4-Benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0531]
[0532] The title compound was prepared using (S)-N-BOC-3-pyrrolidineacetic acid and (R)-4-benzyl-2-oxazolidinone essentially as described in Preparation 10. The crude product was purified by silica gel chromatography using a gradient of 10 to 50% EtOAc / hexanes to give the title compound as a light yellow oil. ES / MS (m / z): 333 (M+H-tert-butyl).
[0533] Preparation 53
[0534] (3R,7aS)-3-phenyl-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]oxazol-5-one
[0535]
[0536] A mixture of (5S)-5-(hydroxymethyl)pyrrolidin-2-one (20.0 g, 174 mmol), benzaldehyde (1.3 eq., 226 mmol), p-toluenesulfonic acid (0.01 eq., 1.74 mmol) and toluene (200 mL) was heated at reflux for 2 days in a round bottom flask equipped with a Dean-Stark trap. The reaction was cooled to room temperature and washed with saturated aqueous NaHCO3, saturated aqueous NaCl, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 70% EtOAc / hexanes to give the title compound (29.0 g, 82%) as a light yellow oil. 1 HNMR(399.80MHz, CDCl3)δ7.48-7.45(m,2H),7.40-7.35(m,3H),6.35(s,1H),4.24(dd,J=6.3,8.0Hz,1H),4.19-4.12(m, 1H), 3.50 (t, J=8.0Hz, 1H), 2.87-2.78 (m, 1H), 2.56 (ddd, J=17.3, 10.0, 3.8Hz, 1H), 2.43-2.37 (m, 1H), 2.00-1.93 (m, 1H).
[0537] Preparation 54
[0538] tert-Butyl 2-[(3R,6R,7aS)-5-oxo-3-phenyl-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]oxazol-6-yl]acetate
[0539]
[0540] Diisopropylamine (1.7 equivalents, 243 mmol) was slowly added to a solution of n-butyl lithium (2.5 M in hexane, 86 mL, 214 mmol) at 0 ° C under nitrogen. After the addition was complete, the red slurry was stirred for 15 minutes and then slowly diluted with THF (200 mL). The resulting orange solution was cooled to -76 ° C, and then a solution of (3R, 7aS)-3-phenyl-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]oxazol-5-one (29.0 g, 143 mmol) in THF (200 mL) was added dropwise at a rate such that the internal temperature did not rise above -68 ° C. The resulting brown solution was stirred for 45 minutes. A solution of tert-butyl bromoacetate (64.1 mL, 85.2 g, 428 mmol) in THF (100 mL) was added dropwise to keep the internal temperature below -72 ° C. After the addition was complete, the mixture was stirred at -78 ° C for 2 hours. Saturated NaHCO3 aqueous solution was added, and the reaction was diluted with Et2O. The mixture was slowly warmed to room temperature overnight. The separation layer was then washed with saturated NaHCO3 aqueous solution, saturated NaCl aqueous solution, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 70% EtOAc / hexane to obtain the title compound (40.7 g, 90%) as a yellow oil. 1 HNMR(399.80MHz, CDCl3)δ7.48-7.45(m,2H),7.40-7.36(m,3H),6.34(s,1H),4.26(dd,J=6.3,8.1Hz,1H),4.18-4.11(m,1H),3.63-3.59( m,1H),3.33-3.27(m,1H),2.84(dd,J=4.4,16.7Hz,1H),2.73-2.66(m,1H),2.41(dd,J=8.7,16.7Hz,1H),1.74-1.65(m,1H),1.48(s,9H).
[0541] Preparation 55
[0542] tert-Butyl (2S,4R)-2-(Hydroxymethyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate
[0543]
[0544] A solution of tert-butyl 2-[(3R,6R,7aS)-5-oxo-3-phenyl-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-c]oxazol-6-yl]acetate (11.30 g, 35.60 mmol) in anhydrous THF (200 mL) was cooled to 0°C under nitrogen, and then borane-tetrahydrofuran complex (1 M in THF, 71 mL, 71 mmol) was added. The resulting mixture was heated to reflux for 3 hours and then concentrated under reduced pressure. The residue was slowly and carefully dissolved in MeOH (50 mL) to cause gas evolution. After the reaction stopped generating gas, HCl (4 M solution in 1,4-dioxane, 50 mL, 200 mmol) was added to cause more gas evolution. The resulting mixture was heated to reflux for 2 hours, then cooled to ambient temperature and concentrated under reduced pressure. The residue was dissolved in EtOAc and washed twice with saturated aqueous NaHCO 3 solution and then with saturated aqueous NaCl solution, then dried over MgSO 4 , filtered and concentrated to give methyl 2-[(3R,5S)-1-benzyl-5-(hydroxymethyl)pyrrolidin-3-yl]acetate (8.78 g, 36.7 mmol).
[0545] The product was suspended in anhydrous THF (300 mL) under nitrogen, then tert-butyl carbonate (8.01 g, 36.7 mmol) and palladium on carbon (5% by weight, 4.0 g) were added, the reaction vessel was purged with hydrogen (1 ATM) and stirred overnight. The flask was purged with nitrogen, then filtered through a diatomaceous earth pad and washed with THF. The filtrate was concentrated and the residue was purified by silica gel chromatography using a gradient of 0 to 80% EtOAc / hexane to obtain the title compound (5.90 g, 65%) as a colorless oil. 1 HNMR(399.80MHz, CDCl3)δ4.00-3.94(m,1H),3.89-3.81(m,1H),3.71(m,4H),3.59(dd,J=7 .2,11.6Hz,1H),2.88(t,J=10.5Hz,1H),2.48-2.39(m,3H),2.31-2.24(m,1H),1.49(s,9H).
[0546] Preparation 56
[0547] (2R,4R)-4-[2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester
[0548]
[0549] To a mixture of imidazole (2.94 g, 43.2 mmol) and triphenylphosphine (8.49 g, 32.4 mmol) in anhydrous THF (100 mL) was added iodine (8.22 g, 32.4 mmol) dropwise as a solution in THF (50 mL) under nitrogen at 0°C. The resulting mixture was stirred for 1 hour, and then a solution of (2S, 4R)-tert-butyl 2-(hydroxymethyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate (5.90 g, 21.6 mmol) in THF (100 mL) was added dropwise. The cooling bath was slowly warmed up, and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with ether and washed with 10% aqueous sodium thiosulfate solution, saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 100% MTBE / hexanes to give tert-butyl (2S,4R)-2-(iodomethyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate (7.30 g, 88%).
[0550] The product is suspended in a mixture of TEA (3.19mL, 2.31g, 22.9mmol) in anhydrous THF (300mL) with palladium carbon (5 mass%, 4.0g) under nitrogen. The reaction vessel is purged with hydrogen (1ATM) and stirred overnight. Additional Pd-C (200mg) is loaded into the reaction and stirred for 24 hours. The reaction vessel is purged with nitrogen, and the reaction mixture is filtered through a diatomaceous earth pad and washed with THF. The filtrate is concentrated, the residue is dissolved in ether, and washed with water, 10% citric acid aqueous solution and saturated NaCl aqueous solution. Organic matter is dried over MgSO4, filtered and concentrated to obtain (2R, 4R) -4- (2- methoxy -2- oxoethyl) -2- methyl - pyrrolidine -1- carboxylic acid tert-butyl ester (5.36g, quantitative yield).
[0551] A mixture of the product in THF (30 mL), water (30 mL), lithium hydroxide (0.748 g, 31.2 mmol) was stirred for 2 hours, then the reaction mixture was acidified with citric acid to pH = 3-4, and the mixture was extracted with ether. The combined organics were dried over MgSO4, filtered and concentrated to give 2-[(3R,5R)-1-tert-butoxycarbonyl-5-methyl-pyrrolidin-3-yl]acetic acid.
[0552] The resulting product was cooled to 0 ° C in anhydrous THF (150 mL) under nitrogen. TEA (3.16 g, 4.35 mL, 31.2 mmol) was added, and pivaloyl chloride (3.14 g, 3.18 mL, 26.0 mmol) was added dropwise over 30 minutes after 5 minutes. The resulting slurry was warmed to room temperature and stirred for 1 hour. The reaction mixture was cooled to 0 ° C, and then a solution of LiCl (5.29 g, 125 mmol) in a minimum amount of THF was added dropwise, followed by addition of (S)-4-benzyl-2-oxazolidinone (4.16 g, 26.0 mmol). The reaction was warmed to room temperature overnight and then diluted with ether. The organic matter was washed with water, saturated NaHCO3 aqueous solution and saturated NaCl aqueous solution, then filtered and concentrated through Na2SO4. The residue was purified by silica gel chromatography using a gradient of 0 to 100% MTBE to obtain the title compound (6.80 g, 81%) as a yellow oil. 1 HNMR(399.80MHz, CDCl3)δ7.39-7.31(m,3H),7.23-7.21(m,2H),4.70(ddd,J=13.0,7.2,3.4Hz,1H),4.27-4.19(m,2H),4.03-4.01(m,2H),3. 31(dd,J=3.3,13.4Hz,1H),3.11-2.96(m,3H),2.83-2.77(m,1H),2.60 -2.53(m,1H),2.48-2.37(m,1H),1.49-1.48(m,9H),1.33-1.24(m,3H).
[0553] Prepare the following essentially as described in Preparation 11 using appropriate starting materials:
[0554]
[0555]
[0556] A. The product was used without purification
[0557] B. Starting material ((3R)-3-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester) was prepared essentially as described in WO 2020 / 247429
[0558] C. The reaction was stirred at 0°C for 20 minutes before the bromide was added. The following were prepared essentially as described in Preparation 12 using appropriate starting materials:
[0559]
[0560]
[0561] A. After reaction completion and aqueous work-up, the crude product was dissolved in MTBE and ammonia (7M in MeOH, 2 eq.) was added, stirred for 1 h, and the resulting solid was filtered, washed with MTBE, and dried in vacuo.
[0562] B. No chiral separation
[0563] Preparation 69
[0564] (3S)-3-[(1R)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0565]
[0566] (2R)-3-(3-bromophenyl)-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 0.530 g, 1.28 mmol) was converted to its free carboxylic acid by acidification with KHSO4 (1N) and extraction with DCM. The organics were evaporated and the residue was dissolved in 2-methyltetrahydrofuran (4 mL). 2-tert-butyl-1,3-diisopropylisourea (1.0 mL, 0.902 g, 3.83 mmol, 85 mass %) was added, and the reaction mixture was heated and stirred at 65 ° C for 4 hours. The reaction was cooled to room temperature, the suspended solid was filtered and discarded, and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography using a gradient of 10 to 40% EtOAc / hexane to give 0.464 g (80%) of the title compound as a colorless oil. ES / MS m / z 476,478 (M+Na).
[0567] Prepare the following essentially as described in Preparation 69 using the appropriate acid:
[0568]
[0569] A. The starting material is used as the free acid and no neutralization step is required
[0570] B. Purify by silica gel chromatography, eluting with acetone:hexanes
[0571] C. Using Isomer 2 of the Starting Material
[0572] Preparation 74
[0573] 4-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 1 and isomer 2)
[0574]
[0575] A mixture of (2S)-3-(3-bromophenyl)-2-(1-tert-butoxycarbonyl-4,4-difluoro-pyrrolidin-3-yl)propanoic acid (1.09 g, 2.31 mmol) and 2-tert-butyl-1,3-diisopropylisourea (1.6 mL, 6.9 mmol) in 2-methyltetrahydrofuran (24 mL) was heated at 60°C for 30 minutes. After 1 hour, more 2-tert-butyl-1,3-diisopropylisourea (0.8 mL, 3 mmol) was added and the mixture was heated at 60°C for 1 hour. The reaction was cooled to room temperature. The white solid was filtered and washed with MTBE. The filtrate was evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 0 to 60% MTBE / hexanes to give Isomer 1 (280 mg, 25%, first eluting isomer) and Isomer 2 (367 mg, 32%, second eluting isomer) as colorless oils. Isomer 1 and Isomer 2: ES / MS m / z 378, 380 (M-2×tBu+H).
[0576] Preparation 75
[0577] (3S)-3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-1-hydroxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 1 and isomer 2)
[0578]
[0579] Diisopropylamine (4.4 mL, 31.5 mmol) was added to the reaction vessel, cooled on an ice bath (0 ° C) under an inert atmosphere, and then n-butyl lithium (2.5 M hexane solution, 12 mL, 29 mmol) was added to form a white slurry after a few minutes. Anhydrous THF (50 mL) was added to the mixture and the reaction was cooled to -78 ° C. (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl] tert-butyl pyrrolidine-1-carboxylate (prepared essentially as described in WO2020 / 247429, 5.50 g, 12.1 mmol) was added as a solution in THF (50 mL), and the mixture was stirred at -78 ° C for 2 hours. A solution of 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (5.87 g, 21.8 mmol) in THF (50 mL) was added at -78 ° C, and the reaction mixture was warmed to room temperature and stirred for 18 hours. The reaction mixture was poured into ice containing citric acid and extracted with DCM (2×100 mL). The organic extracts were combined, dried over MgSO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 40% EtOAc / hexane to obtain the title compound (2.92 g) as a mixture of diastereomers. ES / MS (m / z): 358 / 360 (M+H-2x tert-butyl).
[0580] The diastereomeric mixture was separated by chiral HPLC [column: Lux Amylose-15×25 cm; mobile phase: 85:15 CO2:IPA; the mixture was dissolved in IPA @ 50 mg / mL, 350 mg was injected every 6 minutes] to give isomer 1 (1.136 g, 20%) and isomer 2 (0.956 g, 17%).
[0581] Preparation 76
[0582] (3S)-3-[1-Bromo-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0583]
[0584] To a solution of (3R)-3-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 2 g, 8.2 mmol) in THF (16 mL) was added lithium bis(trimethylsilyl)amide (1.0 M in hexane, 9.9 mL, 9.9 mmol) at -78 ° C under N2 atmosphere. The mixture was stirred at -78 ° C for 30 minutes, and then chlorotrimethylsilane (1.57 mL, 1.34 g, 12.3 mmol) was added. The mixture was stirred at -78 ° C for 30 minutes. A solution of N-bromosuccinimide (1.81 g, 9.86 mmol) in THF (22 mL) was then added at -78 ° C. The reaction was stirred at room temperature overnight, and then saturated NH4Cl aqueous solution was added. The mixture was extracted with EtOAc, and the combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / hexanes to give the title compound (mixture of diastereomers) as a yellow oil. ES / MS m / z 266, 268 (M-tBu+H).
[0585] Preparation 77
[0586] (3S)-tert-Butyl 3-[1-(3-bromophenyl)sulfanyl-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[0587]
[0588] To sodium methoxide (0.5M MeOH solution, 20mL, 8.75mmol) was added a solution of 3-bromothiophenol (0.956mL, 1.65g, 8.75mmol) in THF (3mL), and the mixture was heated at 80°C for 1 hour. A solution of (3S)-3-[1-bromo-2-methoxy-2-oxoethyl] pyrrolidine-1-carboxylic acid tert-butyl ester (1.88g, 5.83mmol) in THF (6mL) was added, and the mixture was heated at 80°C for 30 minutes. Water was added to the reaction mixture and extracted with EtOAc. The combined organic phase was washed with saturated NaCl aqueous solution, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 50 to 100% MTBE / hexane to obtain the title compound (2.2g, 88%, a mixture of diastereomers) as a light yellow oil. ES / MS m / z 374,376 (M-tBu+H).
[0589] Preparation 78
[0590] 2-(3-Bromophenyl)sulfanyl-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]acetic acid
[0591]
[0592] A mixture of (3S)-tert-butyl 3-[1-(3-bromophenyl)sulfanyl-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (2.2 g, 5.1 mmol) and NaOH (5N aqueous solution, 15 mL, 77 mmol) in MeOH (25 mL) and THF (25 mL) was stirred at room temperature for 2.5 hours. The organic solvent was evaporated to dryness, and 1N aqueous HCl solution was added to the residue to make the mixture pH = 2-3. The mixture was extracted with EtOAc, and the combined organic phases were then washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated to give the title compound (1.84 g, 86%) as a white solid (mixture of diastereomers). ES / MS m / z 360, 362 (M-tBu+H).
[0593] Preparation 79
[0594] (3S)-3-[1-(3-Bromophenyl)sulfanyl-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0595]
[0596] A mixture of 2-(3-bromophenyl)sulfanyl-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]acetic acid (1.84 g, 4.42 mmol) and 2-tert-butyl-1,3-diisopropylisourea (4.6 mL, 4.07 g, 19.9 mmol) in 2-methyltetrahydrofuran (44 mL) was heated at 55 °C for 3 hours. The white solid was filtered and discarded, and the filtrate was evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 0 to 50% MTBE / hexane to give the title compound (2 g, 96%, mixture of diastereomers) as a colorless oil. ES / MS m / z 494,496 (M+Na).
[0597] Preparation 80
[0598] 3-(3-Bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-2-methyl-propionic acid (Isomer 1 and Isomer 2)
[0599]
[0600] To a solution of (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 8.4 g, 20 mmol) in THF (100 mL) was added bis(trimethylsilyl)lithium amide (1M THF solution, 41 mmol, 41 mL) under N2 and at -78 °C. The reaction was stirred at -78 °C for 2 hours, then iodomethane (58 g, 25 mL, 410 mmol) was added and the reaction was warmed to room temperature. The mixture was stirred overnight, then saturated NH4Cl aqueous solution was added and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl and dried over MgSO 4 , filtered and concentrated to give tert-butyl (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate (9.2 g, 98%) as a brown oil.
[0601] Tert-butyl (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate (9.2 g, 20 mmol) was dissolved in MeOH (80 mL) and THF (80 mL), then sodium hydroxide (5 M aqueous solution, 81 mL, 410 mmol) was added and the resulting mixture was heated at 60° C. for 3 days. The mixture was cooled to room temperature, then HCl (1 N aqueous solution) was added until pH = 2-3. The aqueous layer was extracted with EtOAc, and the organic layer was dried over MgSO 4 , filtered and concentrated. The residue was purified by chiral SFC [column: Chiralpak AD 25×3 cm, 5 μm; mobile phase: solvent A—CO2, solvent B—MeOH+0.2% DMEA; gradient: isocratic 80 / 20 A / B; flow rate: 120 mL / min] to obtain isomer 1 (first eluting isomer, 1.7 g, 27%,>98% de) as a white solid and isomer 2 (second eluting isomer, 3.4 g, 41%,>98% de) as a white solid. Both isomers: ES / MS (m / z): 356, 358 (M+H-tert-butyl).
[0602] Preparation 81
[0603] (2R,4R)-4-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester
[0604]
[0605] To a solution of (2S)-2-[(3R,5R)-1-tert-butoxycarbonyl-5-methyl-pyrrolidin-3-yl]-3-(3-nitrophenyl)propanoic acid (3.78 g, 9.99 mmol) in toluene (100 mL) was added N,N-dimethylformamide di-tert-butyl acetal (90 mass%, 26.7 mL, 22.6 g, 99.9 mmol) at 80° C. and the reaction was heated overnight at 80° C. The reaction mixture was concentrated in vacuo and the residue was purified by silica gel chromatography using 40% EtOAc / hexanes to give (2R,4R)-4-[(1S)-2-tert-butoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester (2.8 g, 60%) as a yellow oil.
[0606] The oil was dissolved in THF (70 mL) and palladium on carbon (5 mass %, 2.9 g) was added under nitrogen. The reaction vessel was purged with hydrogen and stirred under 1 ATM hydrogen for 6 hours. The resulting slurry was purified by The mixture was filtered through a pad of celite and washed with THF. The filtrate was concentrated to give a yellow oil, which was redissolved in THF (70 mL), slurried with palladium carbon (5 mass %, 2.9 g), and stirred under 1 ATM hydrogen for 24 hours. The reaction mixture was filtered through a celite pad and washed with THF. The filtrate was concentrated to give the title compound (2.2 g, 84%) as a dark yellow oil containing a small amount of diastereoisomer impurities. ES / MS m / z 403 (MH).
[0607] A portion of the product (1 g) was further purified by chiral SFC [column: Chiralpak AD-H2 1×150 mm; mobile phase: 20% IPA in CO2; flow rate: 80 mL / min; column temperature: 40°C] to give the title compound (691 mg, third eluting isomer, 96.7% de)
[0608] Preparation 82
[0609] Tert-butyl (3S)-3-[(1R)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine
[0610]
[0611] A mixture of (3S)-3-[(1R)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.464 g, 1.02 mmol), copper(II) acetylacetonate (0.027 g, 0.102 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione (0.087 mL, 0.408 mmol), Cs2CO3 (0.665 g, 2.04 mmol), DMA (2 mL) and ammonium hydroxide (28% by mass in water, 0.816 mL, 6 mmol) was heated to 110°C overnight and then cooled to room temperature. MTBE was added and the mixture was washed with water. The organics were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 20 to 80% EtOAc / hexanes to give the title compound (0.271 g, 68%). ES / MS (m / z): 291 (M+H-BOC).
[0612] The following were prepared as described in Preparation 82 using the appropriate aryl bromide base:
[0613]
[0614]
[0615] A. Reagents used - copper (I) oxide (1 equivalent), sodium azide (2 equivalents), L-proline (1.3 equivalents) in DMSO (0.2M, 9.6 mL); reaction temperature -100°C
[0616] B. Upon completion, the reaction mixture was absorbed onto silica gel and purified without aqueous workup.
[0617] C. Purification by silica gel chromatography eluting with a mixture of MTBE and hexane
[0618] D. The diastereomers were separated by chiral SFC [column: Chiralcel OD 25×2 cm, 5 μm; mobile phase: CO2-solvent A), MeOH+0.5% DMEA-solvent B; isocratic 85:15 solvent A:solvent B; flow rate: 80 mL / min; column temperature: 40°C], Isomer 1 was the first eluting isomer, and Isomer 2 was the second eluting isomer.
[0619] E. Prepared from isomer 1 of the starting aryl bromide.
[0620] Preparation 88
[0621] 4-[1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (isomers 1, 2, 3 and 4)
[0622]
[0623] To a mixture of 4-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 1, 280 mg, 0.5710 mmol), bis(2,4-pentanedione)copper(II) (15 mg, 0.057 mmol), 2,2,6,6-tetramethyl-3,5-heptanedione (50 μL, 0.24 mmol), Cs2CO3 (372 mg, 1.14 mmol) and DMA (1.2 mL, 13 mmol) was added NH4OH (28% by mass in water, 1.12 mL, 6 mmol) and gas evolution was immediately observed. The reaction was sealed and heated at 110 °C overnight. The mixture was quenched with water and extracted with EtOAc. The combined organic phase was washed with saturated aqueous NaCl solution, dried over anhydrous MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 70 to 90% MTBE / hexanes to give two diastereomeric products, probably resulting from epimerization during the reaction: first eluting isomer - Isomer 1 (100 mg, 41%), colorless oil; second eluting isomer - Isomer 2 (34 mg, 11%), colorless oil. Isomer 1 and Isomer 2: ES / MS m / z 449 (M+Na).
[0624] This procedure was repeated essentially as described above on the same scale for tert-butyl 4-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]-3,3-difluoro-pyrrolidine-1-carboxylate (Isomer 2) to purify the diastereomeric products by silica gel chromatography using 80% MTBE / hexanes to give: first eluting isomer - Isomer 3 (77 mg, 28%), colorless oil; second eluting isomer - Isomer 4 (93 mg, 36%), colorless oil. Isomer 3 and Isomer 4: ES / MS m / z 449 (M+Na).
[0625] Preparation 89
[0626] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-(3-cyanophenyl)propanoic acid
[0627]
[0628] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429; 600 mg, 1.506 mmol), potassium ferrocyanide trihydrate (277 mg, 0.753 mmol, 0.5 equiv), methanesulfonic acid [(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] palladium(II) (tBuXPhos Pd G3, 24 mg, 0.030 mmol) and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl was evacuated and backfilled with nitrogen in a sealed reaction vessel, and this process was repeated three times. To the vessel was then added a solution of 1,4-dioxane (2.5 mL) and potassium acetate (20 mg, 0.188 mmol) in degassed water (2.5 mL) via a syringe. The mixture was heated to 100 ° C. for 1 hour in a microwave. The reaction was filtered and concentrated in vacuo, and the residue was subjected to silica gel flash chromatography using a gradient of 50 to 100% EtOAc / hexanes to give the title compound (235 mg, 45%) as a colorless oil. ES / MS (m / z): 343 (MH).
[0629] Preparation 90
[0630] (2S)-3-[3-(Aminomethyl)phenyl]-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0631]
[0632] Palladium (10% on carbon, 680 mg, 0.638 mmol) was added to a solution of (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-cyanophenyl)propionic acid (220 mg, 0.638 mmol) in acetic acid (10 mL) in a pressure vessel. The mixture was purged with hydrogen and stirred at room temperature under 551.7 KPa hydrogen for 2 days. The mixture was filtered through diatomaceous earth and rinsed with MeOH. The filtrate was collected and the solvent was evaporated under reduced pressure. The residue was purified by strong cation exchange (SCX) purification eluted with ammonia (2 M in MeOH) to give the title compound (123 mg, 39%) with a purity of 70% and used without further purification. ES / MS (m / z): 349 (M+H).
[0633] Preparation 91
[0634] (3S)-3-[2-methoxy-1-(3-nitrophenoxy)-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0635]
[0636] Diisopropylamine (1.4 mL, 9.9 mmol, 1.2 eq) was added to the reaction vessel, cooled on an ice bath (0 ° C) under an inert atmosphere, and n-butyl lithium (2.5 M hexane solution, 3.9 mL, 9.9 mmol) was slowly added. A white slurry was formed after a few minutes. The slurry was diluted with anhydrous THF (20 mL). The solution was cooled to -78 ° C, (3R)-3-(2-methoxy-2-oxoethyl) pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 2.0 g, 8.2 mmol, 1 eq) was added in THF (20 mL), and the mixture was stirred at -78 ° C for 40 minutes. Chlorotrimethylsilane (1.1 mL, 8.6 mmol) was added at -78 ° C and the reaction was stirred for 20 minutes. Solid N-bromosuccinimide (1.60 g, 8.6 mmol) was then added. The cooling bath was warmed to room temperature over 18 hours, and then the reaction was diluted with EtOAc and washed with sodium thiosulfate (10% aqueous solution). The organic phase was dried over MgSO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / hexane to obtain a bromide intermediate [(3S)-3-(1-bromo-2-methoxy-2-oxoethyl) pyrrolidine-1-carboxylic acid tert-butyl ester] as a yellow oil. The bromide intermediate (1.84g, 5.71mmol) was dissolved in acetone (50mL), and potassium carbonate (4.74g, 34.3mmol) and 3-nitrophenol (3.76mL, 34.0mmol) were added. The reaction mixture was stirred for 18 hours under an inert atmosphere, then diluted with EtOAc and washed with water and a saturated NaCl aqueous solution. The organic phase was dried over MgSO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography eluting with 0 to 50% EtOAc / hexanes to give the title compound as a mixture of diastereomers (300 mg, 14%). ES / MS (m / z): 325 (M+H-tert-butyl).
[0637] Preparation 92
[0638] (3S)-3-[2-tert-butoxy-1-(3-nitrophenoxy)-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 1 and isomer 2)
[0639]
[0640] Sodium hydroxide (5N aqueous solution, 8mL, 40mmol) was added to a solution of (3S)-3-[2-methoxy-1-(3-nitrophenoxy)-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (1.24g, 3.27mmol) in MeOH (50mL) and stirred for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was diluted with DCM (100mL) and citric acid (10% aqueous solution, 50mL). The organic phase was collected, extracted with DCM (100mL), and the combined organic extracts were concentrated under reduced pressure. Toluene (20mL) was added to the residue and the mixture was heated to 75°C. N,N-dimethylformamide di-tert-butyl acetal (10mL, 41mmol) was added over 30 minutes and the reaction was stirred at 75°C for 4 hours. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / hexanes to give the title compound as a mixture of diastereomers (1.05 g). ES / MS (m / z): 311 (M+H-2xtert-butyl).
[0641] The mixture of diastereomers was purified by chiral HPLC [column: Lux Cellulose-45×25 cm; mobile phase: 85:15 CO2 / IPA; 1.05 g dissolved in IPA to give a 50 mg / mL solution, 50 mg injected every 1.9 minutes] to give Isomer 1 (first eluting isomer, 376 mg, 27%, >99% de) and Isomer 2 (second eluting isomer, 487 mg, 35%, >99% de)
[0642] Preparation 93
[0643] (3S)-3-[1-(3-aminophenoxy)-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 2)
[0644]
[0645] To a mixture of (3S)-tert-butyl 3-[2-tert-butoxy-1-(3-nitrophenoxy)-2-oxoethyl]pyrrolidine-1-carboxylate (Isomer 2, 486 mg, 1.15 mmol) in EtOH (20 mL) was added Pd (5 mass % on carbon, 250 mg, 0.117 mmol). The slurry was stirred under hydrogen for 4 hours, then filtered and concentrated to give the title compound as an oil (410 mg, 91%), which was carried forward without characterization.
[0646] Preparation 94
[0647] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]carbamoylamino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0648]
[0649] A mixture of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 57.80 g, 148.0 mmol) and 1,1'-carbonyldiimidazole (12 g, 74 mmol) in 2-methyltetrahydrofuran (240 mL) was stirred overnight at 70 °C. The mixture was cooled to room temperature, and water (250 mL) and 2-methyltetrahydrofuran (250 mL) were added. The layers were separated, and the organic layer was dried over MgSO4, filtered and concentrated. The residue was triturated in a mixture of 1:1 IPA / water (600 mL) at 60 °C for 4 hours, and then triturated overnight at room temperature. The resulting solid was filtered, washed with 1:1 IPA / water, and dried under reduced pressure at 40 °C to give the title compound (58 g, 97%). ES / MS (m / z): 706 (M+H-BOC). Analytical chiral SFC [column: Chiralpak IB 4.6×100 mm, 5 μm; mobile phase: solvent A=MeOH+0.2% isopropylamine; flow rate 4 mL / min; column temperature 40°C] showed de>98%.
[0650] Prepare the following essentially as described in Preparation 94 using the appropriate amine:
[0651]
[0652]
[0653]
[0654]
[0655]
[0656] A. Purification by silica gel chromatography eluting with EtOAc:hexanes
[0657] B. Purification by reverse phase flash chromatography; mobile phase: ACN / NH4CO3 aqueous solution pH 9
[0658] C. (3R)-tert-butyl 3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate prepared essentially as described in WO 2020 / 247429
[0659] D. Upon completion, the reaction mixture was concentrated in vacuo and no aqueous work-up was performed.
[0660] E. Purification by silica gel chromatography eluting with acetone:DCM
[0661] F. Purification by silica gel chromatography eluting with acetone:hexanes
[0662] G. Preparation of Isomer 1 Using Amine Starting Materials
[0663] H. Preparation of Isomer 2 Using Amine Starting Materials
[0664] I. Preparation of Isomer 3 Using Amine Starting Materials
[0665] J. Preparation of Isomer 4 Using Amine Starting Materials
[0666] K. Starting Materials: (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]methylamino]methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester prepared essentially as described in WO 2020 / 247429
[0667] L. No MS data available; 1 H NMR(400.21MHz, CDCl3)δ7.28(m,12H),4.60-4.56(m,4H),3.72-3.62(m,6H),3.31-3.22(m,3H),3.05-2 .95(m,9H),2.51-2.43(m,6H),1.99-1.91(m,3H),1.74-1.70(m,3H),1.48(s,27H),1.30-1.28(m,27H).
[0668] M. No MS data, 1H NMR(400.13MHz, DMSO-d6)δ7.55-7.48(m,1H),7.32-7.23(m,2H),7.22-7.14(m,2H),7.14-6. 98(m,6H),6.77(d,J=7.7Hz,1H),5.76(d,J=1.3Hz,1H),4.89-4.76(m,2H),3.56-3.41(m,3H) ,3.39-3.27(m,3H),3.20-3.06(m,3H),2.99-2.88(m,3H),2.80-2.61(m,6H),2.58-2.37(m,3 H),2.35-2.17(m,3H),1.90-1.76(m,3H),1.66-1.49(m,3H),1.39(s,27H),1.24-1.21(m,27H)
[0669] Preparation 107
[0670] (3S)-3-[(1S)-2-tert-butoxy-1-[3-[[3-[(1S)-2-tert-butoxy-1-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]-2-oxo-ethoxy]phenyl]carbamoylamino]phenoxy]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester, isomer 2
[0671]
[0672] (3S)-3-[1-(3-aminophenoxy)-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 2, 410 mg, 1.045 mmol) was dissolved in THF (12 mL) and CDI (102 mg, 0.63 mmol) and DMAP (26 mg, 0.20 mmol) were added to the mixture. The reaction was stirred at room temperature for 56 hours, additional CDI (160 mg, 0.987 mmol) was added and the mixture was stirred at 40 ° C for 18 hours. The reaction mixture was concentrated to dryness under reduced pressure and the residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / hexanes to give the title compound (200 mg, 24%) as a clear glassy solid, which was carried forward without characterization.
[0673] Prepare the following essentially as described in Preparation 107 using the appropriate amine:
[0674]
[0675]
[0676] A: Preparation using isomer 1 of the amine starting material
[0677] B: Upon completion, the reaction was diluted with EtOAc, washed with saturated aqueous NaHCO 3 , saturated aqueous NaCl, dried over Na 2 SO 4 , filtered and concentrated, then purified.
[0678] Preparation 110
[0679] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[3-[3-[(2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxyethyl]phenyl]-2-oxo-hexahydropyrimidin-1-yl]phenyl]propanoic acid
[0680]
[0681] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429; 347 mg, 0.872 mmol), tetrahydro-2(1H)-pyrimidinone (45 mg, 0.436 mmol), sodium tert-butoxide (126 mg, 1.31 mmol), tBuXPhos Pd G3 (35 mg, 0.043 mmol) and 1,4-dioxane (4.36 mL) was purged with nitrogen for 10 minutes, then the reaction vessel was sealed and heated at 100 °C for 16 hours. Additional (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (174 mg, 0.436 mmol), sodium tert-butoxide (126 mg, 1.31 mmol) and tBuXPhosPd G3 (35 mg, 0.043 mmol) were added, then the mixture was purged with nitrogen for 10 minutes, sealed and heated at 100° C. for 16 hours. Additional sodium tert-butoxide (126 mg, 1.31 mmol) and tBuXPhosPd G3 (35 mg, 0.043 mmol) were added, then the mixture was purged with nitrogen for 10 minutes, sealed and heated at 100° C. for 2.5 hours. The reaction was filtered through a pad of celite, washed with DCM and MeOH. The filtrate was concentrated under reduced pressure, and the residue was purified by reverse phase flash chromatography using a gradient of 20 to 50% ACN / NH4CO3 aqueous solution (pH 9) to give the title compound (155 mg, 48%). ES / MS (m / z): 735 (M+H).
[0682] Prepare the following using the appropriate aryl halide and imidazolidin-2-one essentially as described in Preparation 110:
[0683]
[0684] A. Using Isomer 2 of the Starting Aryl Bromide
[0685] B. Precipitation of the product from the reaction mixture using a mixture of MTBE and hexane
[0686] C. Purification by silica gel chromatography using a gradient of 10 to 40% EtOH / hexanes + 1% acetic acid
[0687] Preparation 113
[0688] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[[3-[(2-chloroacetyl)amino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0689]
[0690] TEA (1.5 eq, 0.107 mL, 0.7682 mmol) was added to a mixture of tert-butyl (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429, 200 mg, 0.5122 mmol) in DCM (0.16 M, 3.201 mL) at 0 °C. It was stirred at this temperature for 10 minutes, and then chloroacetyl chloride (1.1 eq, 0.04478 mL, 0.5634 mmol) was added. The mixture was stirred at room temperature overnight. NaHCO3(saturated) (5 mL) was added and the aqueous layer was extracted with DCM. The organic layer was washed with saturated aqueous NaCl solution and filtered through celite. The solution was dried over MgSO4, and the solvent was removed under reduced pressure to obtain the title compound (238 g, 99%). ES / MS (m / z): 368 (M+H-BOC).
[0691] Preparation 114
[0692] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[4-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]-2,5-dioxo-piperazin-1-yl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0693]
[0694] Potassium carbonate (0.1409 g, 1.019 mmol) was added to a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[(2-chloroacetyl)amino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (238 mg, 0.5096 mmol) in ACN (5 mL), and the mixture was stirred at 80 ° C overnight. The reaction was cooled to room temperature, quenched with water, and then extracted with EtOAc. The organic layer was washed with saturated NaCl aqueous solution and filtered through diatomaceous earth. The solution was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase HPLC [column: C18 19×100 mm, 5 μm; mobile phase: solvent A—NH4HCO3 aqueous solution (20 mM, pH 9), solvent B—ACN; flow rate: 25 mL / min] to obtain the title compound (63 mg, 14%) as a colorless oil. ES / MS (m / z): 762 (M+H-BOC).
[0695] Preparation 115
[0696] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-N-carbamoyl-anilino]methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0697]
[0698] A solution of potassium cyanate (115 mg, 1.420 mmol) in water (1.82 mL) was added to a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]anilino]methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO2020 / 247429; 260 mg, 0.284 mmol) in acetic acid (2.27 mL) at room temperature and the mixture was stirred for 30 minutes. Water was added and the aqueous layer was extracted with EtOAc. The organic phase was washed with saturated NaHCO3 aqueous solution. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 15 to 100% MTBE / hexanes to give the title compound (212 mg, 87%). ES / MS (m / z): 821 (M+H).
[0699] Preparation 116
[0700] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[3-[3-[(2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxyethyl]phenyl]-2-oxo-benzimidazol-1-yl]phenyl]propanoic acid
[0701]
[0702] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429; 400 mg, 1.004 mmol), 1,3-dihydrobenzimidazol-2-one (67 mg, 0.5021 mmol, 0.5 eq), potassium carbonate (486 mg, 3.515 mmol, 3.5 eq), cuprous iodide (29 mg, 1.506 mmol, 1.5 eq), N,N'-dimethylethylenediamine (0.322 mL, 3.013 mmol, 3 eq) and anhydrous toluene (1.5 mL, 1.5 mL / mmol) was purged with nitrogen for 10 minutes, then the reaction vessel was sealed and heated at 100 °C for 4 hours. The reaction mixture was filtered through a pad of celite, which was then washed with DCM and MeOH. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by reverse phase chromatography using a gradient of 20 to 50% ACN / NH4CO3 aqueous solution (pH 9) to give a blue solid. The solid was dissolved in MeOH (12 mL) and then added Thiol metal scavenger (1.2 g) was added, and the mixture was stirred at room temperature for 18 hours. The suspension was filtered and washed with MeOH. The filtrate was concentrated under reduced pressure to give the title compound (183 mg, 24%). ES / MS (m / z): 769 (M+H).
[0703] Preparation 117
[0704] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid
[0705]
[0706] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid ammonium salt (see Preparation 24; 2 g, 4.82 mmol), bis(pinacolato)diboron (1.85 g, 7.22 mmol), potassium acetate (0.945 g, 9.63 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (0.286 g, 0.337 mmol) and anhydrous 1,4-dioxane (12 mL) was purged with nitrogen for 10 minutes and stirred at 90°C overnight. The reaction was cooled to room temperature, then water was added and the aqueous layer was extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl solution and filtered through a celite pad. The filtrate was dried over MgSO4, filtered, concentrated under reduced pressure, and then purified by silica gel chromatography using a gradient of 0 to 100% acetone / hexanes to give the title compound (2.14 g, 100%). ES / MS (m / z): 346 (M+H-BOC).
[0707] Preparation 118
[0708] (2R)-2-[(3S)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid
[0709]
[0710] The title compound was prepared essentially as described in Preparation 117 using (2R)-3-(3-bromophenyl)-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid ammonium salt. ES / MS (m / z): 346 (M+H-BOC).
[0711] Preparation 119
[0712] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[3-[(2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxyethyl]phenyl]phenyl]propanoic acid
[0713]
[0714] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid ammonium salt (see Preparation 24; 500 mg, 1.20 mmol), (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid (0.804 g, 1.81 mmol), 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) chloride dichloromethane complex (0.201 g, 0.241 mmol) and KCO (0.499 g, 3.61 mmol) in 1,4-dioxane (12 mL) and water (1.2 mL) was stirred at 110° C. overnight under nitrogen. The reaction was cooled, filtered through a pad of celite and washed with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase HPLC [column: C18 (19×100 mm, 5 μm); mobile phase: solvent A-NH4HCO3 aqueous solution (20 mM, pH 9), solvent B-ACN, 1:3B:A; flow rate: 25 mL / min] to obtain the title compound (442 mg, 58%). ES / MS (m / z): 537 (M+H-BOC).
[0715] Preparation 120
[0716] (2R)-2-[(3S)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[3-[(2R)-2-[(3S)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxyethyl]phenyl]phenyl]propanoic acid
[0717]
[0718] The title compound was prepared essentially as described in Preparation 119 using (2R)-3-(3-bromophenyl)-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid ammonium salt and (2R)-2-[(3S)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid. After completion of the reaction, the reaction mixture was quenched with water and extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography using 90 to 100% EtOAc / hexanes to give the title compound as a colorless oil. ES / MS (m / z): 537 (M+H-BOC).
[0719] Preparation 121
[0720] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-5-(trifluoromethyl)anilino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0721]
[0722] (3R)-3-[(1S)-1-[[3-bromo-5-(trifluoromethyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (250 mg, 0.479 mmol), (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (basic as WO 2020 / 247429, 0.224 g, 0.574 mmol), cesium carbonate (468 mg, 1.44 mmol) and mesylate (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (0.3 equiv., 123 mg, 0.144 mmol) were mixed in 1,4-dioxane (3.35 mL) and stirred at 110 ° C for 16 hours, then filtered through a pad of celite, washed with DCM and MeOH. The filtrate was concentrated under reduced pressure. The material was purified by RP-HPLC / MS [column: C18 (19×100 mm, 5 μm); mobile phase: 20 mM NH4HCO3 / water (pH 9)-solvent A; ACN-solvent B; elution conditions: gradient from 74% to 95% B; flow rate: 25 mL / min; column at room temperature] to obtain the title compound (173 mg, 43%). ES / MS (m / z): 732 (M+H-BOC).
[0723] Prepare the following essentially as described in Preparation 121 using appropriate starting materials:
[0724]
[0725]
[0726] A. Purification on a hydrophobic lipophilic balance (HLB) column, eluting with a gradient of 0 to 100% ACN / NH4HCO3 aqueous solution (pH 9)
[0727] Preparation 124
[0728] (3R)-3-[(1S)-1-[(4-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0729]
[0730] (2S)-3-(4-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (2.73 g, 6.85 mmol) was dissolved in toluene (68 mL), heated at 80 °C, and 1,1-di-tert-butoxy-N,N-dimethyl-methylamine (12.8 mL, 48.0 mmol) was added. The mixture was stirred and heated at 80 °C for 3 hours. Additional 1,1-di-tert-butoxy-N,N-dimethyl-methylamine (3.0 mL, 11 mmol) was added and the reaction was stirred at 80 °C for 16 hours. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0 to 40% EtOAc / hexanes to give the title compound (3.0 g, 90%). ES / MS (m / z): 342 / 344 (M+H-2x tert-butyl).
[0731] Preparation 125
[0732] (3R)-tert-Butyl 3-[(1S)-1-[(4-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[0733]
[0734] A suspension of (3R)-tert-butyl 3-[(1S)-1-[(4-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (1.51 g, 3.32 mmol), copper(I) oxide (0.490 g, 3.32 mmol), L-proline (0.586 g, 4.98 mmol) and sodium azide (0.655 g, 9.97 mmol) in DMSO (16 mL) was degassed with a positive stream of argon. The reaction mixture was heated to 100 °C in a microwave reactor for 36 h. The reaction was carefully vented, poured into EtOAc (100 mL) and washed with saturated aqueous NaHCO3 solution (2×50 mL). The organic extract was dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (quantitative yield, 3.32 mmol). ES / MS (m / z): 291 (M+H-BOC).
[0735] Preparation 126
[0736] (3R)-3-[(1S)-1-[[3-[(3-acetoxyphenoxy)methyl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0737]
[0738] Diethyl azodicarboxylate (0.23 mL, 1.5 mmol) was added to a solution of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO2020 / 247429; 200 mg, 0.493 mmol), triphenylphosphine (196 mg, 0.739 mmol) and (3-hydroxyphenyl) acetate (82 mg, 0.54 mmol) in THF (2 mL) under a nitrogen atmosphere. The mixture was stirred at room temperature for 16 hours and saturated aqueous NaHCO3 was added. The organic phase was separated from the aqueous phase, washed with saturated aqueous NaCl (3×), dried over MgSO4 and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography eluting with EtOAc:hexanes (gradient: 10-60%) to give the title compound (123 mg, 46% yield). ES / MS (m / z): 538 (MH).
[0739] Preparation 127
[0740] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[[3-[(3-hydroxyphenoxy)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0741]
[0742] Potassium carbonate (67 mg, 0.68 mmol) was added to a solution of (3R)-3-[(1S)-1-[[3-[(3-acetoxyphenoxy)methyl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (123 mg, 0.227 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for 15 minutes and the solvent was evaporated under reduced pressure. 0.5N HCl aqueous solution and DCM were added. The organic phase was separated, washed with saturated NaCl aqueous solution, dried over MgSO4 and concentrated under reduced pressure to give the title compound (117 mg, 92% yield). ES / MS (m / z): 398 (M+H-Boc).
[0743] Preparation 128
[0744] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]methoxy]phenoxy]methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0745]
[0746] Diethyl azodicarboxylate (0.11 mL, 0.71 mmol) was added to a solution of tert-butyl (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[(3-hydroxyphenoxy)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (117 mg, 0.253 mmol), triphenylphosphine (93 mg, 0.352 mmol., 1.5 equiv.) and tert-butyl (3R)-3-[(1S)-2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 105 mg, 0.259 mmol) in THF (2 mL) under nitrogen atmosphere. The mixture was stirred at room temperature for 16 hours. More triphenylphosphine (93 mg, 0.352 mmol) and diethyl azodicarboxylate (0.11 mL, 0.705 mmol) were added. After 3 hours, saturated aqueous NaHCO3 was added. The organic phase was separated, washed with saturated aqueous NaCl, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC [column: C185 μm, 19×100 mm; mobile phase: solvent A-NH4HCO3 aqueous solution (20 mM, pH 9.0), solvent B-ACN; gradient: 75-95% solvent B in solvent A; flow rate: 25 mL / min; column temperature: 50°C] to provide the title compound (50 mg, 24%). ES / MS (m / z): 785 (M+H-Boc).
[0747] Preparation 129
[0748] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[5-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-1-(2-phenylethyl)benzimidazol-2-yl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0749]
[0750] (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[(4-fluoro-3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (50 mg, 0.114 mmol) from a freshly prepared stock solution (0.2 M in DMA) was added to 2-phenylethylamine (0.118 mmol) in a tube. DMA (980 μL) was then added and the mixture was stirred at 90 °C for 2 hours. Na2S2O4 (295 μL, 0.59 mmol, 2 M) was added followed by (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[(3-formylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429, 118 μmol, 0.118 mmol) from a stock solution (0.6 M in DMA). The mixture was stirred at 90°C for 2 hours and then at room temperature overnight. The mixture was loaded onto an HLB column (6 g) and then eluted with water (2 column volumes) and ACN (2 column volumes). The solvent of the organic fraction was evaporated under nitrogen. The crude material was purified by RP-HPLC / MS [column: C18 (19×100 mm, 5 μm); mobile phase: solvent A-20 mM NH4HCO3 / water (pH 9), solvent B-ACN, gradient from 74% to 95% solvent B in solvent A; flow rate: 25 mL / min; column at room temperature] to obtain the title compound (45 mg, 44% yield).
[0751] Preparation 130
[0752] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-N-carbamoyl-anilino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0753]
[0754] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]anilino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 0.2 mmol) in toluene (12 mL / mmol, 2.4 mL) was added sodium cyanate (30 mg, 0.5 mmol). TFA (0.072 mL, 0.9 mmol) was then added and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was purified by silica gel chromatography using a gradient of 0 to 100% acetone / hexane to give the title compound (76 mg, 42%). ES / MS (m / z): 708 (M+H-BOC).
[0755] Preparation 131
[0756] (3R)-3-[(1S)-1-[[3-[[2-[bis[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]methyl]amino]ethyl-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]methyl]amino]methyl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0757]
[0758] To a mixture of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]methylamino]methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 185 mg, 0.334 mmol) in EtOH (5 mL) was added glyoxal (16 mg, 13 μL, 0.1667 mmol) and MgSO4. The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (101 mg, 0.467 mmol) was added and the reaction was stirred for 5 hours. Add other glyoxal (6mg, 5μL, 0.0467mmol), then add sodium triacetoxyborohydride (25mg, 0.117mmol) and stir the reaction for 1 hour. Filter the reaction mixture and concentrate. The residue is dissolved in DCM, and washed with saturated NaHCO3 aqueous solution and saturated NaCl aqueous solution, then dried over MgSO4, filtered and concentrated. The residue is purified by silica gel chromatography using a gradient of 10 to 90% EtOAc / hexane to obtain the title compound (89mg, 24%). 1 H NMR (400.13MHz, CDCl3) δ7.17 (s, 8H), 7.04 (s, 8H), 3.73-3.64 (m, 2H), 3.59-3.39 (m, 14H), 3.24 (d, J = 6.1Hz, 4H), 3.07-2.94 (m, 4H), 2.86-2. 72(m,8H),2.64-2.55(m,4H),2.52-2.45(m,4H),2.38-2.34(m,4H),1. 97-1.90(m,4H),1.72-1.62(m,4H),1.48(s,36H),1.26-1.24(m,36H).
[0759] Preparation 132
[0760] (2S)-2-[(3R)-1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-(3-phenylphenyl)propanoic acid
[0761]
[0762] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429, 500 mg, 1.26 mmol), phenylboronic acid (138 mg, 1.13 mmol) and K2CO3 (521 mg, 3.77 mmol) in 1,4-dioxane (12.6 mL) and water (1.3 mL) was purged with N2 for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II)DCM complex (107 mg, 0.126 mmol) was added and the reaction mixture was purged with N2 for 5 minutes and heated at 100 °C overnight. The reaction mixture was shaken between water and DCM, and the layers were separated. The aqueous layer was washed three times with DCM. The organic layers were combined, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 10 to 50% acetone / hexanes to give the title compound (310 mg, 62%). ES-MS m / z 340 (M-tBu).
[0763] Preparation 133
[0764] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[2-(3-cyclopropylphenyl)ethoxy]phenyl]propanoic acid
[0765]
[0766] A reaction vessel containing a mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 415 mg, 1.00 mmol), 8-hydroxyquinoline (19 mg, 0.13 mmol), CuI (14 mg, 0.072 mmol) and tripotassium phosphate (440 mg, 2.03 mmol) was purged with nitrogen, then 2-(3-cyclopropylphenyl)ethanol (500 mg, 2.90 mmol) was added and the reaction mixture was stirred at 110 °C for 24 hours. The mixture was shaken with water, Et2O and HCl (1M aqueous solution, 5 mL). The organic layer was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 17% EtOAc / DCM. Fractions containing the title compound were concentrated and combined with the impure product from a reaction run on a similar scale and repurified by reverse phase HPLC [column: C18 19×100 mm, 5 μm; mobile phase: 45 to 65% ACN / NH 4 HCO 3 aqueous solution (20 mM, pH 9); flow rate 25 mL / min] to give 71 mg (7%) of the title compound as a light yellow oil. ES-MS m / z 424 (M-tBu).
[0767] Preparation 134
[0768] [3-[(2S)-3-tert-Butoxy-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]boronic acid
[0769]
[0770] (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (basically as WO 2020 / 247429; 1.00 g, 2.20 mmol), tetrahydroxydiboron (0.302 g, 3.30 mmol), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (8.8 mg, 0.011 mmol), X-PHOS (0.01 equiv., 0.02201 mmol, 98 mass %, 0.01071 g), potassium acetate (0.65 g, 6.6 mmol) and ethylene glycol (0.37 mL, 0.41 g, 6.6 mmol) in EtOH (22 mL) were stirred for 10 minutes while purging with nitrogen. The mixture was heated to 100 ° C for 3.5 hours and then stirred at room temperature overnight. The mixture was filtered through a short column of diatomaceous earth and washed with EtOH. The filtrate was concentrated to dryness and then placed in a mixture of water and EtOAc, the phases were separated, and the aqueous phase was extracted twice more with EtOAc. The combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and evaporated to dryness. Half of the residue was purified by silica gel chromatography using a gradient of 25 to 100% EtOAc / hexane to give the title compound (294 mg, 64% yield based on the purified portion). ES-MS m / z 280 (M+H-2 t Bu).
[0771] Preparation 135
[0772] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(5-chloro-2-thienyl)phenyl]propanoic acid
[0773]
[0774] A mixture of (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid (150 mg, 0.32 mmol), 2-bromo-5-chlorothiophene (98 mg, 0.48 mmol) in anhydrous DMF (3.2 mL) was purged with N2 for 10 minutes, then potassium dihydrogen phosphate (1M aqueous solution, 1.6 mL, 1.6 mmol) and tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.022 mmol) were added. The reaction mixture was stirred at 100°C for 4 hours and then cooled to room temperature. The mixture was purged with N2 for 5 minutes, then tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.022 mmol) and potassium dihydrogen phosphate (1M aqueous solution, 1.6 mL, 1.6 mmol) were added. The reaction was heated at 100 ° C for 15.5 hours and then cooled to room temperature. The reaction was purged with N2 for 5 minutes, then 2-bromo-5-chlorothiophene (98 mg, 0.48 mmol), tetrakis(triphenylphosphine)palladium(0) (27 mg, 0.022 mmol) and dipotassium hydrogen phosphate (1M aqueous solution, 1.6 mL, 1.6 mmol) were added and the reaction mixture was stirred at 100 ° C for 2 hours and at room temperature for 3 days. The reaction mixture was combined with a reaction mixture run in a similar manner with 0.10 mmol starting boronic acid. The combined mixture was filtered through a diatomaceous earth pad and rinsed with MeOH. Aqueous citric acid solution (5%) was added to the filtrate, and the mixture was extracted with EtOAc. The organic layer was washed with a saturated NaCl aqueous solution, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 10 to 40% acetone / DCM, and then repurified by reverse phase HPLC [column: C18 19×100 mm, 5 μm; mobile phase: 35 to 55% ACN / NH 4 HCO 3 aqueous solution (20 mM, pH 9), flow rate: 25 mL / min] to obtain the title compound as a white solid (22.3 mg, 16%). ES-MS m / z 434 (MH).
[0775] Preparation 136
[0776] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-(3-fluoro-5-thiazol-4-yl-phenyl)propanoic acid
[0777]
[0778] A mixture of (2S)-3-(3-bromo-5-fluoro-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.25 g, 0.60 mmol), bis(pinacolato)diboron (0.18 g, 0.72 mmol), potassium acetate (0.15 g, 1.5 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.027 g, 0.036 mmol) in 1,4-dioxane (4.8 mL) was heated at 100 °C overnight. The mixture was cooled to 80°C and 4-bromothiazole (0.11 g, 0.061 mL, 0.66 mmol), Na2CO3 (2M aqueous solution, 1.8 mL, 1.8 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.013 g, 0.018 mmol) were added. The mixture was heated at 80°C for 5 hours and then cooled to room temperature. The mixture was quenched with HCl (1N aqueous solution) and extracted with EtOAc. The combined organic phases were filtered (celite), washed with saturated NaCl aqueous solution, dried over MgSO4, filtered and evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 0 to 80% EtOAc + 1% acetic acid, and then repurified using reverse phase HPLC [column: Bonus RP 21×100 mm, 5 μm; mobile phase: 30 to 80% ACN / NH4HCO3 aqueous solution (20 mM, pH 8), flow rate: 25 mL / min] to give 88 mg (35%) of the title compound as a white solid. ES-MS m / z 421 (M+H).
[0779] Preparation 137
[0780] Tert-butyl (3R)-3-[(1S)-2-tert-butoxy-2-oxo-1-[(3-tetrahydropyran-4-ylphenyl)methyl]ethyl]pyrrolidine-1-carboxylate
[0781]
[0782] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429, 200 mg, 0.440 mmol), Cs2CO3 (0.431 g, 1.32 mmol) in toluene (3 mL) was purged with N2, then 3,3-difluoropyrrolidine hydrochloride (75.8 mg, 0.528 mmol) and mesylate (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium (II) (RuPhos Palladacycle Gen. 4, 113 mg, 0.132 mmol) were added and the mixture was heated to 85 ° C for 2 days. The reaction mixture was then filtered through celite and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 5 to 25% EtOAc / hexanes to give the title compound as a brown oil (139 mg, 64%). ES-MS m / z 381 (M+H-BOC).
[0783] Preparation 138
[0784] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(5-methyl-2-oxo-indolin-1-yl)phenyl]propanoic acid
[0785]
[0786] To a mixture of 5-methylindolin-2-one (202 mg, 1.35 mmol), (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 500 mg, 1.204 mmol) and K2CO3 (545 mg, 3.90 mmol) was added ACN (4 mL). A steady stream of N2 was bubbled through the suspension as it was heated to 40 °C over 15 min. Cuprous iodide (34.4 mg, 0.181 mmol) and DMF (39 μL) were added. The reaction vessel was sealed and the mixture was heated at 80 °C for 15.5 h. The reaction mixture was cooled to room temperature, quenched with 1N HCl and extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 12 to 50% (1% acetic acid / acetone) / hexane. Toluene was added to the purified product and the mixture was concentrated, then a mixture of MTBE and hexane was added to the residue and concentrated to give the title compound (277 mg, 50%) as a light yellow solid. ES-MS m / z 521 (M+H).
[0787] Preparation 139
[0788] 1-(3-Benzyloxyphenyl)imidazolidin-2-one
[0789]
[0790] A mixture of ethylene urea (1.4 g, 16 mmol), 1-benzyloxy-3-iodobenzene (4.9 g, 16 mmol), cuprous iodide (0.61 g, 3.1 mmol) and potassium dihydrogen phosphate (4.2 g, 31 mmol) was suspended in DMF under an argon atmosphere (argon bubbling, 20 mL), and N,N'-dimethylethylenediamine (0.28 g, 0.33 mL, 3.1 mmol) was then added. The suspension was heated to 120 ° C for 3 hours. The mixture was cooled and filtered through a silica gel pad, which was rinsed with EtOAc. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography using 1:4:15 MeOH:acetone:EtOAc to give the title compound (1.10 g, 26%). ES-MSm / z 269 (M+H).
[0791] Preparation 140
[0792] (2S)-3-[3-[3-(3-benzyloxyphenyl)-2-oxo-imidazolidin-1-yl]phenyl]-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0793]
[0794] To a mixture of 1-(3-benzyloxyphenyl)imidazolidin-2-one (1.09 g, 4.05 mmol) and (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 1.40 g, 3.37 mmol) was added ACN (16.9 mL) and DMF (3 mL) under N2. A steady stream of argon was bubbled through the suspension for 15 minutes, then K2CO3 (1.52 g, 10.9 mmol), CuI (128 mg, 0.674 mmol) and N,N'-dimethylethylenediamine (120 mg, 0.147 mL, 1.35 mmol) were added and the mixture was heated to 100 °C in a microwave reactor for 18 hours. The mixture was quenched with water and extracted twice with EtOAc. The pH of aqueous phase was acidified with 0.5N HCl aqueous solution and extracted with EtOAc, DCM, and then extracted with EtOAc again. The combined organic phase was dried over MgSO4, filtered and evaporated to dryness. The residue was purified by silica gel chromatography using a gradient of 10 to 60% (acetone+1% acetic acid) / hexane ((acetone+1% acetic acid) in hexanes) to obtain 1.10 g (56%) yellow oil, which slowly crystallized. ES-MS m / z 486 (M+H-BOC).
[0795] Preparation 141
[0796] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[[3-(3,3-dimethylindolin-1-yl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0797]
[0798] The title compound was prepared using 3,3-dimethylindoline essentially as described in Preparation 137. ES-MS m / z 521 (M+H).
[0799] Preparation 142
[0800] N,N'-Bis[(4-methoxyphenyl)methyl]-N,N'-diphenyl-malonamide
[0801]
[0802] To a solution of N-[(4-methoxyphenyl)methyl]aniline (2.05 g, 9.61 mmol) in DCM (48 mL) was added malonic acid (500 mg, 0.308 mL, 4.80 mmol) and N,N'-dicyclohexylcarbodiimide (1.98 g, 9.60 mmol). The resulting mixture was stirred at room temperature overnight. The reaction was filtered through celite and the filtrate was concentrated to dryness. The residue was purified by silica gel chromatography using a gradient of 0 to 10% (ammonia / MeOH) / DCM ((ammonia in MeOH) in DCM) to give 1 g (42%) of the title compound as a light grey solid. ES-MS m / z 495 (M+H).
[0803] Preparation 143
[0804] 1,1'-Bis[(4-methoxyphenyl)methyl]-3,3'-spirobis[indoline]-2,2'-dione
[0805]
[0806] To a solution of N,N'-bis[(4-methoxyphenyl)methyl]-N,N'-diphenyl-malonamide (1 g, 2.02 mmol) in 2,2,2-trifluoroethanol (55.2 g, 40 mL, 552 mmol) was added [bis(trifluoroacetoxy)iodo]benzene (1.9 g, 4.4 mmol) in portions. The resulting mixture was stirred at room temperature for 3 days, then diluted with MeOH and concentrated to dryness. The residue was purified by silica gel chromatography using a gradient of 0 to 10% (ammonia / MeOH) / DCM to give 746 mg (74%) of the title compound as a light yellow solid. ES-MS m / z 491 (M+H).
[0807] Preparation 144
[0808] 3,3'-Spirobi[indoline]-2,2'-dione
[0809]
[0810] To a solution of 1,1'-bis[(4-methoxyphenyl)methyl]-3,3'-spirobis[indoline]-2,2'-dione (746 mg, 1.52 mmol) in DCM (15 mL) was added TFA (15 mL, 22.6 g, 198 mmol) and trifluoromethanesulfonic acid (8 mL) dropwise. The resulting mixture was stirred at room temperature and then concentrated under a N2 stream. The residue was dissolved in DCM, then water was added and the phases were separated. The organic phase was washed with saturated NaHCO3 aqueous solution, then dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 10% EtOAc / hexane to give 210 mg (55%) of the title compound as a light yellow solid. ES-MS m / z 251 (M+H).
[0811] Preparation 145
[0812] (2S)-3-[3-(2,2'-dioxo-3,3'-spirobi[indolyl]-1'-yl)phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid
[0813]
[0814] The title compound was prepared essentially as described in Preparation 140 using 3,3'-spirobis[indoline]-2,2'-dione. Upon completion, the reaction mixture was diluted with MeOH, filtered through celite and concentrated to dryness. The residue was purified on an HLB column using a gradient of 0 to 70% ACN / NH4HCO3 in water (pH 9). ES-MS m / z 590 (M+H).
[0815] Preparation 147
[0816] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(2-oxo-3H-benzimidazol-1-yl)phenyl]propanoic acid
[0817]
[0818] A suspension of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 0.20 g, 0.48 mmol), 1,3-dihydrobenzimidazol-2-one (0.13 g, 0.96 mmol), cuprous iodide (0.14 g, 0.72 mmol), potassium carbonate (0.23 g, 1.69 mmol) and N,N'-dimethylethane-1,2-diamine (0.13 g, 1.45 mmol) in toluene (2.4 mL) was sonicated in a pressure tube for 5 minutes. The tube was sealed and the mixture was heated at 110 °C for 16 hours. After cooling to room temperature, saturated NH4Cl aqueous solution was added and the reaction was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by reverse phase chromatography eluting with a gradient of 20% to 50% ACN / NH4HCO3 aqueous solution to give the title compound (68.2 mg, 31%) as a white solid. ES-MS m / z 352 (M+H- t Bu).
[0819] Preparation 148
[0820] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[2-oxo-3-(2,2,2-trifluoroethyl)imidazolidin-1-yl]phenyl]propanoic acid
[0821]
[0822] A sealed tube was charged with (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO 2020 / 247429, 0.15 g, 0.38 mmol), 1-(2,2,2-trifluoroethyl)imidazolidin-2-one (0.19 g, 1.13 mmol), t-BuXPhos Pd G3 (0.03 g, 0.04 mmol) and sodium tert-butoxide (0.22 g, 2.26 mmol) in anhydrous 1,4-dioxane (3.8 mL), purged with nitrogen for 5 minutes and stirred at 100 ° C. overnight. After cooling to room temperature, the reaction was filtered through a pad of celite and rinsed with EtOAc. The filtrate was extracted twice with 1M NaOH aqueous solution, the combined aqueous extracts were acidified to pH 3-4 with 1M HCl aqueous solution, and extracted twice with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a 20% to 80% acetone / hexane gradient to give the title compound (75 mg, 40%) as a white solid. ES-MS m / z 386 (M+H-BOC).
[0823] Preparation 149
[0824] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-fluoro-5-(2-oxoindolin-1-yl)phenyl]propanoic acid
[0825]
[0826] A pressure tube was charged with 2-oxindole (0.11 g, 0.81 mmol), (2S)-3-(3-bromo-5-fluoro-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.30 g, 0.72 mmol) and ACN (2.4 mL). A stream of N was bubbled through the solution as it was heated to 40 °C over 15 min. The reaction was then treated with KCO (0.33 g, 2.34 mmol), cuprous iodide (0.014 g, 0.072 mmol) and N,N'-dimethylethylenediamine (0.013 g, 0.14 mmol) to give a bright blue suspension. The tube was sealed and the mixture was heated at 80 °C overnight. After 16 h, the reaction was cooled to room temperature, quenched with 1 N aqueous HCl, and extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 12% to 50% acetone (with 1% HOAc) in hexanes to give the title compound (0.22 g, 89 mass %, 57%) as a yellow solid. ES-MS m / z 369 (M+H-BOC).
[0827] Preparation 150
[0828] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[4-(2,5-dioxoimidazolidin-1-yl)phenyl]propanoic acid
[0829]
[0830] Hydantoin (0.25 g, 2.4 mmol), (2S)-3-(4-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.32 g, 0.80 mmol), cuprous iodide (0.46 g, 2.4 mmol), K2CO3 (0.33 g, 2.4 mmol) and DMF (5 mL) were combined in a microwave vial under argon. N,N'-dimethylethylenediamine (0.22 g, 2.4 mmol) was added and the vial was sealed. The suspension was heated at 100 °C for 1 hour. The reaction was cooled, diluted with EtOAc, washed with 10% aqueous citric acid, washed with water (x3), and then washed with saturated aqueous NaCl. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% acetone (containing 2% AcOH) / hexanes. The title compound was isolated as a clear wax (23 mg, 7%). ES-MS m / z 362 (M+H-tBu).
[0831] Preparation 151
[0832] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(4-phenyl-1-piperidinyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0833]
[0834] (2S) -3- (3- bromophenyl) -2- [(3R) -1- tert-butoxycarbonyl pyrrolidin-3-yl] propionic acid (prepared substantially as described in WO 2020 / 247429, 0.20 g, 0.44 mmol), cesium carbonate (0.57 g, 1.76 mmol) and toluene (3 mL) were loaded into the tube. The reaction was purged with N2, and then 4-phenylpiperidine hydrochloride (0.10 g, 0.53 mmol) and mesylate (2- dicyclohexylphosphino -2', 6'- diisopropoxy -1, 1'- biphenyl) (2'-amino -1, 1'- biphenyl -2-yl) palladium (II) (0.11 g, 0.13 mmol) were added. The tube was capped and the reaction was stirred at 85 ° C for 16 hours. The reaction was cooled, water was added, and the reaction was extracted with EtOAc. The organic layer was collected, dried over MgSO4 and concentrated under reduced pressure. The residue was taken up in EtOAc, filtered through celite, and the solid was washed with EtOAc. The filtrate was concentrated under reduced pressure to provide a yellow oil, which was purified by silica gel chromatography eluting with a gradient of 0% to 35% EtOAc / hexanes to provide the title compound as a colorless oil (0.19 g, 77%), which was used without analysis.
[0835] Preparation 153
[0836] (2S)-2-[(3R)-1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-[3-(2-fluoro-3-methoxy-phenyl)phenyl]propanoic acid
[0837]
[0838] A pressure tube was loaded with (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 0.25 g, 0.60 mmol), 2-fluoro-3-methoxyphenylboronic acid (0.16 g, 0.90 mmol), potassium carbonate (0.25 g, 1.81 mmol), 1,4-dioxane (4.2 mL), water (0.60 mL) and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) DCM complex (0.05 g, 0.06 mmol). The tube was sealed and the mixture was heated at 100 °C for 2 hours. After cooling, the reaction was quenched with 5% aqueous citric acid and extracted with EtOAc. The combined organic phases were filtered through celite, washed with saturated aqueous NaCl, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (0.27 g, 100%) which was used purified. ES-MS m / z 388 (M+H-BOC).
[0839] Preparation 154
[0840] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(7-methoxybenzothiophen-2-yl)phenyl]propanoic acid
[0841]
[0842] A sealed tube was charged with (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid (0.20 g, 0.45 mmol), 2-iodo-7-methoxy-benzothiophene (0.20 g, 0.68 mmol) and anhydrous DMF (4.5 mL). The reaction was purged with N2 for 10 minutes, then treated with aqueous potassium dihydrogen phosphate (1 M, 2.25 mL, 2.25 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.01 mmol) was added. The tube was sealed and the reaction mixture was stirred at 80 °C for 3 hours. The reaction was cooled to room temperature, purged with nitrogen for 5 minutes, re-treated with tetrakis(triphenylphosphine)palladium(0) (0.01 g, 0.01 mmol), and the reaction was stirred at 80 °C for 3 days. The reaction was cooled to room temperature. The mixture was quenched with 5% aqueous citric acid and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 10% to 40% acetone / hexane to give the title compound (0.15 g, 69%) as a beige solid. ES-MS m / z 480 (MH).
[0843] Preparation 155
[0844] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[3-(2,2,2-trifluoroethoxy)phenyl]phenyl]propanoic acid
[0845]
[0846] To a stirred mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (ammonium salt, 0.25 g, 0.60 mmol), 3-(2,2,2-trifluoroethoxy)phenylboronic acid (0.20 g, 0.90 mmol), potassium carbonate (0.25 g, 1.81 mmol), 1,4-dioxane (4.2 mL) and water (0.60 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) DCM complex (0.05 g, 0.06 mmol) at 100°C. The tube was sealed and the mixture was heated at 100°C overnight. Stir at room temperature for 24 hours. The reaction was quenched with 5% aqueous citric acid and extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (0.30 g, 100%) which was used without purification. ES-MS m / z 516 (M+Na).
[0847] Preparation 156
[0848] (2S)-3-[3-(1,3-Benzothiazol-2-yl)phenyl]-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0849]
[0850] A pressure vial was charged with (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid (0.25 g, 0.56 mmol), 2-bromo-1,3-benzothiazole (0.19 g, 0.84 mmol), DMF (5.6 mL), and aqueous potassium dihydrogen phosphate (1 M, 2.8 mL). The vial was warmed to 80 °C and tetrakis(triphenylphosphine)palladium(0) (0.013 g, 0.011 mmol) was added. The vial was sealed and the mixture was heated at 80 °C for 90 min. The reaction was quenched with 5% aqueous citric acid and extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (0.25 g, 100%), which was used in the next synthetic step without purification. ES-MS m / z 453 (M+H).
[0851] Preparation 157
[0852] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(3-phenylisoxazol-5-yl)phenyl]propanoic acid
[0853]
[0854] The tube was loaded with (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO 2020 / 247429, 100 mg, 0.25 mmol), (3-phenylisoxazol-5-yl)boric acid (61.7 mg, 0.33 mmol) and tetrakis(triphenylphosphine)palladium(0) (23.9 mg, 0.02 mmol). The tube was purged with nitrogen and then 1,4-dioxane (1 mL) was added. Nitrogen was purged and 2M K2CO3 aqueous solution (0.25 mL, 0.50 mmol) was added. The tube was purged with nitrogen for a third time, capped, and the reaction was stirred at 100 °C for 18 hours. An additional 26 mg of (3-phenylisoxazol-5-yl)boric acid was added and the reaction was stirred at 100 °C for an additional 2 hours. After cooling, the reaction was loaded onto an HLB column conditioned with ACN and aqueous NH4HCO3 and eluted with aqueous NH4HCO3 and ACN. The crude material was purified by reverse phase purification to give the title compound (116.1 mg, 100%). ES-MS m / z 463 (M+H).
[0855] Preparation 158
[0856] (2S)-3-(3-Aminophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0857]
[0858] A mixture of (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-nitrophenyl)propanoic acid (prepared essentially as described in WO2020 / 247429, 1.70 g, 4.67 mmol) and palladium (10% on activated carbon, paste type 87L, 0.17 g) in MeOH (25 mL) was stirred under H2 (balloon) at room temperature for 4 hours. The catalyst was removed by filtration through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 10% to 40% ACN / water to give the title compound (1.00 g, 64%) as a white solid. ES-MS m / z 235 (M+H-BOC).
[0859] Preparation 159
[0860] (2S)-3-(3-Azidophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0861]
[0862] The title compound was prepared by flow reaction, which was first prepared by preparing the following solutions: Solution A - (2S)-3-(3-aminophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.80 g, 2.39 mmol) and DMF (80 mL) treated with azidotrimethylsilane (0.34 g, 2.87 mmol); and Solution B - tert-butyl nitrite (0.37 g, 3.59 mmol) in DMF (80 mL). Solutions A and B were mixed through a flow reactor (PTFE tubing, 15 mL volume) with solution A at a flow rate of 0.1 mL / min and solution B at a flow rate of 0.13 mL / min at a temperature of 100°C to obtain a solution of the title compound (120 mL, 0.015 M), which was used without purification.
[0863] Preparation 160
[0864] (2S)-3-[3-(4-Benzyltriazol-1-yl)phenyl]-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0865]
[0866] A 0.015 M solution of (2S)-3-(3-azidophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid in DMF (10 mL, 0.15 mmol) was combined with a solution of prop-2-ynylbenzene (30 mg, 0.26 mmol), aqueous sodium ascorbate (0.2 M, 0.40 mL, 0.08 mmol), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (8.0 mg, 0.02 mmol) and aqueous copper(II) sulfate pentahydrate (0.05 M, 0.30 mL, 0.02 mmol). The reaction was stirred at 50 °C for 2 hours. Analysis indicated mainly starting material. More tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (8.0 mg, 0.02 mmol), aqueous sodium ascorbate solution (0.2 M, 0.40 mL, 0.08 mmol), and aqueous copper(II) sulfate pentahydrate solution (0.05 M, 0.30 mL, 0.02 mmol) were added. The reaction was stirred at 50 °C. Analysis indicated that some starting material was still present. Sodium ascorbate (0.2 M, 0.40 mL, 0.08 mmol) and aqueous copper(II) sulfate pentahydrate solution (0.05 M, 0.30 mL, 0.02 mmol) were added and the reaction was stirred at 50 °C for 2 hours. After cooling, water was added. The aqueous layer was extracted with EtOAc and the organic layer was dried over Na2SO4. The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase chromatography eluting with 20% to 50% ACN / water to give the title compound as a yellow thick oil (60.7 mg, 85%). ES-MS m / z 477 (M+H).
[0867] Prepare the following compounds essentially as described in Preparation 160 - using appropriate reagents, adjusting temperature and reaction time to ensure reaction completion, and adjusting the purification system as appropriate.
[0868]
[0869]
[0870] Preparation 164
[0871] (2S)-2-[(3R)-1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-(3-tetrahydropyran-4-ylphenyl)propanoic acid
[0872]
[0873] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429, 0.14 g, 0.35 mmol) and dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (0.01 g, 0.014 mmol) in anhydrous 2-methyltetrahydrofuran (1.1 mL) was degassed with nitrogen for 5 minutes. Then, bromo(tetrahydropyran-4-yl)zinc (3 mL, 0.5 mol / L in THF, 1.40 mmol) was added, the reaction vessel was sealed, and the reaction was heated to 100 °C for 30 minutes under microwave irradiation. Analysis still indicated the presence of starting material. 2-Methyltetrahydrofuran (1.1 mL) and dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (0.01 g, 0.014 mmol) were added, followed by bromo(tetrahydropyran-4-yl)zinc (4 mL, 0.5 mol / L in THF, 2.09 mmol) at room temperature under a nitrogen atmosphere. The reaction was heated again to 100°C for 30 minutes under microwave irradiation. The crude material from 50 mg of the reaction was added to the reaction. The mixture was filtered through a diatomaceous earth pad, and the filtrate was evaporated under reduced pressure. The residue was suspended in DMSO (2 mL) and ACN (3 mL). The suspension was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The remaining DMSO solution was purified by C18 reverse phase chromatography eluting with a gradient of 0% to 100% ACN / water. The resulting material was purified by reverse phase chromatography ( C18) was repurified to give the title compound as a white solid (10.5 mg, 7%). ES-MS m / z 402 (MH).
[0874] Preparation 165
[0875] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[(3-cyclobutylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0876]
[0877] Tert-butyl (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.44 mmol), dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) (7.36 mg, 0.01 mmol) were degassed several times in THF (1.76 mL). Cyclobutylzinc bromide (0.5 mol / L in THF, 1 mL) was added dropwise and the reaction was stirred at 70 °C for 1 hour. The reaction was evaporated under reduced pressure and the residue was dissolved in DCM and filtered to remove inorganics. The filtrate was evaporated under reduced pressure to give a brown oil which was purified by silica gel chromatography eluting with a gradient of 0% to 15% EtOAc / hexanes to give the title compound as an amber oil (0.11 g, 56%). ES-MS m / z 318 (M+H-2(tBu)).
[0878] Preparation 166
[0879] (Z)-3-Amino-3-ethoxy-prop-2-enenitrile
[0880]
[0881] Malononitrile (0.51 g, 7.57 mmol) and EtOH (0.38 g, 8.32 mmol) were dissolved in 2M HCl / Et2O (HCl in Et2O) (60.5 mL) at 0°C under nitrogen atmosphere. The reaction was allowed to warm to room temperature and stirred for 4 hours. The resulting precipitate was removed by filtration and washed thoroughly with Et2O. The solid was treated with saturated aqueous K2CO3 and extracted with Et2O. The organic layer was collected, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (0.51 g, 60%) as a white solid. 1 HNMR (400MHz, DMSO-d6) δppm 1.21 (t, J = 6Hz, 3H), 3.85 (d, J = 6Hz, 2H), 6.51 (s, 1H).
[0882] Preparation 167
[0883] (3R)-3-[(1S)-1-[[3-[[(E)-1-amino-2-cyano-vinyl]amino]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0884]
[0885] (Z)-3-amino-3-ethoxy-prop-2-enenitrile (50 mg, 0.45 mmol), (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429; 210 mg, 0.54 mmol) and EtOH (0.45 mL) were loaded into a tube. The reaction was stirred overnight at room temperature under a nitrogen atmosphere. After 20 hours, the reaction was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 5% to 20% acetone / DCM. The resulting material was repurified by reverse phase chromatography eluting with a gradient of 50% to 80% ACN / NH4HCO3 aqueous solution to give the title compound (64 mg, 31%) as a beige solid, which was a 60:40 mixture of cis and trans isomers. ES-MS m / z 457 (M+H).
[0886] Preparation 168
[0887] (3R)-3-[(1S)-2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-benzylsulfanylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0888]
[0889] Nitrogen was bubbled through a suspension of (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429, 1.0 g, 1.79 mmol) in toluene (4 mL) followed by the addition of tris(dibenzylideneacetone)dipalladium(0) (0.17 g, 0.18 mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.21 g, 0.36 mmol), N,N-diisopropylethylamine (0.26 g, 1.97 mmol) and benzyl mercaptan (0.23 g, 1.79 mmol). The reaction was stirred at 100 °C. After 16 hours, the reaction was cooled and filtered. The filtrate was treated with water and extracted with EtOAc. The organic layer was collected, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 20% to 50% EtOAc / hexanes. The resulting material was repurified by silica gel chromatography, washed with DCM, then eluted with a gradient of 20% to 50% EtOAc / hexanes to give the title compound (0.97 g, 71% purity, 64%). ES-MS m / z 501 (M+H-BOC).
[0890] Preparation 169
[0891] (3R)-3-[(1S)-2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0892]
[0893] A 0°C solution of (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-benzylsulfanylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (1.02 g, 1.21 mmol, 71 mass %) in ACN:acetic acid:water 40:1.5:1 (15 μL) was slowly treated with 1,3-dibromo-5,5-dimethylhydantoin (0.70 g, 2.41 mmol) in portions. The reaction was stirred at 0°C for 10 minutes. The reaction was concentrated under reduced pressure. The residue was dissolved in DCM, cooled to 0°C, and treated with 5% aqueous NaHCO3. After stirring for 5 minutes, the organic layer was collected, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound (1.1 g, 64 mass %, 100%), which was used in the next synthetic reaction without purification. ES-MS m / z 521 (M+H-BOC).
[0894] Preparation 170
[0895] (3R)-3-[(1S)-2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[[3-(dimethylsulfamoyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0896]
[0897] A room temperature solution of (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.54 g, 64 mass %, 0.60 mmol) in DCM (5 mL) was treated with TEA (0.12 g, 1.21 mmol) and dimethylamine (0.04 g, 40% in water, 0.90 mmol). The reaction was stirred at room temperature for 60 minutes. Water was added, the reaction was acidified with 1M aqueous HCl solution, and extracted with DCM. The organic layer was collected, dried over MgSO4, collected and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 25% to 100% EtOAc / hexanes to give the title compound (0.33 g, 93%) as an oil. ES-MS m / z 530(M+H- t Bu).
[0898] Preparation 171
[0899] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(dimethylsulfamoyl)phenyl]propanoic acid
[0900]
[0901] A solution of (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[[3-(dimethylsulfamoyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.33 g, 0.56 mmol) in THF (5 mL) was treated with 1M lithium hydroxide aqueous solution (0.84 mL, 0.84 mmol) and hydrogen peroxide (0.44 mL, 35 mass %, 4.48 mmol). The reaction was stirred for 16 hours. The reaction was treated with 1N NaOH aqueous solution and extracted with MTBE. The aqueous layer was collected, acidified with 1N HCl aqueous solution and extracted with EtOAc. The organic layer was collected, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 20% to 40% ACN / 20 mM aqueous NH4HCO3 to give the title compound as a white solid (73 mg, 30%). ES-MS m / z 371 (M+H- t Bu).
[0902] Preparation 172
[0903] (3R)-3-[2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-2-oxo-1-[[4-(trifluoromethyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0904]
[0905] A solution of (3R)-3-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429, 0.30 g, 0.77 mmol) in THF (7.72 mL) was treated with lithium bis(trimethylsilyl)amide (1.0 mol / L in THF) (0.93 mL, 0.93 mmol) at -78 °C, and the mixture was stirred for 90 minutes. The reaction was then treated with a solution of 4-(trifluoromethyl)benzyl bromide (0.20 g, 0.82 mmol) in THF (3.86 mL), and the resulting mixture was allowed to reach room temperature and stirred overnight. The reaction was quenched with saturated aqueous NH4Cl solution and extracted with EtOAc. The organic phase was washed with saturated aqueous NaCl solution, collected, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 60% to 90% ACN / NH4HCO3 aqueous solution to give the title compound as a colorless oil (0.20 g, 47%). ES-MS m / z 491 (M+H- t Bu).
[0906] Preparation 173
[0907] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[4-(trifluoromethyl)phenyl]propanoic acid
[0908]
[0909] A solution of (3R)-3-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxo-1-[[4-(trifluoromethyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.20 g, 0.37 mmol) in THF (2.5 mL) and water (0.48 mL) was treated with hydrogen peroxide (0.30 mL, 30% by mass in water, 2.93 mmol) at 0°C and then with lithium hydroxide (0.02 g, 0.64 mmol) in water (0.73 mL). The reaction mixture was stirred at 0°C. After 30 minutes, the reaction was quenched with sodium thiosulfate (0.24 g, 1.46 mmol) in water (0.73 mL) at 0°C and allowed to reach room temperature. The solution was extracted with EtOAc. The organic phase was concentrated under reduced pressure. The pH of the residue was adjusted to about 3 with 5% aqueous citric acid solution and extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 20% to 50% ACN / NH4HCO3 aqueous solution to give the title compound (60 mg, 40%) as a white solid. ES-MS m / z 288 (M+H-BOC).
[0910] Preparation 174
[0911] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]propanoic acid
[0912]
[0913] The title compound was prepared essentially as described in Preparation 23 using isothiazolidine 1,1-dioxide. Upon completion, the reaction was filtered through a pad of celite and the filtrate was concentrated to dryness. The residue was purified using an HLB column eluting with 0 to 100% ACN / NH4HCO3 in water (pH 9). ES-MS m / z 383 (M+H- t Bu).
[0914] Preparation 175
[0915] (3R)-3-[(1S)-1-[[3-[(3-bromophenoxy)methyl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0916]
[0917] A stirred solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 100 mg, 0.25 mmol) in anhydrous THF (2.47 mL) was treated with 3-bromophenol (0.06 g, 0.37 mmol) and triphenylphosphine (0.10 g, 0.37 mmol). After purging the reaction with N2, diisopropyl azodicarboxylate (0.07 g, 0.37 mmol) was added and the resulting mixture was allowed to stir at room temperature for 16 hours. The reaction was concentrated under reduced pressure and the residue was loaded onto diatomaceous earth. The residue was purified by silica gel chromatography eluting with a gradient of 10% to 40% MTBE / hexanes to give the title compound (107 mg, 75%). ES-MS m / z 558 / 560 (M+H).
[0918] Preparation 176
[0919] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-[(3-phenylphenoxy)methyl]phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0920]
[0921] A stirred suspension of (3R)-3-[(1S)-1-[[3-[(3-bromophenoxy)methyl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.11 g, 0.19 mmol), phenylboronic acid (0.03 g, 0.29 mmol), K2CO3 (0.08 g, 0.57 mmol) in 1,4-dioxane (1.9 mL) and water (0.19 mL) was treated with 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) DCM complex (0.02 g, 0.02 mmol). The resulting mixture was degassed for 5 minutes and heated at 90°C for 2 hours. The reaction was cooled, treated with water and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl solution, collected, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 5% to 20% MTBE / hexanes to give the title compound as a colorless oil (91 mg, 85%). ES-MS m / z 458 (M+H-BOC).
[0922] Preparation 177
[0923] (3R)-3-[(1S)-2-[(4S)-4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-benzyloxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0924]
[0925] Prepare the title compound essentially as described in Preparation 11 using 1-benzyloxy-3-(bromomethyl)benzene and purify the reaction product by silica gel chromatography using a gradient of 10 to 40% acetone / hexanes. ES-MS m / z 607 (M+Na).
[0926] Preparation 178
[0927] (2S)-3-(3-Benzyloxyphenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[0928]
[0929] The title compound was prepared essentially as described in Preparation 12 using (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-benzyloxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester and the reaction was stirred at room temperature for 3 hours, then additional portions of hydrogen peroxide and lithium hydroxide were added and the reaction was stirred at 0°C for an additional 2 hours. The reaction product was purified by silica gel chromatography using a gradient of 20 to 80% EtOAc / hexanes + 1 T acetic acid. ES-MS m / z 448 (M+Na).
[0930] Preparation 179
[0931] (3R)-3-[(1S)-1-[(3-benzyloxyphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0932]
[0933] A solution of (2S)-3-(3-benzyloxyphenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (4.86 g, 11.4 mmol) in toluene (103 mL) was treated with a solution of N,N-dimethylformamide di-tert-butyl acetal (12.9 g, 90 mass %, 57.1 mmol) in toluene (11.4 mL) at 80°C for 1 hour. After 3 hours, another aliquot of N,N-dimethylformamide di-tert-butyl acetal (12.9 g, 90 mass %, 57.1 mmol) in toluene (11.4 mL) was added dropwise and stirring was continued at 80°C overnight. The reaction was cooled to room temperature, diluted with EtOAc, washed with water and saturated aqueous NaCl solution, collected, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (5.7 g, 98%) as a yellow oil, which was used without purification. ES-MS m / z 370(M+H-2 t Bu).
[0934] Preparation 180
[0935] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0936]
[0937] A mixture of (3R)-tert-butyl 3-[(1S)-1-[(3-benzyloxyphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (4.45 g, 7.84 mmol) and palladium (10% on activated carbon, paste type 87L, 0.45 g, 0.42 mmol) in EtOAc (39 mL) was stirred under a hydrogen balloon at room temperature for 4 days. The reaction was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 10% to 40% acetone / hexanes to give the title compound (2.85 g, 93%) as a white solid. ES-MS m / z 280 (M+H-2 t Bu).
[0938] Preparation 181
[0939] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)methoxy]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0940]
[0941] A tube was loaded with tert-butyl (3R)-3-[(1S)-2-tert-butoxy-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (100 mg, 0.26 mmol), 5-(bromomethyl)-2,2-difluoro-1,3-benzodioxole (76.9 mg, 0.31 mmol), Cs2CO3 (100 mg, 0.31 mmol) and DMF (1.3 mL). The reaction was allowed to stir at room temperature overnight. The reaction temperature was raised to 45 °C, an additional ~0.32 mg of 5-(bromomethyl)-2,2-difluoro-1,3-benzodioxole was added and the reaction was stirred for an additional 3 hours. The reaction was concentrated under a stream of nitrogen and filtered through a celite column. The filtrate was diluted with EtOAc and washed with water, the organic layer was collected and concentrated under reduced pressure. The residue was purified by reverse phase chromatography under basic conditions to give the title compound as a white solid (66.7 mg, 47%). ES-MS m / z 584 (M+Na).
[0942] Prepare the following compounds essentially as described in Preparation 181 - using appropriate reagents, adjusting temperature and reaction time to ensure reaction completion, and adjusting the purification system as appropriate.
[0943]
[0944] Preparation 183
[0945] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(2-pyridylmethylaminothiocarbonylamino)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0946]
[0947] A 0°C solution of 1,1'-thiocarbonyldiimidazole (0.11 g, 90 mass %, 0.58 mmol) in ACN (1.4 mL) was slowly treated with a solution of tert-butyl (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 0.150 g, 0.38 mmol) in ACN (1.4 mL). The cooling bath was removed and the reaction was allowed to reach room temperature and stirred for 20 minutes. 2-(Aminomethyl)pyridine (0.08 g, 0.77 mmol) in ACN (1.4 mL) was added and the reaction was stirred at room temperature for 1.5 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography eluting with a gradient of 15% to 60% acetone / hexanes to give the title compound as a yellow solid (0.22 g, 107%). ES-MS m / z 541 (M+H).
[0948] Preparation 184
[0949] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-(imidazo[1,5-a]pyridin-3-ylamino)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0950]
[0951] (3R)-3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-(2-pyridylmethylaminothiocarbonylamino)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (0.22 g, 0.41 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.11 g, 0.56 mmol) and toluene (3.7 mL) were loaded into a sealed tube. The tube was sealed and heated at 110 ° C for 1 hour. The reaction was cooled to room temperature, quenched with saturated NaHCO3 aqueous solution and extracted with EtOAc (2x). The organic layers were combined, washed with saturated NaCl aqueous solution, collected, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 60% to 90% ACN / NH4HCO3 aqueous solution. The resulting material was repurified by reverse phase chromatography eluting with a gradient of 40% to 60% ACN (with 0.05% TFA) / water (with 0.05% TFA) to give the title compound as a white solid (41.3 mg, 20%). ES-MS m / z 507 (M+H).
[0952] Preparation 185
[0953] (R)-tert-Butyl 3-((S)-3-(3-(N-(Benzo[d][1,3]dioxol-5-ylmethyl)sulfamoyl)phenyl)-1-(tert-butoxy)-1-oxopropan-2-yl)pyrrolidine-1-carboxylate
[0954]
[0955] and (3R)-3-[(1S)-2-tert-butoxy-1-[[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethylsulfamoyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0956]
[0957] A room temperature solution of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (0.45 g, 64 mass %, 0.60 mmol) in DCM (3 mL) was treated with TEA (0.12 g, 1.21 mmol) and 1,3-benzodioxol-5-ylmethylamine; hydrate (0.11 g, 0.72 mmol). The reaction was stirred for 3 hours. Analysis of the reaction showed only sulfonyl chloride. 2,3-Dihydro-1,4-benzodioxin-6-ylmethylamine (0.12 g, 0.72 mmol) was added and stirring was continued for 2 hours. The reaction was diluted with 1N aqueous HCl (3 mL) and extracted with DCM. The organic layer was collected, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 25% to 75% EtOAc / hexanes. The two compounds were purified by reverse phase chromatography eluting with a gradient of 60% to 80% ACN / 20 mM NH4HCO3 aqueous solution to give (3R)-3-[(1S)-1-[[3-(1,3-benzodioxol-5-ylmethylsulfamoyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (20 mg, 6%, ES-MS m / z 489 (M+H-BOC)) and (3R)-3-[(1S)-1-[[3-(1,3-benzodioxol-5-ylmethylsulfamoyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (27 mg, 7%, ES-MS m / z 503 (M+H-BOC)).
[0958] The following were prepared using tert-butyl (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate and the appropriate amine essentially as described in Preparation 121. Prior to purification, the reaction mixture was concentrated and loaded onto SCX resin, which was washed with MeOH (the wash was discarded), then eluted with 2M NH3 / MeOH and the eluate was concentrated.
[0959]
[0960]
[0961] Preparation 189
[0962] (3R)-3-[(1S)-2-tert-Butyl-1-[[3-[(4-oxazol-5-ylanilino)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[0963]
[0964] The title compound was prepared essentially as described in Preparation 20 using 4-oxazol-5-ylaniline. Upon completion, the reaction was concentrated and loaded onto SCX resin which was washed with MeOH (wash discarded) and then eluted with 2M NH3 / MeOH and the eluent concentrated. The material was purified by reverse phase chromatography [column C1821×100mm, 5μm; mobile phase 70% to 90% ACN / NH4HCO3 aqueous solution (20mM, pH 9); flow rate 25mL / min] to obtain the title compound (98mg, 40%). ES-MS m / z548 (M+H).
[0965] Preparation 190
[0966] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-[(3-methoxy-N-methyl-anilino)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[0967]
[0968] The title compound was prepared essentially as described in Preparation 20 using 3-methoxy-N-methylaniline. Upon completion, the reaction was concentrated and loaded onto SCX resin, which was washed with MeOH (the wash discarded), then eluted with 2M NH3 / MeOH and the eluent concentrated. The residue was purified by reverse phase HPLC [column: C1821×100mm, 5μm; mobile phase: 70% to 90% ACN / NH4HCO3 aqueous solution (20mM, pH 9); flow rate 25mL / min] to obtain the title compound (46.5mg, 20%). ES-MSm / z 525 (M+H)
[0969] Preparation 191
[0970] (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (mixture of diastereomers)
[0971]
[0972] THF (90 mL) and diisopropylamine (4.60 g, 45.2 mmol) were added to a 500 mL round-bottom flask equipped with an N2 inlet, and the mixture was cooled to -70 °C. n-Butyl lithium n-Butyl lithium (11 g, 2.5 mol / L in hexane, 41.10 mmol) was added dropwise and stirred for 10 minutes. A solution of (3R)-3-(2-methoxy-2-oxoethyl) pyrrolidine-1-carboxylic acid tert-butyl ester (10 g, 41.1 mmol) in THF (30 mL) was added dropwise, and the mixture was stirred for 30 minutes. 3-Bromobenzyl bromide (11.3 g, 45.2 mmol) was added and the mixture was warmed to room temperature. After stirring at room temperature for 1 hour, the reaction was diluted with MeOH, concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluted with 20% EtOAc / hexane to obtain the title compound (11.5 g, 68%) as a colorless oil. ES-MS m / z 357(M+H- t Bu).
[0973] Preparation 192
[0974] 3-(3-Bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (isomer 1 and isomer 2)
[0975]
[0976] A solution of (3R)-tert-butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (10 g, 24.25 mmol) in MeOH (218 mL) and THF (218 mL) was treated with 1 M aqueous NaOH (243 mL). The resulting mixture was stirred at 50 °C for 2 hours. After cooling to room temperature, the reaction was concentrated under reduced pressure. The residue was dissolved in EtOAc, neutralized to pH 4 with aqueous citric acid and extracted with EtOAc (3x). The organic layers were combined, washed with saturated aqueous NaCl (2x), collected, dried over MgSO4, filtered and concentrated under reduced pressure to give the title compound as a colorless oil (9.5 g, 98%). ES-MS m / z 343 [M+H- t Bu] + .
[0977] By using 20% CO2 / IPA (CO2 in IPA) elution Chiral SFC chromatography on an AD column (5×25 cm, 5 μm) obtained isomer 1 and isomer 2 of tert-butyl (3R)-3-[rac-1-[(3-benzyloxyphenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (20.3 g, 51.0 mmol). The obtained isomers were separately dissolved in EtOAc and washed with 0.5 M aqueous HCl. The organic layer was collected, dried over Na2SO4 and concentrated under reduced pressure to obtain isomer 1 (first eluting isomer, 7.2 g, 36%) and isomer 2 (second eluting isomer, 8.1 g, 40%) as light yellow solids. ES-MS m / z 344 (M+H- t Bu).
[0978] Preparation 193
[0979] (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (isomer 2)
[0980]
[0981] A room temperature suspension of 3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (Isomer 2, 7.7 g, 19 mmol) in MeOH (19 mL) was slowly treated with (trimethylsilyl)diazomethane (12 g, 2M in hexanes, 33 mmol) and the reaction was stirred for 10 minutes. Two additional aliquots of (trimethylsilyl)diazomethane (12 g, 2M in hexanes, 33 mmol) were added and the reaction was stirred for 10 minutes after each addition. The reaction was concentrated under reduced pressure. The residue was dissolved in DCM and filtered through a small pad of silica gel. The filtrate was concentrated under reduced pressure to give the title compound (8.0 g, 100%) as a light brown oil. ES-MS m / z 356 / 358 (M+H- t Bu).
[0982] Preparation 194
[0983] (3R)-3-[1-(Benzyloxymethyl)-1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (mixture of diastereomers)
[0984]
[0985] A solution of (3R)-3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (1.01 g, 2.45 mmol) in THF (24.5 mL) was treated with potassium bis(trimethylsilyl)amide (5.39 mL, 1 M in THF, 5.39 mmol) at -78 °C. After 30 minutes, chloromethoxymethylbenzene (0.77 g, 4.90 mmol) dissolved in 5 mL of THF was added. The mixture was allowed to slowly warm to room temperature and then stirred at room temperature overnight. Saturated aqueous NH4Cl solution was added and the aqueous layer was extracted with EtOAc. The organic layer was collected, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by normal phase chromatography eluting with a gradient of 7% to 30% EtOAc / hexane to give the title compound (1.20 g, 73% by mass, 67%) as a colorless oil. ES-MS m / z 476 / 478 (M+H- t Bu).
[0986] Preparation 195
[0987] 2-(Benzyloxymethyl)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (mixture of diastereomers)
[0988]
[0989] Tert-butyl (3R)-3-[1-(benzyloxymethyl)-1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (1.2 g, 2.3 mmol) was dissolved in THF (9 mL) and MeOH (9 mL) and treated with 1 M aqueous NaOH solution (23 mL, 23 mmol). The reaction was stirred at 60 °C overnight. The reaction was treated again with 1 M aqueous NaOH solution (23 mL, 23 mmol) and continued to stir at 60 °C overnight. The reaction was diluted with MeOH (9 mL) and the reaction was heated at 80 °C for 5 hours. Due to slow hydrolysis, the reaction was concentrated under reduced pressure, and the residue was dissolved in MeOH (15 mL) and THF (9 mL), and the solution was treated with 5 M aqueous NaOH solution (9 mL, 370 mmol). The reaction was stirred at 80 °C overnight. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was placed in EtOAc and water. The pH of the aqueous layer was acidified with 1N aqueous HCl and extracted with EtOAc. The organic layer was collected, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 40% to 70% ACN / water to give the title compound as a white solid (0.58 g, 50%). ES-MS m / z 462 / 464 (M+H-t Bu).
[0990] Preparation 196
[0991] 2-(Benzyloxymethyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-phenylphenyl)propanoic acid (Isomer 1 and Isomer 2)
[0992]
[0993] A stirred mixture of 2-(benzyloxymethyl)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (0.58 g, 1.11 mmol), phenylboronic acid (0.209 g, 1.67 mmol) and potassium carbonate (0.46 g, 3.33 mmol, 100 mass %) in 1,4-dioxane (11.1 mL) and water (1.1 mL) was treated with 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) DCM complex (0.09 g, 0.11 mmol) at 100°C. The tube was sealed and the mixture was heated at 100°C overnight. The reaction was cooled to room temperature, diluted with EtOAc, filtered through celite and concentrated to dryness under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 40% to 70% ACN / water to give the title compound (700 mg).
[0994] The isomers were separated by SFC chromatography using a Chiralpak AD column (2×25 cm, 5 μm) eluted with 25% CO2 / IPA (containing 0.2% DMEA) to give Isomer 1 (130.3 mg, 23%) as a white solid. Isomer 2 was repurified by SFC chromatography using a Claricep C-series C18 column (20×250 mm, 5 μm) eluted with 25% CO2 / IPA (containing 0.2% DMEA) to give Isomer 2 (278.1 mg, 49%) as a white solid. ES-MS m / z 460 (M+H- t Bu).
[0995] Preparation 197a 2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-(hydroxymethyl)-3-(3-phenylphenyl)propanoic acid (isomer 2)
[0996]
[0997] A mixture of 2-(benzyloxymethyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-phenylphenyl)propanoic acid (Isomer 2, 100 mg, 0.19 mmol) and palladium (10% on activated carbon, paste type 87L, 0.1 g, 0.01 mmol) in EtOAc (1.9 mL) was stirred overnight at room temperature under hydrogen (balloon). The reaction progressed slowly, so it was filtered through diatomaceous earth and concentrated under reduced pressure. The residue was dissolved in EtOH (2.9 mL) and treated with palladium hydroxide / carbon (0.05 g) and stirred under hydrogen at 90-100 psi over the weekend. The reaction was filtered through diatomaceous earth and concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 30% to 60% ACN / water to give the title compound (0.12 g, 70% by mass, 24%). ES-MS m / z 326[M+H-Boc] + .
[0998] Preparation 197b
[0999] 2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-(hydroxymethyl)-3-(3-phenylphenyl)propanoic acid (isomer 1`1)
[1000]
[1001] The title compound was prepared essentially as described in Preparation 197a: using 2-(benzyloxymethyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-phenylphenyl)propanoic acid (Isomer 1), the starting material was stirred in EtOH with palladium hydroxide on carbon under H2 (100 psi) over the weekend. ES-MS m / z 326 [M+H-Boc] + .
[1002] Preparation 198
[1003] (3R)-3-[1-[(3-bromophenyl)methyl]-1-[(1,3-dioxoisoindolin-2-yl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (mixture of diastereomers)
[1004]
[1005] A solution of (3R)-tert-butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (1.22 g, 2.96 mmol) in THF (29.6 mL) was treated with potassium bis(trimethylsilyl)amide (1 M in THF, 6.51 mL, 6.51 mmol) at -78 °C. After 30 minutes, 2-(bromomethyl)isoindoline-1,3-dione (1.42 g, 5.92 mmol) dissolved in 10 mL of THF was added. The reaction was allowed to slowly warm to room temperature and stirred at room temperature overnight. The reaction was quenched with saturated aqueous NH4Cl solution and extracted with EtOAc. The organic layer was collected, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 15% to 60% acetone / hexanes to give the title compound as a white solid (0.60 g, 94 mass %, 33%). ES-MS m / z 473 (M+H-BOC).
[1006] Preparation 199
[1007] 2-[[3-(3-Bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-2-carboxy-propyl]carbamoyl]benzoic acid (mixture of diastereomers)
[1008]
[1009] A solution of (3R)-tert-butyl 3-[1-[(3-bromophenyl)methyl]-1-[(1,3-dioxoisoindolin-2-yl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (mixture of diastereomers, 0.60 g, 1 mmol) dissolved in MeOH (7 mL) and THF (7 mL) was treated with 5 M aqueous NaOH (4 mL, 20 mmol) and the reaction was stirred at 80 °C overnight. The reaction was allowed to cool to room temperature and then concentrated under reduced pressure. The residue was suspended in water and washed with Et2O. The aqueous layer was cooled to 0 °C and the pH was adjusted to 3 with 1 N aqueous HCl to obtain a solid, which was removed by filtration and washed with water to give the title compound (0.58 g, 100%) as a white solid after drying at 40 °C overnight. ES-MS m / z 475 / 477 (M+H-BOC).
[1010] Preparation 200
[1011] 2-[[2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxy-3-(3-phenylphenyl)propyl]carbamoyl]benzoic acid (mixture of diastereomers)
[1012]
[1013] A pressure tube was loaded with 2-[[3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-2-carboxy-propyl]carbamoyl]benzoic acid (mixture of diastereomers, 78 mg, 0.14 mmol), phenylboronic acid (25.6 mg, 0.20 mmol), potassium carbonate (56.2 mg, 0.41 mmol), 1,4-dioxane (1.4 mL) and water (0.14 mL). The reaction was warmed to 100 °C and treated with 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) DCM complex (11.3 mg, 0.01 mmol). The tube was sealed and the mixture was heated at 100 °C overnight. The reaction was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography eluting with a gradient of 20% to 50% ACN / water to give the title compound (35 mg, 45%). ES-MS m / z 473 (M+H-BOC).
[1014] The following were prepared essentially as described in Preparation 11: using (3R)-3-[2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429) and an appropriate alkyl bromide, the reaction was stirred at 0°C for 40-50 minutes, then the alkyl bromide was added and the product was purified by silica gel chromatography using a gradient of EtOAc / petroleum ether (starting at 0% EtOAc and increasing to 50-100% EtOAc).
[1015]
[1016]
[1017]
[1018]
[1019] These were prepared essentially as described in Preparation 12 using the appropriate starting materials, stirring the reaction mixture at room temperature for 16 hours before adding lithium hydroxide and omitting any chromatography steps after the reaction work-up.
[1020]
[1021]
[1022]
[1023] Preparation 218
[1024] (3R)-tert-Butyl 3-[(1S)-1-[(5-bromopyrazin-2-yl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[1025]
[1026] The title compound was prepared essentially as described in Preparation 79 using (2S)-3-(5-bromopyrazin-2-yl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid, THF as solvent and the reaction heated at 65°C for 16 hours. The reaction mixture was filtered, the filtrate poured into saturated aqueous NaCl solution and extracted with EtOAc. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / petroleum ether. f = 0.6, on silica gel plate, eluted with 17% EtOAc / petroleum ether and visualized with iodine. TLC (1:5 EtOAc / petroleum ether) R f =0.6.
[1027] Preparation 219
[1028] (3R)-3-[(1S)-1-[(3-Bromo-5-methyl-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1029]
[1030] The title compound was prepared essentially as described in Preparation 79: using (2S)-3-(3-bromo-5-methyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid, THF as solvent and heating the reaction at 65°C for 16 hours. The reaction mixture was filtered, the filtrate was poured into saturated aqueous NaCl solution and extracted with EtOAc. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / petroleum ether. TLC (1:5 EtOAc / petroleum ether) R f =0.6.
[1031] Preparation 220
[1032] 5-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]pyrazine-2-carboxylic acid methyl ester
[1033]
[1034] A mixture of (3R)-tert-butyl 3-[(1S)-1-[(5-bromopyrazin-2-yl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (150 mg, 0.30 mmol, 90 mass %) in MeOH (6 mL) was treated with TEA (0.5 mL, 4 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (26 mg, 0.03 mmol) at 25 °C in one portion. The reaction was stirred at 100 °C under CO (2 MPa) for 16 hours. The reaction was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 30% EtOAc / petroleum ether to give the title compound (100 mg, 62%) as a yellow oil. ES-MS m / z 436 (M+H).
[1035] Preparation 221
[1036] 5-[(2S)-3-tert-Butoxy-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]pyrazine-2-carboxylic acid
[1037]
[1038] A mixture of methyl 5-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]pyrazine-2-carboxylate (100 mg, 80 mass %, 0.18 mmol) in THF (2 mL), MeOH (1 mL) and water (0.5 mL) was treated with lithium hydroxide (50 mg, 1.98 mmol) at 25°C in one portion. The reaction mixture was stirred at 25°C for 3 hours. The pH of the reaction was adjusted to 7 with 1N HCl aqueous solution. The reaction was extracted with EtOAc (3×10 mL). The organic phases were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (90 mg, 105%) as a yellow oil, which was used in the next synthetic step without purification. ES-MS m / z 310 (M+H-2 t Bu).
[1039] Preparation 222
[1040] (3R)-3-[(1S)-1-[(2-bromo-4-iodo-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1041]
[1042] The title compound was prepared essentially as described in Preparation 79: using (2S)-3-(2-bromo-4-iodo-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid, the reaction was heated to 65°C for 16 hours. The reaction mixture was filtered, the filtrate was poured into saturated aqueous NaCl solution and extracted with EtOAc. The organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / petroleum ether. TLC (1:3 EtOAc / petroleum ether) R f =0.6.
[1043] Preparation 223
[1044] (3R)-tert-Butyl 3-[(1S)-1-[(2-bromo-4-cyanophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[1045]
[1046] A solution of (3R)-3-[(1S)-1-[(2-bromo-4-iodo-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (320 mg, 80 mass %, 0.44 mmol) in DMF (4 mL) was treated with zinc cyanide (165 mg, 1.36 mmol) and tetrakis(triphenylphosphine)palladium(0) (110 mg, 0.09 mmol). The reaction was stirred at 80 °C for 3 hours. The reaction was cooled to room temperature, diluted with water (100 mL) and extracted with EtOAc (3×40 mL). The organic layers were combined, washed with saturated aqueous NaCl solution (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 30% EtOAc / petroleum ether to give the title compound (230 mg, 98%) as a yellow oil. 1 H NMR (400MHz, methanol-d4) δppm 7.99(m,1H),7.67-7.65(m,1H),7.46-7.43(m,1H),3.70-3.60(m,1H),3.50-3.40(m,1H),3.35-3.00(m,4 H),2.75-2.65(m,1H),2.50-2.40(m,1H),2.00-1.90(m,1H),1.80-1.65(m,1H),1.47(s,9H),1.30(s,9H).
[1047] Preparation 224
[1048] (3R)-3-[(1S)-1-[(3-Azidophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1049]
[1050] A mixture of tert-butyl nitrite (280 mg, 2.58 mmol) and azidotrimethylsilane (160 mg, 1.32 mmol) in THF (10 mL) was treated portionwise at 0°C with a solution of tert-butyl (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 100 mg, 0.26 mmol) in THF (10 mL). The reaction was stirred at 25°C for 16 hours. The reaction was poured into saturated aqueous NaCl solution (15 mL) and extracted with EtOAc (3×15 mL). The organics were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (60 mg, 85 mass %, 48%) as a yellow oil, which was used in the next synthetic step without purification. 1 HNMR(400MHz,CDCl3)δppm 7.10-7.06(m,1H),6.82-6.76(m,1H),6.75-6.70(m,1H),6.69-6.64(m,1H),3.56-3.42(m,2H),3.373.30(m,1H),3.15-3.05(m,1H),2.9 0-2.80(m,1H),2.74-2.64(m,1H),2.63-2.56(m,1H),2.33-2.27(m,1H),2.25-2.17(m,1H),1.86-1.73(m,1H),1.32(s,9H),1.16(s,9H).
[1051] Preparation 225
[1052] tert-Butyl (2S)-3-(3-methylsulfanylphenyl)-2-[(3R)-pyrrolidin-3-yl]propanoate
[1053]
[1054] A solution of (3R)-tert-butyl 3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.51 mmol) in methyl disulfide (4 mL) was treated with copper(II) chloride (7 mg, 0.05 mmol) and isoamyl nitrite (60 mg, 0.50 mmol) at 25 °C. The reaction was stirred at 60 °C under N2 (15 psi). When the starting material had been consumed, the reaction was poured into saturated aqueous NaCl solution (100 mL) and extracted with DCM (3×200 mL). The organics were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 10% MeOH / DCM to give the title compound (120 mg, 39%) as a brown solid. ES-MS m / z 322[M+H-Boc] + .
[1055] Preparation 226
[1056] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[[3-(1-ethoxyvinyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[1057]
[1058] A solution of (3R)-tert-butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 501 mg, 1.05 mmol) in DMF (5 mL) was treated with tributyl(1-ethoxyvinyl)tin (1.35 g, 3.63 mmol) and tetrakis(triphenylphosphine)palladium(0) (246 mg, 0.21 mmol). The reaction was stirred at 100 °C for 3 hours. The reaction mixture was quenched with saturated aqueous KF solution (5 mL), stirred at 20 °C for 16 hours and filtered. The filtrate was diluted with water (50 mL) and extracted with EtOAc (3×40 mL). The combined organics were washed with saturated aqueous NaCl solution (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 30% EtOAc / petroleum ether to give the title compound as a yellow oil (200 mg, 90 mass %, 39%). 1H NMR (400 MHz, methanol-d4) δ ppm 7.46-7.45 (m, 2H), 7.30-7.12 (m, 2H), 4.64-4.63 (d, 1H, J = 2.4 Hz), 4.22-4.21 (d, 1H, J = 2.4 Hz), 3.91 (c, 2H, J = 6.8 Hz), 3.70-3.55 (m, 1H), 3.50-3.40 (m, 1H), 3.30-3.20 (m, 1 H),3.10-3.00(m,1H),2.85-2.80(m,2H),2.60-2.50(m,1H),2.40-2.30(m,1H),2.00- 1.90(m,1H),1.75-1.60(m,1H),1.47(s,9H),1.41(t,3H,J=6.8Hz),1.28-1.27(m,9H).
[1059] Preparation 227
[1060] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(2-trimethylsilylethynyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1061]
[1062] A mixture of (3R)-tert-butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.44 mmol) and trimethylsilylacetylene (180 mg, 1.80 mmol) in TEA (6 mL) was treated with 1,3-bis(diphenylphosphino)propane (40 mg, 0.1 mmol), tris(dibenzylideneacetone)dipalladium(0) (41 mg, 0.04 mmol) and copper(I) iodide (8.5 mg, 0.05 mmol) at 25 °C in one portion. The reaction was stirred at 120 °C under N2 (15 psi) for 16 h. The reaction was poured into saturated aqueous NaCl solution (20 mL) and extracted with EtOAc (3 x 25 mL). The combined organics were washed with water (2×20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 30% EtOAc / petroleum ether. The resulting material was repurified by reverse phase chromatography eluting with a gradient of 75% to 95% ACN / water (containing NH3 and NH4HCO3) to give the title compound (50 mg, 90 mass %, 22%) as a yellow oil. ES-MS m / z 472 (M+H).
[1063] Preparation 228
[1064] (3R)-3-[(1S)-2-tert-Butoxy-1-[(3-formyl-5-methyl-phenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1065]
[1066] A mixture of (3R)-3-[(1S)-1-[(3-bromo-5-methyl-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (400 mg, 90 mass %, 0.77 mmol) in THF (4 mL) was treated with n-butyl lithium (0.80 mL, 2.0 mmol, 2.5 mol / L in hexanes) in portions at -78 °C. The reaction was stirred at -78 °C for 1 hour. The reaction was then treated with a solution of DMF (0.30 mL, 3.9 mmol) in THF (1 mL) and the reaction was stirred at 25 °C for 16 hours. The reaction was poured into saturated aqueous NaCl solution (20 mL) and extracted with EtOAc (4×30 mL). The combined organics were collected, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 20% EtOAc / petroleum ether to give the title compound as a yellow oil (60 mg, 60 mass%, 11%). ES-MS m / z 318 (M+H-BOC).
[1067] Preparation 229
[1068] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[(3-methoxycarbonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[1069]
[1070] A mixture of (3R)-tert-butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 400 mg, 0.88 mmol), TEA (1.3 mL, 9.3 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (68 mg, 0.09 mmol) in MeOH (5 mL) was degassed 3 times with a CO atmosphere and stirred overnight at 110 °C under a CO atmosphere (2 MPa) for 72 hours. The reaction was cooled, poured into water (50 mL) and extracted with EtOAc (3×30 mL). The combined organics were washed with saturated aqueous NaCl (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% EtOAc / petroleum ether to give the title compound as a yellow oil (270 mg, 90 mass%, 83%). ES-MS m / z 334 (M+H).
[1071] Preparation 230
[1072] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-[(tert-butoxycarbonylamino)methyl]-5-methyl-phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1073]
[1074] A mixture of (3R)-3-[(1S)-1-[(3-bromo-5-methyl-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (500 mg, 1.07 mmol), potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (400 mg, 1.61 mmol), PdCl2(1,1'-bis(di-tert-butylphosphino)ferrocene))(140 mg, 0.213 mmol) and K2CO3 (470 mg, 3.23 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was degassed and purged with N2 three times. The mixture was stirred at 100° C. under N2 atmosphere overnight. The reaction mixture was combined with a reaction run essentially as described above using 100 mg (0.214 mmol) of starting aryl bromide. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (50 mL×3). The organics were washed with saturated aqueous NaCl (50 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / petroleum ether to give the title compound (300 mg, 40%) as a yellow oil. ES-MS m / z 419 (M+H-Boc).
[1075] Preparation 231
[1076] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1077]
[1078] A mixture of (3R)-3-[(1S)-1-[(3-bromo-5-methyl-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (1.0 g, 2.14 mmol) and pinacol borane (0.85 g, 6.44 mmol) in 1,2-dichloroethane (10 mL) was treated with dichlorobis(triphenylphosphine)palladium(II) (80 mg, 0.11 mmol) and TEA (1.5 mL, 11 mmol) at 25 °C. The reaction was stirred at 90 °C under an atmosphere of N2 (15 psi) for 16 hours. The reaction was concentrated under reduced pressure. The residue was purified by reverse phase HPLC eluting with a gradient of 60% to 100% ACN / water (containing NH3 and NH4HCO3) to give the title compound (0.35 g, 90 mass %, 29%) as a yellow oil. ES-MS m / z 516[M+H] + .
[1079] Preparation 232
[1080] (3R)-3-[(1S)-2-tert-Butoxy-1-[(3-hydroxy-5-methyl-phenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1081]
[1082] A solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (250 mg, 0.49 mmol) in THF (6 mL) was treated with sodium hydroxide (40 mg, 0.99 mmol) and hydrogen peroxide solution (110 mg, 30% by mass in water, 0.97 mmol) at 0°C. The reaction was stirred at 25°C for 3 hours. The reaction was combined with 50 mg of the reaction for post-processing. The reaction was poured into saturated aqueous NaCl solution (50 mL) and extracted with EtOAc (4×100 mL). The organics were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% EtOAc / petroleum ether to give the title compound as a yellow oil (240 mg, 80 mass%, 98%). ES-MS m / z 406.4 [M+H] + .
[1083] Preparation 233
[1084] (2S)-3-(2-Bromo-4-carbamoyl-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid
[1085]
[1086] A mixture of (3R)-3-[(1S)-2-[(4S)-4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(2-bromo-4-cyanophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (430 mg, 80 mass %, 0.59 mmol) in THF (8 mL) was treated with hydrogen peroxide (140 mg, 30% in water, 1.23 mmol) at 0°C in one portion. Then, a solution of lithium hydroxide (30 mg, 1.24 mmol) in water (2 mL) was added to the mixture in portions at 0°C. The reaction was stirred at 20°C for 3 hours. Saturated aqueous sodium bisulfite solution (30 mL) was added to the reaction over 5 minutes to raise the temperature to 30°C. The pH was adjusted to >12 with 5N aqueous NaOH and extracted with EtOAc (3×30 mL). The pH of the aqueous layer was adjusted to 2 with 2N HCl aqueous solution and extracted with EtOAc (3×30 mL). The organics from the acidic extractions were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (160 mg, 70 mass %, 43%) as a colorless oil. TLC (1:1 EtOAc / petroleum ether) R f =0.2.
[1087] Preparation 234
[1088] (3R)-tert-Butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[1089]
[1090] A mixture of (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (400 mg, ammonium salt, 0.96 mmol) in DMF (5 mL) was treated with sodium bicarbonate (250 mg, 2.98 mmol) and iodomethane (420 mg, 2.93 mmol) at 25 °C. The reaction was stirred at 25 °C for 16 hours. The reaction was poured into saturated aqueous NaCl solution (15 mL) and extracted with EtOAc (3×20 mL). The organics were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 20% EtOAc / petroleum ether to give the title compound (300 mg, 76%) as a yellow oil, which was used in the next synthetic step without characterization.
[1091] Preparation 235
[1092] (2S)-3-(3-Bromophenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid methyl ester
[1093]
[1094] Tert-butyl (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate (390 mg, 0.95 mmol) was treated with HCl (5 mL, 4 M in 1,4-dioxane, 20 mmol) at 25 °C. The reaction was stirred at 25 °C for 3 hours. The pH of the reaction was adjusted to 8 with saturated aqueous NaHCO3 and extracted with EtOAc (4×30 mL). The organics were collected, dried over Na2SO4, filtered and concentrated to react under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 80% EtOAc / petroleum ether to give the title compound (230 mg, 90 mass %, 70%) as a colorless oil. ES-MS m / z 312.1 (M+H).
[1095] Preparation 236
[1096] (2S)-2-[(3R)-pyrrolidin-3-yl]-3-(3-vinylphenyl)propanoic acid methyl ester
[1097]
[1098] A mixture of methyl (2S)-3-(3-bromophenyl)-2-[(3R)-pyrrolidin-3-yl]propanoate (230 mg, 0.74 mmol) and vinylboronic acid pinacol ester (180 mg, 1.11 mmol) in water (1 mL) and 1,2-dimethoxyethane (10 mL) was treated with potassium carbonate (200 mg, 1.45 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (58 mg, 0.08 mmol) at 25 °C. The reaction was stirred at 90 °C under N2 (15 psi) for 16 hours. The reaction mixture was combined with 20 mg of the reaction and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 20% MeOH / DCM to give the title compound (120 mg, 45%) as a yellow oil. TLC (DCM / MeOH=10:1) R f =0.5, observed by I2 staining.
[1099] Preparation 237
[1100] (3R)-3-[(1S)-2-tert-Butoxy-1-[[3-(hydroxymethyl)-5-methyl-phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1101]
[1102] A solution of (3R)-3-[(1S)-1-[(3-bromo-5-methyl-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (500 mg, 1.07 mmol), tributylstannylmethanol (412 mg, 1.28 mmol) and methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (100 mg, 0.12 mmol) in 1,4-dioxane (5 mL, 58.57 mmol) was degassed and purged with N2 three times. The reaction was stirred at 100 °C under N2 atmosphere overnight. This reaction was combined with 100 mg reaction for workup. The reaction was diluted with H2O (30 mL) and extracted with EtOAc (3×50 mL). The combined organics were washed with saturated aqueous NaCl (50 mL), dried over anhydrous Na2SO4, filtered and concentrated in a gradient of 0% to 50% EtOAc / petroleum ether to give the title compound as a yellow oil (400 mg, 90 mass%, 80%). ES-MS m / z 442 (M+Na).
[1103] Preparation 238
[1104] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1105]
[1106] A mixture of (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.44 mmol), bis(pinacolato)diboron (170 mg, 0.66 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (34 mg, 0.04 mmol) and potassium acetate (132 mg, 1.33 mmol) in 1,4-dioxane (3 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C overnight. The reaction was diluted with H2O (15 mL) and extracted with EtOAc (2×20 mL). The organic layer was washed with saturated aqueous NaCl solution (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% EtOAc / petroleum ether to give the title compound as a pale yellow oil (190 mg, 80 mass%, 69%). ES-MS m / z 502 (M+H).
[1107] Preparation 239
[1108] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-[1-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1109]
[1110] A mixture of [1-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]boronic acid (150 mg, 0.62 mmol), (3R)-tert-butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO2020 / 247429; 200 mg, 0.44 mmol), Na2CO3 (132 mg, 1.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (46 mg, 0.06 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was purged with N2 (3 times) and the reaction was stirred at 100° C. overnight. The reaction was diluted with H2O (25 mL) and extracted with EtOAc (2×20 mL). The organic layer was washed with saturated aqueous NaCl solution (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% EtOAc / petroleum ether to give the title compound (180 mg, 80% by mass, 41%) as a light yellow oil. ES-MS m / z 572 (M+H).
[1111] Preparation 240
[1112] (3R)-3-[(1S)-2-tert-Butoxy-2-oxo-1-[[3-(1H-pyrazol-3-yl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1113]
[1114] A solution of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-[1-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]phenyl]methyl]ethyl]pyrrolidine-1-carboxylate (180 mg, 80 mass%, 0.25 mmol) in THF (4 mL) was treated with tetrabutylammonium fluoride (1.3 mL, 1 N in THF, 1.3 mmol) and the reaction was stirred at 50 °C for 16 hours. The reaction was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organics were washed with saturated aqueous NaCl (30 mL), dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated under reduced pressure to give the title compound (150 mg, 80 mass%, 108%), which was used in the next synthetic step without purification. ES-MS m / z 442.3 (M+H).
[1115] Preparation 241
[1116] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[1-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]pyrazol-3-yl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1117]
[1118] A solution of (3R)-3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (100 mg, 80 mass % 0.16 mmol) and (3R)-3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-(1H-pyrazol-3-yl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (140 mg, 80 mass %, 0.25 mmol) in pyridine (4 mL) was treated with copper (II) acetate (60 mg, 0.33 mmol). The reaction was stirred at 70 °C under O2 overnight. The reaction was diluted with water (10 mL) and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with saturated aqueous NaCl solution (30 mL), collected, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 20% EtOAc / petroleum to leave an impure product. Secondary purification was performed by SFC [column: Daicel CHIRALPAKIC TM (250 mm×30 mm, 10 μm); mobile phase: solvent A=CO2, solvent B=EtOH+0.1% NH4OH; isocratic 35% solvent B in solvent A; flow rate 80 mL / min] to obtain the title compound (50 mg, 90 mass%, 35%) as a white solid. ES-MS m / z 815.7 (M+H).
[1119] Preparation 243
[1120] 3-[(2S)-3-tert-Butoxy-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]benzoic acid
[1121]
[1122] A solution of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[(3-methoxycarbonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (390 mg, 95 mass %, 0.85 mmol) in THF (4 mL) and MeOH (2 mL) was treated with lithium hydroxide (150 mg, 3.50 mmol) in water (1 mL) at 25°C. The reaction was stirred at 25°C for 12 hours. The reaction was concentrated under reduced pressure. The pH of the mixture was adjusted to 6 with HCl (1 N). The mixture was extracted with EtOAc (3×30 mL). The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (370 mg, 98%) as a white solid. ES-MS m / z 320 (M+H-BOC).
[1123] Preparation 244
[1124] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]carbamoyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1125]
[1126] A mixture of 3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]benzoic acid (320 mg, 0.72 mmol) and (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 290 mg, 0.74 mmol) in DMF (15 mL, 194 mmol, 100 mass %) was treated with N,N-diisopropylethylamine (380 mg, 2.94 mmol) and HATU (420 mg, 1.10 mmol) at 25 °C. The reaction was stirred at 25 °C for 15 h. The reaction was poured into saturated aqueous NaCl solution (30 mL) and extracted with EtOAc (3×50 mL). The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% EtOAc / petroleum ether to give the title compound (460 mg, 85 mass %, 68%) as a yellow oil. ES-MS m / z 692 (M+H-BOC).
[1127] Preparation 245
[1128] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]sulfonylamino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1129]
[1130] A mixture of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 270 mg, 0.69 mmol) in THF (5 mL) and pyridine (36 mg, 0.45 mmol) was stirred at room temperature for 0.5 h and treated with (3R)-3-[(1S)-2-tert-butoxy-1-[(3-chlorosulfonylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (300 mg, 90 mass %, 0.56 mmol) and stirred at room temperature for 2 h. The reactants were diluted with H2O (10 mL) and extracted with EtOAc (2×20 mL). The combined organic layers were washed with saturated aqueous NaCl solution (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 60% EtOAc / petroleum ether to give the title compound as a light yellow solid (330 mg, 90 mass%, 63%). ES-MS m / z 829 (M+H).
[1131] Preparation 246
[1132] (3R)-tert-Butyl 3-[(1S)-2-tert-butoxy-1-[(3-ethynylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[1133]
[1134] A mixture of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-(2-trimethylsilylethynyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylate (300 mg, 80 mass%, 0.51 mmol) in THF (2 mL) was treated with tetrabutylammonium fluoride (940 mg, 3.60 mmol) at 25 °C. When the reaction was complete [monitored by TLC (1:5 EtOAc: petroleum ether)], the mixture was poured into NH4Cl (20 mL) and extracted with EtOAc (3×25 mL). The combined organic phases were washed with water (2×20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (240 mg, 77 mass%, 91%) as a yellow oil. ES-MS m / z 422 (M+Na).
[1135] Preparation 247
[1136] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[1-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]triazol-4-yl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1137]
[1138] To a mixture of (3R)-3-[(1S)-1-[(3-azidophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (180 mg, 0.432 mmol) and (3R)-3-[(1S)-2-tert-butoxy-1-[(3-ethynylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (180 mg, 0.451 mmol) in tert-butanol (2 mL) and water (4 mL) were added copper sulfate (7 mg, 0.044 mmol), sodium ascorbate (26 mg, 0.13 mmol) and benzoic acid (30 mg, 0.25 mmol) in one portion at 25° C. The reaction mixture was stirred at 25° C. for 16 hours and then concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 30% EtOAc / petroleum ether to give the title compound as a yellow oil (200 mg, 51%). ES-MS m / z 816.5.
[1139] Preparation 248
[1140] (R)-3-((S)-1-(tert-butoxy)-3-(3-(5-((S)-3-(tert-butoxy)-2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-3-oxopropyl)pyrazine-2-carboxamido)phenyl)-1-oxopropan-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester
[1141]
[1142] To a mixture of 5-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]pyrazine-2-carboxylic acid (130 mg, 0.308 mmol) and (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 120 mg, 0.307 mmol) in DMF (4 mL) at 25° C. was added N,N-diisopropylethylamine (160 mg, 1.24 mmol) and HATU (180 mg, 0.473 mmol) in one portion. The reaction mixture was stirred at 25° C. for 5 hours and then combined with the reaction mixture run with 20 mg (0.038 mmol) of the starting carboxylic acid. The mixture was poured into a saturated aqueous NaCl solution (15 mL) and extracted with EtOAc (25 mL×4). The combined organic phase was dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 10% EtOAc / petroleum ether to give the title compound (200 mg, 69%) as a yellow oil. ES-MS m / z 694.6.
[1143] Preparation 249
[1144] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[2-[3-[4-[(2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-2-carboxyethyl]-2-pyridinyl]-2-oxo-imidazolidin-1-yl]-4-pyridinyl]propanoic acid
[1145]
[1146] A mixture of (2S)-3-(2-bromo-4-pyridinyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (2.1 g, 4.7 mmol), imidazolidin-2-one (330 mg, 3.83 mmol), methanesulfonic acid [(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] palladium (II) (400 mg, 0.493 mmol), sodium tert-butoxide (1.4 g, 14 mmol) in 1,4-dioxane (15 mL) was stirred at 100° C. for 16 hours under N2 (15 psi). The reaction mixture was concentrated and the residue was purified by HPLC [column: Welch C18 250×50 mm, 10 μm; mobile phase: solvent A=aqueous formic acid, solvent B=ACN; gradient 20 to 100% solvent B in solvent A] to give the title compound as a yellow oil (100 mg, 3%). ES-MS m / z 723.5.
[1147] Preparation 250
[1148] (3R)-3-[(1S)-1-[(2-Bromo-5-iodo-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1149]
[1150] To a mixture of (2S)-3-(2-bromo-5-iodo-phenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (4.9 g, 6.5 mmol) in THF (60 mL) was added 2-tert-butyl-1,3-diisopropylisourea (4 g, 19.6 mmol) at 25 ° C. The reaction mixture was stirred at 70 ° C for 16 hours, then diluted with water (150 mL) and extracted with EtOAc (200 mL×3). The combined organic layer was washed with saturated aqueous NaCl solution (100 mL×2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / petroleum ether to give the title compound (2 g, 48%) as a yellow oil. TLC (1:3 EtOAc / petroleum ether) R f =0.7.
[1151] Preparation 251
[1152] (3R)-tert-Butyl 3-[(1S)-1-[(2-bromo-5-cyanophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate
[1153]
[1154] Zinc cyanide (380 mg, 3.14 mmol) and tetrakis(triphenylphosphine)palladium(0) (730 mg, 0.625 mmol) were added to a solution of (3R)-3-[(1S)-1-[(2-bromo-5-iodo-phenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (2 g, 3.1 mmol) in DMF (30 mL) at 25 ° C, and the mixture was stirred at 80 ° C for 1 hour under N2. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL×3). The combined organic layers were washed with saturated aqueous NaCl solution (100 mL×2), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / petroleum ether to give the title compound (1.38 g, 88%) as a yellow oil. TLC (1:3 EtOAc / petroleum ether) R f =0.6.
[1155] Preparation 252
[1156] (3R)-3-[(1R)-2-tert-butoxy-1-[[3-[2-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-4-cyano-anilino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1157]
[1158] To a solution of (3R)-tert-butyl 3-[(1S)-1-[(2-bromo-5-cyanophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (180 mg, 0.376 mmol) in 1,4-dioxane (15 mL) was added potassium tert-butoxide (130 mg, 1.12 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (60 mg, 0.082 mmol) and (3R)-tert-butyl 3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 180 mg, 0.461 mmol). The reaction mixture was stirred at 100 °C under N2 for 4 hours. The reaction mixture was poured into water (100 mL), and the aqueous layer was extracted with EtOAc (100 mL×3). The organic layer was dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 100% EtOAc / petroleum ether to give the title compound (20 mg, 5%) as a yellow solid. ES-MS m / z 633.3 (M-Boc-tert-butyl).
[1159] Preparation 253
[1160] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-5-methyl-phenyl]methylamino]methyl]-5-methyl-phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1161]
[1162] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[(3-formyl-5-methyl-phenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (300 mg, 0.719 mmol) in THF (3 mL) was added ammonium acetate (250 mg, 3.24 mmol) and the mixture was stirred at 20° C. for 30 minutes. Sodium triacetoxyborohydride (460 mg, 2.17 mmol) was then added to the mixture and the mixture was stirred at 20° C. for 2 hours. Saturated aqueous NaCl solution (300 mL) was added to the reaction mixture and the mixture was extracted with EtOAc (200 mL×3). The combined organic phases were washed with water (200 mL×2, then 150 mL×3), then dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 50% EtOAc / petroleum ether to give the title compound (150 mg, 25%). TLC (3:1 petroleum ether:EtOAc) R f =0.2.
[1163] Preparation 254
[1164] (3R)-3-[(1S)-1-[[3-[[bis[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-5-methyl-phenyl]methyl]amino]methyl]-5-methyl-phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1165]
[1166] To (3R)-3-[(1S)-2-tert-butoxy-1-[(3-formyl-5-methyl-phenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 0.359 mmol) and (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3- To a solution of tert-butyl]-[[(2-((2-((((((((((((((((((((((((((-(((-1-oxypropyl-5-methyl-phenyl-1-oxypropyl-5-methyl-phenyl-1-oxypropyl-amino)methyl-5-methyl-phenyl-1-oxyethyl-2-oxoethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (( ...
[1167] Preparation 255
[1168] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-5-methyl-phenyl]methyl-[(3-fluoro-5-methoxy-phenyl)methyl]amino]methyl]-5-methyl-phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1169]
[1170] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]-5-methyl-phenyl]methylamino]methyl]-5-methyl-phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (50 mg, 0.061 mmol) in THF (3 mL) was added acetic acid (20 mg, 0.33 mmol), and the mixture was stirred at 20° C. for 30 minutes, and then sodium triacetoxyborohydride (40 mg, 0.19 mmol) was added. The mixture was stirred at 20° C. under N2 for 1 hour, then diluted with H2O (20 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with saturated aqueous NaCl solution (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the title compound (100 mg, quantitative yield), which was used without further purification. ES-MS m / z 959.5 (M+H).
[1171] Preparation 256
[1172] (3R)-3-[(1S)-1-[(3-allylphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1173]
[1174] To a mixture of (3R)-3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 500 mg, 1.10 mmol) and 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (560 mg, 3.33 mmol) in water (1 mL) and 1,2-dimethoxyethane (10 mL) was added potassium carbonate (460 mg, 3.33 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (90 mg, 0.12 mmol), and the reaction mixture was stirred at 90 °C under N2 for 16 h. Saturated aqueous NaCl solution (20 mL) was added to the reaction mixture. Then, the mixture was extracted with EtOAc (30 mL×3), the combined organic phases were washed with water (20 mL×2), dried over Na2SO4, filtered and concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 20% EtOAc / petroleum ether to give the title compound (300 mg, 59%) as a yellow oil. TLC (1:5 EtOAc / petroleum ether) R f =0.7 (I2 staining).
[1175] Preparation 257
[1176] (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]propyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1177]
[1178] To a mixture of (3R)-tert-butyl 3-[(1S)-1-[(3-allylphenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (120 mg, 0.289 mmol) and (3R)-tert-butyl 3-[(1S)-1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.440 mmol) in 1,4-dioxane (4 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (25 mg, 0.034 mmol), TEA (80 mg, 0.80 mmol) and the reaction mixture was stirred at 70 °C under N2 for 16 h. The mixture was combined with a reaction run essentially as described above using 200 mg (0.481 mmol) of starting olefins, and the resulting mixture was concentrated to dryness under reduced pressure. The residue was purified by silica gel chromatography using a gradient of 0 to 10% EtOAc / petroleum ether to give (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[(E)-3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]allyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 59%) as a yellow oil.
[1179] To a mixture of (3S)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[[3-[(E)-3-[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]allyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (130 mg, 0.148 mmol) in MeOH (10 mL) was added palladium (10 wt% on carbon, 30 mg, 0.0282 mmol) at 25° C. The reaction mixture was stirred at 25° C. under H (45 PSI) for 16 h.
[1180] The reaction mixture was combined with a mixture run with 20 mg (0.022 mmol) of the starting olefin. The mixture was filtered and the filtrate was concentrated to dryness under reduced pressure to give the title compound (110 mg, 54%) as a yellow oil. TLC (1:5 EtOAc: petroleum ether) R f =0.6.
[1181] Preparation 258
[1182] (2S)-2-[(3R)-1-tert-Butoxycarbonylpyrrolidin-3-yl]-3-[3-[2-(cyclohexyloxy)-3-pyridinyl]phenyl]propanoic acid
[1183]
[1184] (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO2020 / 247429, 100 mg, 0.25 mmol), 2-(cyclohexyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (114 mg, 0.38 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (19 mg, 0.03 mmol), 2M aqueous potassium carbonate solution (0.38 mL) and 1,4-dioxane (1.7 mL) were transferred to a reaction vessel, purged with N2, sealed and stirred at 100°C for 2 hours. The reaction was concentrated under a stream of nitrogen. The residue was taken up in EtOAc and extracted with water. The aqueous layer was acidified with 5% acetic acid and extracted with EtOAc. The organic layer was concentrated under a stream of nitrogen and purified by reverse phase chromatography to give the title compound as a white solid (57.4 mg, 46%). ES-MS m / z 495 (M+H).
[1185] Prepare the following essentially as described in Preparation 258 using the appropriate boronic acid or boronate ester.
[1186]
[1187] The following were prepared essentially as described in Preparation 10 using 2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]acetic acid (prepared essentially as described in WO2020 / 247429) and appropriate heterocyclic starting materials. The compounds in the following table were purified by HPLC (column: C1875×30mm, 3μm; mobile phase: solvent A-NH4OH+NH4HCO3 aqueous solution, solvent B-ACN; flow rate: 25mL / min).
[1188]
[1189]
[1190]
[1191]
[1192] Example 1a
[1193] 3-(3-Ethynylphenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid; hydrochloride - isomer 1
[1194]
[1195] To 2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-ethynylphenyl)propanoic acid isomer 1 (454 mg, 1.32 mmol) was added HCl in Et2O (2.0 M, 13 mL, 26 mmol) and the mixture was stirred at room temperature for 6 hours. The solvent was removed and the residue was dried in vacuo at 40°C overnight to give the title compound as a white powder (370 mg, 100%). ES-MS m / z 244 (M+H).
[1196] Example 1b
[1197] 3-(3-Ethynylphenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid; hydrochloride - isomer 2
[1198]
[1199] Prepare the title compound essentially as described in Example 1a using 2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-ethynylphenyl)propanoic acid Isomer 2. ES-MS m / z 244 (M+H).
[1200] Example 2a
[1201] 3-(6-Chloro-3-pyridinyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid; hydrochloride - isomer 1
[1202]
[1203] To a solution of 2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(6-chloro-3-pyridyl)propanoic acid-isomer 1 (20 mg, 0.056 mmol) in DCM (2 mL) was added HCl (4 M in 1,4-dioxane, 2 mL) and the reaction was stirred at room temperature for 1 hour. The solvent was removed in vacuo, and the residue was then dissolved in water and loaded onto 5 g of SCX resin. The resin was eluted with ACN, and the eluent was discarded. The resin was then eluted with 2M NH3 / MeOH, and the eluent was concentrated in vacuo to give the title compound as a white solid (13 mg, 91%). ES-MS m / z 255 (M+H).
[1204] Example 2b
[1205] 3-(6-Chloro-3-pyridinyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid; hydrochloride - isomer 2
[1206]
[1207] The title compound was prepared essentially as described in Example 2a using 2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(6-chloro-3-pyridinyl)propanoic acid Isomer 2. ES-MS m / z 255 (M+H).
[1208] Example 3
[1209] (2S)-3-(3-Methyl-5-ureido-phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid; hydrochloride
[1210]
[1211] Prepare the title compound essentially as described in Example 1a using (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-(3-methyl-5-ureido-phenyl)propanoic acid. ES-MS m / z 292 (M+H).
[1212] Example 4
[1213] (2S)-3-[3-[(3-Fluoro-5-methoxy-anilino)methyl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid; dihydrochloride
[1214]
[1215] To a solution of (3R)-3-[(1S)-2-tert-butoxy-1-[[3-[(3-fluoro-5-methoxy-anilino)methyl]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (433 mg, 0.82 mmol) in DCM (10 mL) was added hydrochloric acid (4M in 1,4-dioxane, 10 mL, 40 mmol) and the mixture was stirred at room temperature for 4 hours. The solvent was removed in vacuo. The residue was dissolved in water and concentrated to remove residual solvent to obtain the title compound (350 mg, 99%). ES / MS m / z 373 (M+H).
[1216] The following examples were prepared essentially as described in Example 4 using the appropriate starting materials, either Boc-protected 2-(pyrrolidin-3-yl)propanoic acid (Preparations 12, 23-33, and 50) or Boc-protected tert-butyl 2-(pyrrolidin-3-yl)propanoate (Preparations 13-22, 34-40, 43-46, and 51). Examples 5a and 5b were prepared using (2S)-3-(3-bromophenyl)-2-(1-tert-butoxycarbonyl-4,4-difluoro-pyrrolidin-3-yl)propanoic acid-isomer 1 and isomer 2 (Preparation 12) as starting materials, respectively.
[1217]
[1218]
[1219]
[1220]
[1221]
[1222]
[1223]
[1224]
[1225]
[1226]
[1227] A.RP-HPLC / MS[column:XBridge TM C18; mobile phase: solvent A = 20 mM NH4HCO3 aqueous solution (pH 9), solvent B = ACN]. After purification, the compound was dissolved in water and 1N HCl aqueous solution was added, then evaporated to dryness and further dried in vacuo
[1228] B. Use HCl (2M) in Et2O instead of HCl (4M in 1,4-dioxane)
[1229] C. Use hydrochloric acid (4M in 1,4-dioxane) as solvent
[1230] D. Use water as solvent
[1231] E. RP-HPLC / MS [column: Kinetex EVO 30×100 mm, 5 μm; mobile phase: solvent A=10 mM NH4HCO3 aqueous solution (pH 10)+5% MeOH, solvent B: ACN; flow rate: 80 mL / min]. After purification, the compound was dissolved in water and 1N HCl aqueous solution was added, then evaporated to dryness and further dried in vacuo.
[1232] Embodiment 39
[1233] (2S)-3-[3-[[3-[(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl]carbamoylamino]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid; dihydrochloride
[1234]
[1235] A solution of HCl (4.0 M in 1,4-dioxane, 170 mL, 694 mmol) was added to a mixture of (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[[3-[[3-[(2S)-3-tert-butoxy-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]carbamoylamino]phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate (56 g, 69.4 mmol) in 1,4-dioxane (56 mL). The mixture was stirred at room temperature overnight. The resulting solid was filtered, washed with 1,4-dioxane, and dried under reduced pressure at 40°C. The solid was triturated in tert-amyl alcohol (600 mL) overnight. The solid was collected, washed with tert-amyl alcohol, and then dried under reduced pressure at 40°C. The solid was stirred with tert-amyl alcohol (400 mL) and water (60 mL) to obtain a solution, which was concentrated in vacuo. The resulting solid was stirred in tert-amyl alcohol (400 mL) at room temperature for 72 hours, then filtered and washed with tert-amyl alcohol, and dried in vacuo at 40°C to obtain the title compound (39.0 g, 99%). ES / MS (m / z): 494 (M+H). Analytical chiral HPLC [column: C18 2.1×50mm, 3.5μm, mobile phase: ACN / NH4HCO3 aqueous solution (10mM, pH 9.0); flow rate: 1.2mL / min; column temperature: 50℃] showed de>98%.
[1236] Prepare the following essentially as described in Example 39 using the appropriate starting material, Boc-protected 2-(pyrrolidin-3-yl)propanoic acid or Boc-protected tert-butyl 2-(pyrrolidin-3-yl)propanoate.
[1237]
[1238]
[1239]
[1240]
[1241]
[1242]
[1243]
[1244]
[1245]
[1246]
[1247]
[1248]
[1249]
[1250]
[1251]
[1252]
[1253]
[1254]
[1255]
[1256]
[1257]
[1258]
[1259]
[1260]
[1261]
[1262]
[1263]
[1264]
[1265]
[1266] A. Reverse phase HPLC purification [column: Bonus RP 21×100 mm, 5 μm; mobile phase: solvent A—TFA aqueous solution (0.05%) pH 2.5, solvent B—ACN+0.05% TFA]
[1267] B. HCl (2 M) in Et2O) was used instead of HCl (4 M in 1,4-dioxane), and DCM was used as the reaction solvent.
[1268] C. After complete deprotection, the product is isolated by concentrating the reaction mixture to dryness
[1269] D. Using Isomer 1 of the Starting Material
[1270] E. Using Isomer 2 of the Starting Material
[1271] F. Using Isomer 3 of the Starting Material
[1272] G. Using Isomer 4 of the Starting Material
[1273] H. The product was prepared with ACN + water
[1274] I. After complete deprotection, the product was isolated by adding MTBE and the solid was collected by filtration
[1275] J. Preparation of products with MTBE
[1276] K. After purification, the HCl salt was prepared by mixing the free base with water and 2M HCl / Et2O, then evaporated to dryness and further dried in vacuo.
[1277] L. Reversed-Phase Flash Chromatography with ACN / NH4HCO3 Aqueous Gradient Elution
[1278] M. Reverse phase HPLC purification [column: XBridge TM C18; mobile phase: solvent A = 20 mM NH4HCO3 aqueous solution (pH 9), solvent B = ACN]
[1279] N. After purification, the HCl salt was prepared by mixing the free base with water and 1 N aqueous HCl solution, then evaporated to dryness and further dried in vacuo.
[1280] O. Use HCl (5.5 M) in IPA instead of HCl (4 M in 1,4-dioxane)
[1281] P. Starting material used: (3R)-3-[(1S)-1-[[3-[[(E)-1-amino-2-cyano-vinyl]amino]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1282] Q. Strong cation exchange (SCX) purification, eluting with NH3 / MeOH
[1283] R. Reverse phase HPLC purification [column: Welch C18150×25mm,5μm; mobile phase-solvent A=HCl aqueous solution, solvent B=ACN]
[1284] S. Reverse phase HPLC purification [column: NX C1875×30mm, 3μm; mobile phase: solvent A = 10mM NH4HCO3 aqueous solution, solvent B = ACN]
[1285] T. Reverse phase HPLC purification [column: Welch C18150×25mm,5μm; mobile phase-solvent A=NH4HCO3 aqueous solution, solvent B=ACN]
[1286] U. Starting material used: (2S)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-3-[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]propanoic acid; the 1,2-thiazolidine ring was opened under these conditions.
[1287] V. Starting material used: (3R)-tert-butyl 3-[(1S)-2-tert-butoxy-1-[[3-(1-ethoxyvinyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate
[1288] W. Starting material used: (3R)-3-[(1S)-2-tert-butoxy-1-[[3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester
[1289] Embodiment 69
[1290] (2S)-3-[3-[[3-[(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]-5-(trifluoromethyl)phenyl]carbamoylamino]-5-(trifluoromethyl)phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid; dihydrochloride
[1291]
[1292] A mixture of (3R)-3-[(1S)-1-[[3-amino-5-(trifluoromethyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (346mg, 0.755mmol) and 1,1'-carbonyldiimidazole (61mg, 0.38mmol) in THF (7.5mL) was stirred for 16 hours. The reaction mixture was acidified with 1M HCl aqueous solution and extracted with EtOAc. The organic layer was separated and dried over MgSO4, filtered and concentrated. The crude material was dissolved in DCM (2mL) and 4MHCl / dioxane (HCl in dioxane) (3mL) was added. The reaction was stirred for 16 hours. The solvent was evaporated in vacuo. The residue was purified by reverse phase flash chromatography using a gradient of 20 to 60% ACN / NH4CO3 aqueous solution (pH9) to obtain a free base product. This material was treated with 1 M aqueous HCl (1 mL) and the solvent was evaporated to afford the title compound (30 mg, 5%). ES / MS (m / z): 631 (M+1).
[1293] Embodiment 70
[1294] (2S)-3-[4-[4-[(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]anilino]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid; dihydrochloride
[1295]
[1296] (3R)-tert-butyl 3-[(1S)-1-[(4-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (620 mg, 1.36 mmol), (3R)-tert-butyl 3-[(1S)-1-[(4-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (799 mg, 2.05 mmol), [tBuBrettPhos Pd(allyl)]OTf (80 mg, 0.10 mmol) and cesium carbonate (1.33 g, 4.09 mmol) were combined in a microwave vessel and then argon-bubbled dioxane (14 mL) was added. The reaction mixture was heated to 100 °C in a microwave reactor for 12 hours. The reaction mixture was then concentrated to dryness under reduced pressure and the residue was purified by silica gel chromatography eluting with a gradient of 0-50% EtOAc / hexanes. The residue was dissolved in 4N HCl-dioxane (24 mL), stirred until the desired product was observed, concentrated to a solid, and purified by reverse phase HPLC [column: Kinetex Evo 100×30 mm 5 μm; mobile phase: solvent A=10 mM NH4HCO3 aqueous solution+5% MeOH, solvent B=ACN; gradient: 0 to 10% solvent B in solvent A]. The isolated product was dissolved in HCl (1N aqueous solution) and lyophilized to give the title compound (130 mg, 18%) as a yellow solid. ES / MS (m / z): 452 (M+H).
[1297] Embodiment 146
[1298] (2S)-3-[3-(Pyrimidin-5-yl)phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride
[1299]
[1300] A mixture of pyrimidin-5-ylboronic acid (40 mg, 0.33 mmol), tetrakis(triphenylphosphine)palladium(0) (24 mg, 20 mmol), (2S)-3-(3-bromophenyl)-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (prepared essentially as described in WO 2020 / 247429, 100 mg, 251 mmol), K2CO3 (2M aqueous solution, 251 μL, 0.502 mmol) and 1,4-dioxane (1 mL) was purged with N2 and incubated at 100°C for 18 hours. The reaction mixture was concentrated under N2 and the residue was then purified on a hydrophobic lipophilic balance (HLB) column eluting with a gradient of 0 to 100% ACN / NH4HCO3 aqueous solution (pH 9). To the residue was added HCl (4M in 1,4-dioxane, 627 μL, 2.51 mmol) and the reaction was stirred at room temperature for 3 hours. The mixture was concentrated to give the title compound (71 mg, 85%). ES-MS m / z 298 (M+H).
[1301] Embodiment 147
[1302] (2S)-3-(3-{[3-(hydrazinecarbonyl)phenoxy]methyl}phenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride
[1303]
[1304] To a reaction vessel containing (3R)-3-[(1S)-2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared substantially as described in WO 2020 / 247429; 125 mg, 0.308 mmol) was added sequentially: 3-(1,3,4-oxadiazole-2-yl)phenol (75 mg, 0.462 mmol), triphenylphosphine (123 mg, 0.462 mmol), THF (1 mL) and finally diethyl azodicarboxylate (73 μL, 81 mg, 0.462 mmol). The reaction mixture was stirred at room temperature for 24 hours, and the mixture was then evaporated to dryness. The residue was placed in DCM and passed through a silica gel plug, eluted with 20 / 80 acetone / hexane. The filtrate was concentrated, and the residue was purified by reverse phase HPLC [column: C1819×100mm, 5μm; mobile phase: solvent A=20mM NH4HCO3 (pH 9), solvent B=ACN, gradient: 62-93% solvent B in solvent A; flow rate 25mL / min]. The product was treated with HCl (4M solution in 1,4-dioxane, 77μL) at 50°C overnight, and then the solvent was evaporated to give the title compound (12mg, 7%). ES-MS m / z 384 (M+H).
[1305] Embodiment 148
[1306] (2S)-3-{3-[3-(3-hydroxyphenyl)-2-oxoimidazolidin-1-yl]phenyl}-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride
[1307]
[1308] To a solution of (2S)-3-[3-[3-(3-benzyloxyphenyl)-2-oxo-imidazolidin-1-yl]phenyl]-2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid (1.10 g, 1.88 mmol) in toluene (18.8 mL) at 70 °C was added N,N-dimethylformamide di-tert-butyl acetal (3.39 g, 4.02 mL 15.0 mmol) and the reaction was heated at 70 °C for 3 days. The reaction was concentrated and the residue was purified on silica gel using a gradient of 0 to 50% EtOAc / hexanes to give (3R)-tert-butyl 3-[(1S)-1-[[3-[3-(3-benzyloxyphenyl)-2-oxo-imidazolidin-1-yl]phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate (345 mg, 27%), a portion of which (120 mg, 0.187 mmol) was diluted with DCM (6 mL) and cooled to 0° C. Boron tribromide (1M in heptane, 0.56 mL, 0.56 mmol) was added dropwise and the reaction was stirred at 0° C. for 30 minutes. MeOH was added and the reaction was concentrated. The residue was purified by HPLC [column: Kinetex Evo C18 3×100 mm, 5 μm; mobile phase: solvent A=0.1% aqueous formic acid, solvent B=ACN, gradient: 5-38% solvent B in solvent A; column temperature: 50° C.] to give the title compound (42 mg, 51%) as a white solid. ES-MS m / z 396.2 (M+H)
[1309] Embodiment 149
[1310] 3-Amino-2-(biphenyl-3-ylmethyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid dihydrochloride (mixture of diastereomers)
[1311]
[1312] A mixture of 2-[[2-[(3R)-1-tert-butoxycarbonylpyrrolidin-3-yl]-2-carboxy-3-(3-phenylphenyl)propyl]carbamoyl]benzoic acid (mixture of diastereomers, 28 mg, 0.049 mmol) and concentrated aqueous HCl (0.489 mL) was heated at 100 °C overnight. The mixture was cooled to room temperature and loaded onto SCX resin (previously washed with CH3CN-H2O 50%). The column was eluted with CH3CN-H2O 50% and then with NH3 (2M in MeOH and then 7M in MeOH). The MeOH-NH3 fractions were collected and concentrated under reduced pressure. The residue was dried under reduced pressure at 40 °C overnight and then treated with HCl (1N aqueous solution, 0.462 mL, 0.462 mmol) for 1 hour and then the solvent was removed under a stream of nitrogen. The residue was dried under reduced pressure at 40° C. overnight to give the title compound as a light brown solid (9 mg, 73%). ES-MS m / z 325 (M+H).
[1313] Embodiment 150
[1314] (2S)-3-(3-ethynylphenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride
[1315]
[1316] To a mixture of (3R)-3-[(1S)-2-tert-butoxy-2-oxo-1-[[3-(2-trimethylsilylethynyl)phenyl]methyl]ethyl]pyrrolidine-1-carboxylic acid tert-butyrate (40 mg, 0.085 mmol) in DCM (1 mL) was added TFA (2 mL) at 25° C., and the mixture was stirred at 0° C. for 16 hours. The reaction mixture was concentrated to dryness and purified by HPLC [column: Welch C18 150×30 mm, 5 μm; mobile phase: solvent A=HCL aqueous solution, solvent B=ACN, gradient: 0-100% solvent B in solvent A, flow rate: 25 mL / min] to obtain the title compound as a white solid (5.18 mg, 24%). ES-MS m / z 244.0 (M+H).
[1317] Embodiment 151
[1318] (2S)-3-(3-Hydrazinophenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride
[1319]
[1320] To a solution of (3R)-3-[(1S)-1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester (prepared essentially as described in WO 2020 / 247429; 200 mg, 0.512 mmol) in water (9.6 mL) and concentrated HCl (3.2 mL) was slowly added sodium nitrite (53 mg, 0.77 mmol) in water (2.4 mL) at 0°C. The reaction mixture was stirred at 0°C for 0.1 hour, then stannous chloride (200 mg, 1.03 mmol) in HCl (1.2 mL) was added at 0°C, and the mixture was stirred under N2 0-25°C for 16 hours. The reaction mixture was purified by HPLC [column: NX C18 75×30 mm, 3 μm; mobile phase: solvent A=aqueous HCl, solvent B=ACN, gradient: 0-100% solvent B in solvent A] to give the title compound as a white solid (22 mg, 16%). ES-MS m / z 250.2 (M+H).
[1321] Embodiment 152
[1322] 3-{(2S)-2-Carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl}benzoic acid hydrochloride
[1323]
[1324] To a solution of (2S)-3-[3-(methoxycarbonyl)phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid hydrochloride (120 mg, 0.351 mmol) in THF (1 mL) and water (1 mL) was added LiOH (37 mg, 1.47 mmol) at 25° C. The resulting mixture was stirred at 40° C. for 2 hours, and the reaction mixture was purified by HPLC [column: NX C18 75×30 mm, 3 μm; mobile phase: solvent A=aqueous HCl, solvent B=ACN, gradient: 0-100% solvent B in solvent A] to give the title compound as a yellow oil (16 mg, 18%). ES-MS m / z 264.1 (M+H).
[1325] Embodiment 153
[1326] (2S)-3-(3-vinylphenyl)-2-[(3R)-pyrrolidin-3-yl]propanoic acid ammonium salt
[1327]
[1328] To a mixture of (2S)-2-[(3R)-pyrrolidin-3-yl]-3-(3-vinylphenyl)propanoic acid methyl ester (290 mg, 1.12 mmol) in THF (4 mL), MeOH (2 mL) and water (1 mL) was added LiOH (290 mg, 11.5 mmol) in one portion at 25° C. The reaction mixture was stirred at 25° C. for 3 hours and then the pH was adjusted to 7 by the addition of 1N aqueous HCl. The mixture was concentrated to dryness under reduced pressure and the residue was purified by HPLC [column: NXC1875×30mm, 3μm; mobile phase: solvent A=aqueous HCl solution, solvent B=ACN, gradient: 0-100% solvent B in solvent A], and repurified by HPLC [column: same; mobile phase: solvent A=NH4OH+aqueous NH4HCO3 solution, solvent B=ACN; gradient: 0-100% solvent B in solvent A] to give the title compound as a white solid (18.1 mg, 6%). ES-MS m / z 246.2 (M+H).
[1329] Biological Detection
[1330] In vitro Apo(a) binding assay
[1331] Compounds were tested for in vitro binding affinity to the intended target human Apo(a) protein in a competitive binding assay. Human Apo(a) protein containing 17 Kringle repeats was affinity purified from the conditioned medium of transiently transfected HEK-293F cells. All reagents were prepared in assay buffer containing 50 mM Tris-HCl pH 7.4, 0.1% BSA. Binding assays were performed by adding 50 μl of each of (1) a dilution series of the test compound (final concentration 0.32-10000 nM), (2) Apo(a) protein (6 ng / well), (3) resuspended wheat germ agglutinin polyvinyltoluene SPA beads (20 mg / ml), and (4) the radioligand tritiated labeled (2S)-3-[3-[2-oxo-3-[3-(tritritiomethoxy)phenyl]imidazolidin-1-yl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propionic acid hydrochloride (prepared essentially as described in WO 2020 / 247429; final concentration 0.52 nM) to each well of a clear bottom plate. Plates were incubated at room temperature for 60 minutes and counted on a TRILUX LSC. Nonspecific binding, defined as binding in the presence of 10 μM cold (i.e., non-radiolabeled) ligand: (2S)-3-[3-[2-oxo-3-[3-(methyloxy)phenyl]imidazolidin-1-yl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propionic acid hydrochloride (prepared essentially as described in WO 2020 / 247429), was subtracted to determine specific binding. Data were analyzed by fitting to a standard one-site binding model and IC values of the test compounds of the examples were determined. 50 .
[1332] In this assay, the compound of Example 6 had an IC of 4.68 nM. 50 (SEM 2.26 nM, n=2), indicating that it binds to human Apo(a) protein. Inhibition of the assembly of LDL particles with apo(a) by binding to Apo(a) protein supports the reduction of Lp(a) levels.
[1333] In vitro Lp(a) assembly assay
[1334] The ability of compounds to inhibit Lp(a) particle formation in vitro was assessed by a cell-free assembly assay. Conditioned media (DMEM supplemented with 10% FBS, 20 mM HEPES, and 1x penicillin / streptomycin) were collected from confluent wild-type HepG2 cells (source of endogenously expressed ApoB) and from a HEK293 stable cell line expressing a human Apo(a) protein containing 17 Kringle repeats (selected on 1 mg / ml geneticin) after 24 h of incubation at 37°C and 5% CO2. In vitro assembly assays were performed by combining equal parts of HepG2 and HEK293 conditioned media with test compounds added in a dilution series (final concentrations 0.01-100 nM). The reaction was incubated at 37°C for 2 h and then terminated by the addition of 6-aminohexanoic acid (EACA) to a final concentration of 150 mM. Lp(a) was detected using a sandwich ELISA with an anti-Lp(a) capture antibody and an HRP-labeled anti-ApoB detection antibody. The ELISA was developed using TMB, terminated using 1N sulfuric acid and read at 450 nm on a Molecular Devices plate reader. The % inhibition of Lp(a) formed under each experimental condition was determined by setting the assembly reaction in the absence of inhibitor (with matching DMSO concentration at 1%) as 0% inhibition and the assembly reaction in the presence of minimal HepG2 conditioned medium (50-fold dilution) as 100% inhibition. The data were fitted to a 4-parameter curve to determine the IC summarized in Table 1. 50 Addition of the test compounds of the examples to conditioned medium containing ApoB and Apo(a) resulted in a concentration-dependent inhibition of Lp(a) formation in vitro as summarized in Table 1. The results indicate that these compounds inhibit the assembly of Lp(a) from Apo(a) and LDL particles.
[1335] Table 1.
[1336]
[1337]
[1338]
[1339]
[1340]
[1341]
Claims
1. A compound of the formula: in L 1 Connect in A 1 , A 2 or A 3 and selected from a bond, -(CH 2 ) p NHC(O)NH(CH 2 ) p -、-(CH 2 ) p C(O)NH(CH 2 ) p -、-(CH 2 ) p S(O) 2 NH(CH 2 ) p -、-(CH 2 ) q -、-(CH 2 ) p NH(CH 2 ) p -、 or L 1 With a position A on a ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring: R 1 , R 1’ , R 2 and R 2’ independently selected at each occurrence from H, C 1-4 Alkyl and F; R 3 , R 3’ , R 4 and R 4’ is H or F independently at each occurrence; R 5 and R 5’ H, C independently at each occurrence 1-4 Alkyl or cyclopropyl; Z and Z' are independently H, C 1-4 Alkyl, OH, cyclopropyl, CH 2 OH, CH 2 NH 2 or CH 2 OCH 2 Phenyl; Y and Y' are independently CH at each occurrence 2 、CH(CH 3 ), O or S; A 1 , A 1’ , A 2 , A 2’ , A 3 , A 3’ , A 4 , A 4’ , A 5 , A 5’ and A 6 is independently C or N at each occurrence, wherein each ring A 1 , A 2 , A 3 , A 4 and A 5 No more than two of them are N, or A on each ring 1’ , A 2’ , A 3’ , A 4’ , A 5’ and A 6 No more than two of them are N; Q 3 and Q 3’ is independently H at each occurrence; -(CH 2 ) n O(CH 2 ) n R 10 ;-(CH 2 ) n NR 15 (CH 2 ) n R 10 ;-CN;-(CH 2 ) n CO 2 R 10 ; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n NR 15 S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n S(O) m NR 15 (CH 2 ) n R 10 ;-(CH 2 ) n NHCONR 15 R 10 ; -NHCO(CH 2 ) n R 10 ;-NHCOOR 10 ; NO 2 CF 3 ; C 3-6 Cycloalkyl; -NH(C=NH)CH 2 CN; a 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; optionally substituted by one or two CH 3 substituted indoline; optionally substituted with (CH 2 )CF 3 , CH 3 or (CH 2 ) n Phenyl-substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally replaced by OH or OCH 3 substituted; optionally with one or two independently selected from OCH 3 , CH 3 and halogen-substituted indolin-2-one, isoindolin-1-one or benzimidazol-2-one; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein phenyl and heteroaryl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH 2 , C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted by 1 to 3 independently selected from -OCH 3 CF 3 , CH 3 , CN and halogen substituents, or optionally substituted by CH 2 OH substituted pyridine; or Q 4 YesR 11 CF 3 , OR 11 、OCF 3 , halogen or CN; m is independently 0, 1, or 2 at each occurrence; n is independently 0, 1, 2, or 3 at each occurrence; R 10 is independently H at each occurrence; halogen; OH; carboxyl; -S(O) 2 OH; optionally 1 to 4 OH or OCH 3 Substituted C 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH 3 NH 2 ; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted by one or two halogens; optionally substituted by C(O)CH 3 Substituted indoline; optionally C 1-4 Alkyl, C 1-4 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF 3 、CN、-(CH 2 ) 2 C(O)OH、-C(O)NHNH 2 、-OCF 3 、-N(CH 3 ) 2 , C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OCH 2 C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH 2 ) n (5- or 6-membered heterocyclic group) or -(CH 2 ) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens; R 11 It is H, C 1-4 Alkyl or cyclopropyl; L 2 Connect in A 1’ , A 2’ or A 3’ and is C 1-3 an alkylene group or a bond; and p ranges from 0 to 3 independently at each occurrence; q is 1 to 5; r is 1, 2, or 3; R 15 Is H or C 1-3 alkyl; or a pharmaceutically acceptable salt thereof, Wherein the compound is not of the formula: in L 1 Choose from -CH 2 NHCH 2 -、-CH 2 NH-、-NH-、 The group composed of; R 5 is H or CH 3 ;and Z is H or CH 3 .
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L 1 Select from bonds, -(CH 2 ) p NHC(O)NH(CH 2 ) p -、-(CH 2 ) p C(O)NH(CH 2 ) p -、-(CH 2 ) p S(O) 2 NH(CH 2 ) p -、-(CH 2 ) q -、 or L 1 With a position A on a ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L 1 Yes-(CH 2 ) p NH(CH 2 ) p -、 And at least one Q 3 Not H.
4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein L 1 A connected to each ring 2 A on a ring 2 A on another ring 3 A on each ring 3 A in a ring 1 A on another ring 2 Place.
5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein L 1 A connected to each ring 2 Place.
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L 1 Selected from: bond, -(CH 2 ) p NHC(O)NH(CH 2 ) p -、-(CH 2 ) p C(O)NH(CH 2 ) p -、-(CH 2 ) p S(O) 2 NH(CH 2 ) p -、-(CH 2 ) q -、-(CH 2 ) p NH(CH 2 ) p -、 or L 1 With a position A on a ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein L 1 Selected from: bond, -NHC(O)NH-, -NHC(O)NHCH 2 -、-C(O)NH-、-S(O) 2 NH-, -CH 2 CH 2 CH 2 -、-NH-、 or L 1 With a position A on a ring 2 and A 3 The carbons at the ends of the rings are joined together to form a fused ring:
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L 1 Selected from:
9. The compound according to claim 8 or a pharmaceutically acceptable salt thereof, wherein L 1 Selected from:
10. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein L 1 Selected from:
11. The compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 All H or R 1 and R 2 One is H and the other is CH 3 .
12. The compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 All H or R 3 and R 4 All F.
13. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein at each occurrence R 5 It's H.
14. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein Z at each occurrence is H, CH 3 or OH.
15. The compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein on each ring A 1 , A 2 , A 3 , A 4 and A 5 All are C.
16. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein at each occurrence Q 3 It is H, F, CF 3 or CN.
17. Compounds of the formula: in R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F; R 3 and R 4 are independently H or F; R 5 It is H, C 1-4 Alkyl or cyclopropyl; Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH 2 OH, CH 2 NH 2 or CH 2 OCH 2 Phenyl; Y is CH 2 , CH(CH 3 ), O or S; A 1 , A 2 , A 3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N; Q 1 Yes-(CH 2 ) n O(CH 2 ) n R 10 ;-(CH 2 ) n NR 15 (CH 2 ) n R 10 ;-CN;-(CH 2 ) n CO 2 R 10 ;-B(OR 10 ) 2 ; Ethylene glycol borate; Pinacol borate; Propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N 3 ; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n NR 15 S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n S(O) m NR 15 (CH 2 ) n R 10 ;-(CH 2 ) n NHCONR 15 R 10 ; -NHCO(CH 2 ) n R 10 ;-NHCOOR 10 ; NO 2 CF 3 ; C 3-6 Cycloalkyl; -NH(C=NH)CH 2 CN; a 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; optionally substituted by one or two CH 3 substituted indoline; optionally substituted with (CH 2 )CF 3 , CH 3 or (CH 2 ) n Phenyl-substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally replaced by OH or OCH 3 substituted; optionally with one or two independently selected from OCH 3 , CH 3 and halogen-substituted indolin-2-one, isoindolin-1-one or benzimidazol-2-one; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein phenyl and heteroaryl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH 2 , C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted by 1 to 3 independently selected from -OCH 3 CF 3 , CH 3 , CN and halogen substituents, or optionally substituted by CH 2 OH substituted pyridine; or Q 2 YesR 11 CF 3 , OR 11 、OCF 3 , halogen or CN; m is 0, 1, or 2; n is 0, 1, 2, or 3; R 10 is H; halogen; OH; carboxyl; -S(O) 2 OH; optionally 1 to 4 OH or OCH 3 Substituted C 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH 3 NH 2 ; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted by one or two halogens; optionally substituted by C(O)CH 3 Substituted indoline; optionally C 1-4 Alkyl, C 1-4 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF 3 、CN、-(CH 2 ) 2 C(O)OH、-C(O)NHNH 2 、-OCF 3 、-N(CH 3 ) 2 , C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OCH 2 C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH 2 ) n (5- or 6-membered heterocyclic group) or -(CH 2 ) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens; R 11 It is H, C 1-4 Alkyl or cyclopropyl; r is 1, 2, or 3; and R 15 Is H or C 1-3 alkyl; or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 17, which is of the formula: or a pharmaceutically acceptable salt thereof.
19. A compound according to claim 17 or claim 18, selected from: or a pharmaceutically acceptable salt thereof.
20. The compound according to any one of claims 17 to 19, or a pharmaceutically acceptable salt thereof, wherein Q 1 Selected from: -(CH 2 ) n O(CH 2 ) n R 10 ;-(CH 2 ) n NR 15 (CH 2 ) n R 10 ;-CN;-(CH 2 ) n CO 2 R 10 ;-N 3 ; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n NR 15 S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n S(O) m NR 15 (CH 2 ) n R 10 ;-(CH 2 ) n NHCONR 15 R 10 ; -NHCO(CH 2 ) n R 10 CF 3 ; C 3-6 Cycloalkyl; -NH(C=NH)CH 2 CN; a 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; optionally substituted by one or two CH 3 substituted indoline; optionally substituted with (CH 2 )CF 3 or (CH 2 ) n Phenyl substituted imidazolidinone or imidazolidin-2,5-dione, wherein the phenyl group is optionally substituted by OH; indolin-2-one or benzimidazol-2-one optionally substituted by CH3; phenyl, 5- or 6-membered heteroaryl or 9-membered bicyclic heteroaryl, wherein the phenyl and heteroaryl groups are optionally substituted by one or two substituents independently selected from the following: halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, C 1-4 Alkoxy, optionally substituted by OH or halogen 1-6 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted by 1 to 3 independently selected from -OCH 3 and halogen substituents; or 21. A compound according to any one of claims 17 to 20, or a pharmaceutically acceptable salt thereof, wherein Q 2 It is H, CH 3 , F or Br.
22. The compound according to any one of claims 17 to 21, or a pharmaceutically acceptable salt thereof, wherein R 5 It's H.
23. The compound according to any one of claims 17 to 22, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and R 4 All are H.
24. The compound according to claim 23 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 is H, and R 3 and R 4 It's F.
25. The compound according to any one of claims 17 to 24, or a pharmaceutically acceptable salt thereof, wherein Z is selected from H, methyl, CH 2 OH, CH 2 NH 2 and CH 2 OCH 2 Phenyl.
26. Compounds of the formula: in R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F; R 3 and R 4 are independently H or F; R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group; X is OH, -OR 6 or R 6 It is C 1-4 alkyl; D and E are each independently O or S; R 7 It is H, C 1-4 alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino; R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino; Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH 2 OH, CH 2 NH 2 or CH 2 OCH 2 Phenyl; Y is CH 2 , CH(CH 3 ), O or S; A 1 , A 2 , A 3 , A 4 and A 5 are independently C or N, wherein A 1 , A 2 , A 3 , A 4 or A 5 No more than two of them are N; Q 1 Yes-(CH 2 ) n O(CH 2 ) n R 10 ;-(CH 2 ) n NR 15 (CH 2 ) n R 10 ;-CN;-(CH 2 ) n CO 2 R 10 ;-B(OR 10 ) 2 ; Ethylene glycol borate; Pinacol borate; Propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N 3 ; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; Halogen; -C(O)-R 10 ;-C(O)NR 15 R 10 ; -S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n NR 15 S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n S(O) m NR 15 (CH 2 ) n R 10 ;-(CH 2 ) n NHCONR 15 R 10 ; -NHCO(CH 2 ) n R 10 ;-NHCOOR 10 ; NO 2 CF 3 ; C 3-6 Cycloalkyl; -NH(C=NH)CH 2 CN; a 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; optionally substituted by one or two CH 3 substituted indoline; optionally substituted with (CH 2 )CF 3 , CH 3 or (CH 2 ) n Phenyl-substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally replaced by OH or OCH 3 substituted; optionally with one or two independently selected from OCH 3 , CH 3 and halogen-substituted indolin-2-one, isoindolin-1-one or benzimidazol-2-one; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein phenyl and heteroaryl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH 2 , C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted by 1 to 3 independently selected from -OCH 3 CF 3 , CH 3 , CN and halogen substituents, or optionally substituted by CH 2 OH substituted pyridine; or Q 2 YesR 11 CF 3 , OR 11 、OCF 3 , halogen or CN; m is 0, 1, or 2; n is 0, 1, 2, or 3; R 10 is H; halogen; OH; carboxyl; -S(O) 2 OH; optionally 1 to 4 OH or OCH 3 Substituted C 1-4 Alkyl; C optionally substituted by one or two halogens 3-6 Cycloalkyl; C 1-4 Haloalkyl; -C 2-6 Alkynyl; 1-benzyl-4-piperidinyl; 2-tert-butoxy-2-oxoethyl; benzyloxyphenyl optionally substituted by one or two halogens; O(C 1-2 alkyl) r OCH 3 NH 2 ; 2,3-dihydro-1H-indene; 2,3-dihydrobenzo[b][1,4]dioxin; benzo[d][1,3]dioxole optionally substituted by one or two halogens; optionally substituted by C(O)CH 3 Substituted indoline; optionally C 1-4 Alkyl, C 1-4 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl substituted with alkoxy, halogen or phenyl; phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-4 Alkoxy, hydroxyl, C 1-4 Alkyl, CF 3 、CN、-(CH 2 ) 2 C(O)OH、-C(O)NHNH 2 、-OCF 3 、-N(CH 3 ) 2 , C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OCH 2 C 3-6 Cycloalkyl, 5- or 6-membered heteroaryl, -(CH 2 ) n (5- or 6-membered heterocyclic group) or -(CH 2 ) n Phenyl, wherein the phenyl is optionally substituted with one or two halogens; R 11 It is H, C 1-4 Alkyl or cyclopropyl; r is 1, 2, or 3; and R 15 Is H or C 1-3 alkyl; or a salt thereof, If X is OH, then R 5a must be a protecting group; and Wherein the compound is not: tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-methoxy-2-oxoethyl]pyrrolidine-1-carboxylate; 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-2-methyl-propionic acid; 3-[2-[4-Benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-bromophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylic acid tert-butyl ester; tert-Butyl 3-[(2-[4-benzyl-2-oxo-oxazolidin-3-yl]-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate; 3-(3-Bromophenyl)-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]propanoic acid; 2-[(1-tert-Butyloxycarbonylpyrrolidin-3-yl]-3-(3-nitrophenyl)propanoic acid; tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[1-[(3-bromophenyl)methyl]-2-tert-butoxy-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[(2-tert-butoxy-1-[(3-nitrophenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[2-tert-butoxy-1-[(3-formylphenyl)methyl]-1-methyl-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[1-[[3-(Aminomethyl)phenyl]methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[1-[(3-aminophenyl)methyl]-2-tert-butoxy-2-oxoethyl]pyrrolidine-1-carboxylate; tert-Butyl 3-[2-tert-butoxy-1-[[3-(hydroxymethyl)phenyl]methyl]-2-oxoethyl]pyrrolidine-1-carboxylate; [3-[3-tert-Butoxy-2-[1-tert-butoxycarbonylpyrrolidin-3-yl]-3-oxopropyl]phenyl]boronic acid; Tert-butyl 3-[2-tert-butoxy-1-[(3-hydroxyphenyl)methyl]-2-oxoethyl]pyrrolidine-1-carboxylate.
27. The compound or salt thereof according to claim 26, wherein Q 1 is -CN; -(CH 2 ) n CO 2 R 10 ; Ethylene glycol borate; Pinacol borate; Propane-1,3-diol borate; 2,2-dimethyl-propane-1,3-diol borate; -N 3 ; C 1-6 Alkyl; -C 2-6 Alkenyl; -C 2-6 Alkynyl; -C(O)NR 15 R 10 ; -S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n NR 15 S(O) m (CH 2 ) n R 10 ;-(CH 2 ) n S(O) m NR 15 (CH 2 ) n R 10 ;-(CH 2 ) n NHCONR 15 R 10 ; -NHCO(CH 2 ) n R 10 ;-NHCOOR 10 CF 3 ; C 3-6 Cycloalkyl; -NH(C=NH)CH 2 CN; a 5- or 6-membered heterocyclic group optionally substituted by 1 to 4 halogen or phenyl groups; optionally substituted by one or two CH 3 substituted indoline; optionally substituted with (CH 2 )CF 3 , CH 3 or (CH 2 ) n Phenyl-substituted imidazolidinone, pyrrolidone, imidazolidin-2,5-dione, pyrrolidine-2,5-dione or oxazolidin-2-one, wherein the phenyl group is optionally replaced by OH or OCH 3 substituted; optionally with one or two independently selected from OCH 3 , CH 3 and halogen-substituted indolin-2-one, isoindolin-1-one or benzimidazol-2-one; phenyl, 5- or 6-membered heteroaryl or 9- or 10-membered bicyclic heteroaryl, wherein phenyl and heteroaryl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, OC 1-4 Haloalkyl, C 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, OH, C 1-4 Alkoxy, optionally substituted by OH or 1 to 4 halogen 1-6 Alkyl, NH 2 , C 1-6 Alkyl COOC 1-2 alkyl, phenyl or benzyl, the phenyl or benzyl being optionally substituted by 1 to 3 independently selected from -OCH 3 CF 3 , CH 3 , CN and halogen substituents, or optionally substituted by CH 2 OH substituted pyridine; or 28. A compound or salt thereof according to claim 26 or claim 27, wherein R 5a is a protecting group and the protecting group is selected from the group consisting of tert-butoxycarbonyl, carboxybenzyl, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, trimethylsilylethoxycarbonyl, trichloroethoxycarbonyl, trifluoroacetamide, benzamide, benzylamine, triphenylmethylamine and p-toluenesulfonamide.
29. The compound or salt thereof according to any one of claims 26 to 29, wherein X is selected from: Where R 12 H or C independently at each occurrence 1-4 alkyl.
30. Compounds of the formula: in R 1 and R 2 Independently selected from H, C 1-4 Alkyl and F; R 3 and R 4 are independently H or F; R 5a It is H, C 1-4 Alkyl, cyclopropyl or protecting group; D and E are each independently O or S; R 7 It is H, C 1-4 alkyl, phenyl or benzyl, wherein the phenyl and benzyl are optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino; R 8 and R 9 Each independently is H, C 1-4 alkyl or phenyl optionally substituted by one or two substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, trifluoromethyl, amino, C 1-4 Alkylamino and di-C 1-4 Alkylamino; Z is H, C 1-4 Alkyl, OH, cyclopropyl, CH 2 OH, CH 2 NH 2 or CH 2 OCH 2 Phenyl; or a salt thereof, Wherein the compound is not:
31. Use of a compound according to any one of claims 17 to 30 or a salt thereof in the preparation of an oligomer.
32. An oligomer prepared from a compound as claimed in any one of claims 17 to 30.
33. The oligomer of claim 32 comprising at least two pyrrolidine moieties.
34. The oligomer of claim 32 comprising at least three pyrrolidine moieties.
35. A pharmaceutical composition comprising the oligomer according to any one of claims 32 to 34.
Citation Information
Cited By
Arylpropionic acid compound, preparation method therefor, and use thereof
WO2026051995A1
Pyrrolidine derivative and use thereof in drugs
WO2026130347A1
Method for preparing pyrrolidine derivative or salt thereof
WO2026130471A1
Aromatic acid compound and medical use thereof
WO2026145708A1
Urea-containing compound, pharmaceutical composition comprising same, and use thereof
WO2026184518A1
